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Abstract 
 
Up to now, current therapies for Alzheimer’s disease (AD) can treat the 
symptoms with modest effect and have little impact on the overall progression. 
AD is a complex, multifactorial disorder, featured by aggregation of toxic 
proteins, inflammation, oxidative stress, synaptic deficits, and cognitive 
decline. Thus, the multi-target therapeutic strategy is of particular interest as it 
uses a combination of drugs to affect different molecular targets and converge 
on neuroprotection or even disease modification. 
In drug discovery for neurodegenerative processes, an interesting role 
emerged for the histone-deacetylase enzymes Sirtuins (SIRTs), and SIRT1 
and SIRT2 have been associated with neuroprotection and 
neurodegeneration, respectively.  
The availability of SIRTs small molecule modulators allowed the achievement 
of good results of SIRT1 activation or SIRT2 inhibition in models of 
neurodegeneration and AD, as both SIRTs are actively involved, to different 
extent, in the regulation of amyloidogenic processing, inflammatory and 
oxidative cascades. A direct intervention on such molecular players could be 
beneficial in obtaining cognitive or pathologic phenotype improvement deriving 
from multiple pathways targeting.  
In this work, we aimed at combining SIRT1 activation and SIRT2 inhibition to 
study a possible multi-target approach on AD models, both in vitro and in vivo.  
An initial drug dose-response and biochemical assessment was performed on 
the AD in vitro model H4-sw, focusing on the increase of the neuroprotective 
sAPPα fragment. 
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Next, 3xTg-AD mice received the single or the combined treatment with SIRT1 
activator SRT2104 and SIRT2 inhibitor AK7 for two weeks, and the effects on 
cognitive performance and key biochemical parameters were assessed.  
Results showed that both SIRT1 and SIRT2 single modulation independently 
improved cognitive performance in treated mice. Combined treatment showed 
complete memory recovery too. Some differences between single and double 
treatment emerged in biochemical assessments.  
Double-treated mice had increased NRF2, sAPPα and reduced Aβ oligomers 
in hippocampus, already seen upon SIRT2 inhibition, suggesting that cognitive 
improvement given by SIRT2 modulation could be attributed to those 
underlying effects.  
Together with memory recovery, SIRT1 activator treated mice showed 
decreased hippocampal CD11b and GFAP, increased synaptophysin, SOD1, 
sAPPα and NRF2, all seen upon double treatment too.  
Thus, SIRT1 and SIRT2 independent modulations could improve memory 
deficit acting both on peculiar or common protein targets.  
In conclusion, the combined treatment resumed all the behavioural and  
biochemical effects of single modulations. Our data support the concept that, 
with a multi-target strategy, it could be possible to take full advantage of the 
complementarity of SIRT1/SIRT2 treatments and obtain cognitive 
improvement based on changes on several underlying biochemical 
mechanisms that with single modulation could only be partially achieved.  
All these observations could open up new insights for research on SIRTs 
involvement in AD and neurodegeneration. 
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1.1 Alzheimer’s disease 
 
Alzheimer’s disease (AD), is the most frequent disease of the central nervous 
system (CNS) and  the most common cause of dementia. As other 
neurodegenerative disorders, is characterized by progressive loss of 
functionality and specific neuronal populations’ death. Given the fact that 
neurons cannot replicate, the disease is incurable and totally disabling. AD is 
characterized by memory and cognitive deterioration, has an incidence of 1-
3% of the total population above 65 years-old, and an estimated prevalence of 
10-30% [Masters CL et al., 2015]. 
If we consider the sole European population, a recent metanalysis study 
highlighted a 5.05% (7.13% for women and 3.31% for men) prevalence of AD, 
and an annual incidence of 11.08 (13.25 for women and 7.02 for men) every 
1000 people. These values are higher in women and tend to increase with 
ageing [Niu H et al., 2017].  
AD treatments are only able to reduce symptoms and slow down the course of 
the disease. Despite the huge amount of clinical trials for the identification of a 
cure, the search for a therapy that could arrest the disease is still ongoing 
[Godiń J et al., 2016]. The current pharmacological approach aims at the 
molecular targets responsible of the two main physiopathological signs of AD: 
β-amyloid peptide and tau protein. 
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1.1.1 CLINICAL SIGNS AND SYMPTOMS 
 
Dr. Alois Alzheimer, a German neuropathologist and psychiatrist, described 
AD for the first time in 1907. He described the case of a 51 years old woman 
with clinical signs unrelated to known diseases. The woman presented with 
disorientation and memory loss, with a strong paranoid behaviour [Alzheimer 
A et al., 1995]. After her death, 4 years later, Alzheimer analysed her brain 
and noticed two characteristic alterations, currently known as extracellular β-
amyloid senile plaques and neurofibrillary tangles of hyperphosphorylated tau 
protein. These two are nowadays the typical post-mortem features for AD 
diagnosis confirmation [Thal DR et al., 2005].  
AD pathological process starts at least one decade before the appearance of 
the first symptoms (pre-clinical phase). Thus, it is essential to immediately 
recognize and diagnose early-stage AD, in order to offer the better therapeutic 
possibilities to patients [Herman L et al., 2017].  
AD clinical course can be divided in phases, with common symptoms between 
different patients. 
Mild cognitive impairment (MCI) is considered as light memory and cognitive 
deficit, typical of the elderly population, which is not necessarily related with 
dementia. It would be very important to know whether MCI is the prodromal 
phase of AD to have an early diagnosis, which nowadays is often uncertain 
[Tarawneh et al., 2012]. However, MCI is currently the only chance to 
diagnose dementia prior to serious and irreversible cognitive decline, and 
usually requires multiple tests over months to rule out other non-reversible 
causes of the cognitive deficit.  
20 
 
An early AD intervention is of particular importance given the progressive 
nature of the disease. In fact, AD progression can be classified in three clinical 
phases [De-Paula VJ et al., 2012]: 
- A pre-symptomatic AD, that can last decades before the Aβ accumulates 
and initiate its pathological cascade.  
- A pre-dementia phase, in which MCI detection is a key point, and 
neuropathological changes include mild neuronal dystrophy or early-stage 
Braak pathology. This phase can last for years depending on individual 
resilience. 
- Dementia phase, where cognitive impairment has exceeded the dementia 
threshold. The patient presents accumulation of neuritic plaques and 
neurofibrillary tangles.  
After the early stage of the disease, in the intermediate phase there is evident 
language deficits (aphasia), bad motor coordination and long-term memory is 
compromised [Tree J et al., 2015].  
In the advanced stage of AD, the patient is no more able to communicate and 
manage daily activities [Frank EM, 1994]. This leads to infection vulnerability, 
in fact pneumonia is the main cause of death in AD patients [Glampedakis E 
et al., 2016].  
AD has a variable duration, however the mean time of survival after the 
diagnosis is between 3.2 and 6.6 years [Todd S et al., 2013]. 
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1.1.2 DIAGNOSIS 
 
AD diagnosis can be confirmed by post-mortem histological analysis on the 
brain tissue of patients. However, there is a 95% accuracy in the diagnosis 
based on patient’s family anamnesis and neuropsychological tests, which 
allow the evaluation of cognitive functions typically compromised in AD 
(memory, language, perceptive and constructive abilities). These 
neuropsychological tests are part of the NINCDS-ADRDA criteria (National 
Institute of Neurological and Communicative Disorders and Stroke and the 
Alzheimer’s Disease and Related Disorders Association), diagnostic criteria 
used to discriminate with >80% accuracy AD patients and subjects without 
dementia.  
Biomarkers are measurable parameters that can be detected in vivo, and 
reflect a specific physiological or pathological process. β-amyloid peptide 
(Aβ42) and tau/phospho-tau protein can be used as CSF and plasma 
biomarkers in AD [Olsson B et al., 2016]. Research on novel AD biomarkers 
discovery is still very active as they can be of relevance for the early diagnosis. 
Another useful diagnostic instrument is represented by neuroimaging 
techniques as PET, MRI and SPECT [Pietrzak K et al., 2018]. Despite the 
increase in specificity, the accordance between clinical and post-mortem 
diagnosis is only 62% [Grandal Leiros B et al., 2018].  
AD is commonly diagnosed when the patient is already in the MCI due to AD 
(MCI-AD) stage of the disease, using clinical and biomarkers assays. On the 
other hand, detection of preclinical AD stage is still a challenge for an early 
diagnosis that could make more effective the proposed therapeutic 
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interventions, improve care planning of the patient, give access to symptomatic 
treatments, clinical trials and innovative available therapies [Barnett JH et al., 
2014; Herman L et al., 2017]. 
 
1.1.3 PHYSIOPATHOLOGY 
 
As already mentioned, the two characteristic neuropathological elements of 
AD are β-amyloid senile plaques and tau protein NFTs (Figure 1.1), in the form 
of insoluble aggregates [Perl DP, 2010]. However, it is wrong to think that 
these elements are the unique key aspects of the disease.  
AD physiopathological picture is very complex, and include a huge neuronal 
loss, mitochondrial dysfunction, oxidative stress, neuroinflammation and 
cerebral atrophy. 
Amyloid plaques are extracellular spherical lesions, with a diameter generally 
between 10 and 200 µm. They are composed of a central β-amyloid nucleus 
surrounded by proteins and neuronal fragments with peripheral deposits 
[Takahashi RH et al., 2002]. 
Aβ42 peptide deriving from amyloidogenic processing of amyloid precursor 
protein (APP), is prone to auto-aggregation in two coexistent physical forms: a 
non-fibrillary form (non-βsheet), composed by 2-6- units oligomers, and a 
fibrillary one (βsheet). The latter is organized in insoluble fibrils that are 
particularly stable and accumulate to form senile plaques [Breydo L et al., 
2016]. β-amyloid core is surrounded by protein deposits (apolipoprotein E, 
hyperphosphorylated tau, antichymotrypsin) and fragments from dead brain 
cells (neurons, astrocytes and microglia). These elements are crucial for 
23 
 
neuronal homeostasis alteration, as energy imbalance and oxidative stress 
[Tramutola A et al., 2017]. 
Inside the brain, senile plaques are typically present in the hippocampus, 
frontal and temporal-parietal cortex, and cingulate gyrus. Moreover, these 
alterations are also present in blood vessels (vascular plaques), where they 
trigger a pathological cycle between Aβ deposition and cerebrovascular 
diseases [Lee CW et al., 2014]. 
 
 
 
 
 
 
Figure 1.1 Left: high potency microphotography of a neuritic plaque (dashed white line) in 
which is present a neurofibrillary tangle (black arrow). Right: immunohistochemistry of wide 
spread Aβ plaques (thick arrows) and cerebral amyloid angiopathy (thin arrow) (modified from 
[Holtzman DM et al., 2011]) 
 
NFTs are mainly composed by tau protein, a microtubule associated protein 
with a role in their stability maintenance. 
Tau protein is subject of aberrant modifications like hyperphosphorylation, and 
detaches from microtubules accumulating in double-helix filaments (oligomers 
or bigger structures) in the dendritic space (Figure 1.2) [Avila J et al., 2016]. 
The consequences of these events are mitochondrial dysfunction and 
neuronal loss, which lead to cognitive decline. NFTs extend predominantly 
along neuronal extensions in hippocampus and cerebral cortex. 
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Figure 1.2 Accumulation of hyperphosphorylated tau protein in neuronal cell bodies (arrow) 
(modified from [Holtzman DM et al., 2011]) 
 
Neuronal death can be considered as the main hallmark of AD [Spires-Jones 
TL et al., 2014]. The progressive loss of synapses gradually inhibits 
neurotransmitters release, and the amount of post-synaptic receptors 
decreases. In particular, the expression of the α7 nicotinic subtype (α7-
nAChR) is altered in AD in vivo models and patients, thus suggesting an 
important role of this receptor in the pathogenesis of the disease and a new 
potential pharmacological target [Shen J et al., 2015]. However, a recent 
study on a murine AD model has highlighted the importance of other 
neurotransmitter systems, such as the dopaminergic one. In fact, they noticed 
dopaminergic neuronal loss in the ventral-tegmental area (VTA) at a pre-
plaques stage of the disease, which contributes to memory and synaptic 
plasticity impairment [Nobili A et al., 2017]. 
All these molecular pathological processes eventually lead to an extensive 
brain atrophy, associated with cortical and hippocampal shrinkage and 
ventricles dilatation (Figure 1.3).  
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Figure 1.3 MRI images comparing brain atrophy related to ageing (left) and AD (right). 
 
1.1.4 EPIDEMIOLOGY 
 
Age is the most important risk factor for AD. The risk increases between 65 
and 85 years of age, and beyond 65 years the incidence of the disease doubles 
every 5 years [Isik AT, 2010]. 
The rise of lifespan is a global process that proves the improvement of health 
in the last century. However, a negative aspect of ageing is the significant 
increase in the amount of senile dementia cases worldwide. It is estimated that 
the number of subjects with dementia could rise from the current 44 to 135 
million in 2050 [Prince M et al., 2013]. 
Despite this, life expectancy of individuals developing the disease at the time 
of the diagnosis is destined to remain unchanged. 
The progressive increase in the number of people affected by dementia is 
proportionally higher in developing countries (Low and Middle Income 
Countries - LMIC) with a young population, with respect to Western Europe or 
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USA (High Income Countries – HIC), which have an older population 
[Scheltens P et al., 2016].  
AD incidence seems to be significantly higher in women, and a recent study 
reported that women compose almost two-thirds of AD patients. A reason for 
this can be attributable to the fact that women have a longer life expectancy 
than men. However, it has been also highlighted that there is no difference 
between the two genders on the degree of disease development. A low 
education level is also associated to a higher AD incidence, whereas the 
training of cognitive abilities helps to reduce the risk to develop dementia in 
the early stage of the disease [Mielke MM et al., 2014]. 
 
1.1.5 ETIOLOGY 
 
AD can be classified in relation to the parameter taken into consideration 
(Table 1.1). 
If we consider age as the main parameter, AD can be classified into: 
- Early Onset Alzheimer’s Disease (EOAD): age of onset <65 years; 6-7% of 
all cases; 
- Late Onset Alzheimer’s disease (LOAD): age of onset >65 years; 93-94% 
of all cases. 
If we consider instead the familial history, it is possible to define these AD 
forms: 
- Autosomic Dominant: < 5% of EOAD cases; 
- Familial (FAD): 15-25% of LOAD cases, 47% of EOAD cases; 
- Sporadic (SAD): ~75% of all cases.  
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Table 1.1 AD classification according to American College of Medical Genetics and National 
Society of Genetics Counselors (modified from [Alves L et al., 2012]). 
 
EOAD is a familial autosomal dominant pathology (FAD) characterized by 
mutations in three main genes: APP, Presenilin1 and 2. LOAD is instead a 
heterogeneous sporadic pathology (SAD) related to ageing, genetics and 
environmental risk factors [Kim DH et al., 2014]. 
Both EOAD and LOAD are characterized by an excessive accumulation of β-
amyloid toxic forms, resulting from an imbalance between its production and 
clearance. In the case of EOAD both production and clearance seem to be 
altered, while in LOAD it has been highlighted a decrease in elimination only 
[Mawuenyega KG et al., 2010]. 
 
1.1.5.1 AD non-genetic risk factors 
 
Currently, reducing the risk of developing AD depends mainly on lifestyle 
changes and prevention. Modifiable risk factors include age, genetics and 
traumatic brain injury [Ballard C et al., 2011].  
Among non-genetic modifiable risk factors, instead, we can mention: 
- Cardiovascular diseases: these include haemorrhagic stroke, cerebral 
ischemia and hypertension [O'Brien JT et al., 2014].   
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- Obesity and dyslipidaemia: high total plasma cholesterol and middle age 
BMI have been associated with development of senile dementia and AD 
[Baumgart M et al., 2015].  
- Type II diabetes mellitus: the correlation between LOAD and diabetes is 
not fully clear, but it may include BMI and cardiovascular mechanisms, 
since type II diabetes is a risk factor for stroke, hypertension and 
dyslipidaemia [Reitz C et al., 2014].  
- Smoke: its role is controversial. Some studies suggest that smoke 
reduces AD risk, while other studies demonstrated that AD risk is 
increased [Durazzo TC et al., 2014].  
- Alcoholism 
 
1.1.5.2 AD genetics 
 
There are three main genes involved in EOAD development: Amyloid 
Precursor Protein (APP), Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2). 
Mutations in these genes determine abnormal amyloid β production, the 
most important cause of neuronal death, and dementia. 
 
• APP: the gene is located on chromosome 21 and up to now 30 different 
mutations have been identified, of which 25 are involved in autosomic 
dominant EOAD development. In Down’s Syndrome patients, which 
harbour three copies of the chromosome 21, an earlier AD development 
with respect to subjects without trisomy has been reported [Bagyinszky E 
et al., 2014].  
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A relevant mutation of APP is the Swedish one, identified for the first time 
in two Swedish families. It is a double mutation resulting from the double 
substitution of two aminoacids: Lysine (K) and Methionine (M) with 
Asparagine (N) and Leucine (L) respectively (K595N/M596L). This 
mutation is associated with EOAD and is known to cause an abnormal 
APP amyloidogenic metabolism increase, with an increase in Aβ peptide 
production and AD early onset [Shin J et al., 2010]. 
 
• PSEN1: its gene is located on chromosome 14. PSEN1 mutation is the 
most common cause of severe form of familial EOAD, with an onset at 30 
years of age. More than 180 PSEN1 mutations have been observed: the 
most important is a missense mutation with a substitution of an aminoacid, 
which causes Aβ42 abnormal accumulation [Alonso Vilatela ME et al., 
2012]. 
 
 • PSEN2: its gene is located on chromosome 1. The missense mutation 
in PSEN2 is a rare cause of EOAD and the mechanism leading to brain 
Aβ accumulation in AD patients is still unclear [Kim DH et al., 2014].  
 
Together with non-genetic risk factors, some genes involved in LOAD 
development have been described. Apolipoprotein E (ApoE) gene, located 
on chromosome 19, is the most important genetic risk factor for LOAD. 
ApoE is the main cholesterol carrier in the brain and is involved in neurons 
physiology maintenance. In the CNS, ApoE can bind different membrane 
receptors, which are involved in lipids transport, glucose metabolism, 
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neuronal communication and mitochondrial metabolism [Yu JT et al., 
2014]. There are 3 different ApoE allelic variants (ε2, ε3 and ε4), which 
correspond to 3 different isoforms of the protein: E2, E3 and E4. The most 
common isoform is ApoE 3 with a global frequency of 77.9%, followed by 
ApoE 4 (13.7%) and ApoE 2 (8.4%) [Mahoney-Sanchez L et al., 2016]. 
ApoE ε4 is present in 50% of LOAD patients. The presence of a copy of 
the ApoE ε4 allele increases the risk of developing LOAD by about three 
times, while the presence of two copies of the allele increases it twelve 
times [Neu SC et al., 2017].  
In addition to ApoE, several Genome-Wide Association Studies (GWAS) 
identified genes involved in LOAD development. GWAS consider the 
common genetic variability in the genome of big populations in order to 
identify correlations between specific genetic variants and AD. Some of 
the genes identified with this method are:  
• Clusterin (CLU): is the major apolipoprotein related to inflammatory 
response and is expressed in all tissues. Clusterin has a protective role 
against apoptosis, cellular damage and oxidative stress. 
• Complement Receptor 1 (CR1) e C3b: involved in Aβ clearance to 
prevent its aggregation. 
• PICALM, SORL1, BIN1, CTNNA3, GAB2, TREM2 and ADAM10 
[Bagyinszky E et al., 2014]. 
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1.2 AD pathogenesis: Amyloid Cascade Hypothesis 
 
The pathogenetic mechanism of AD is still unknown, and its identification is a 
main objective for research in this field. The Amyloid Cascade Hypothesis 
(ACH), formulated by Hardy and Higgins in 1992, focuses on APP, β-amyloid 
toxicity and aggregation, and tau protein (Figure 1.4). According to original 
ACH, the abnormal Aβ42 production and aggregation is crucial to determine 
senile plaques formation in some specific brain regions. The plaques would in 
turn cause neuronal damage, neurofibrillary tangles formation and finally, 
neuronal death and synaptic loss [Hardy JA et al., 1992]. 
During the past years, the ACH has been revised mostly because of the failure 
of therapies targeting Aβ deposition and aggregation. Several genetic studies 
demonstrated that genetic factors have an important role in AD development 
and progression, and that neurodegenerative processes are the result of an 
imbalance between Aβ production and clearance [Tarasoff-Conway JM et 
al., 2015]. 
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Figure 1.4 Main pathological events according to ACH. Blue arrow indicates that Aβ oligomers 
can directly cause synaptic damage and tau hyper-phosphorylation (from [Selkoe DJ et al., 
2016]). 
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1.2.1 Amyloid Precursor Protein (APP) 
 
APP is a transmembrane glycoprotein highly expressed in the CNS. The 
protein has a transmembrane hydrophobic region and a short intracellular C-
terminal domain (AICD) [Zhang H et al., 2012]. APP has 8 isoforms deriving 
from its alternative splicing. The 695 aminoacids isoform (APP695) is mainly 
present in neurons, while the other isoforms (APP751, APP770) are typical of 
other tissues.  
APP is member of a highly conserved family of APP-like proteins (APLPs): 
among the members of the family, APLP1 is expressed solely in mammalian 
brain and APLP2 is ubiquitously expressed [Nhan HS et al., 2015]. 
Although the pathologic role of APP in AD is well established, less is known 
about its physiological functions. Several recent studies suggested that APLPs 
are involved in CNS development, axonal growth, and synaptic functions such 
as plasticity, learning and memory formation [Müller UC et al., 2017].  
Moreover, it seems that APP processing pathways can regulate cholesterol 
metabolism and sphingomyelin production, confirming a connection between 
lipids level and AD pathogenesis [Grimm MO et al., 2005]. 
 
1.2.2 APP PROTEOLYTIC PROCESSING 
 
Neurons produce high amounts of APP that is rapidly metabolized. The protein 
is synthetized in the endoplasmic reticulum (ER), transported in Golgi 
apparatus via trans-Golgi-network (TGN) and finally sent to the synaptic 
terminal. Aβ peptide is produced both in the ER and in the Golgi/TGN 
[Greenfield JP et al., 1999]. Once in the TGN, APP can be transported into 
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vesicles to the cell surface, where it’s subjected to proteolysis or re-internalized 
for lysosomal degradation [Zhang YW et al., 2011].  
APP processing can follow two main destinies: the amyloidogenic pathway and 
the non-amyloidogenic pathway (Figure 1.5).  
 
Figure 1.5 Schematic representation of APP metabolic pathways (modified from [Pajak B et 
al., 2016]). 
 
In the non-amyloidogenic pathway APP is cleaved by the enzyme α-secretase 
at the 17th amino acid of the Aβ sequence, to produce the extracellular soluble 
fragment sAPPα and a membrane-associated C-terminal fragment called 
CTF83.  
CTF83 is subsequently cut by another enzyme, the γ-secretase, with the 
release of AICD and P3 fragments, that are rapidly degraded.  
In the amyloidogenic pathway, instead, APP is cleaved at a different site of the 
Aβ sequence by β-secretase, with the production of the extracellular soluble 
fragment sAPPβ and the membrane-bound fragment CTF99. 
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γ-secretase cuts CTF99 to generate AICD fragment and the Aβ peptide, which 
tends to aggregate in insoluble forms that initiate the amyloid plaques 
deposition [Kamenetz F et al., 2003].  
As mentioned above, the enzymes responsible for APP metabolism are part 
of the proteases family and are called secretases: 
- α-secretase: the main constitutive family of α-secretases is the ADAM (A 
Disintegrin And Metalloprotease) one. ADAM9, ADAM10, ADAM17 are the 
main members of the family. ADAM10 is considered the constitutive α-
secretase in neurons; in fact, ADAM10 deletion leads to the suppression of 
sAPPα production, an event that other ADAM members cannot compensate 
[Kuhn PH et al., 2010].  
ADAM10 is a 748 amino acids protein, and is composed by an extracellular 
glycosylated ectodomain, a trans-membrane domain and an intracellular 
domain. The pro-peptide is metabolized to its active form during the transit in 
Golgi apparatus [Saftig P et al., 2015; Yuan XZ et al., 2017].  
ADAM10 in vitro and in vivo over-expression increased sAPPα and lowered 
Aβ production, stimulating the interest in this enzyme as therapeutic target 
[Yuan XZ et al., 2017]. 
- β-secretase: this protease is called BACE-1 (β-site APP Cleaving Enzime-1) 
and is a type I trans-membrane protein belonging to the aspartyl-proteases. 
BACE-1 higher expression is in brain and pancreas, and in neurons it’s 
localized in the pre-synaptic terminal [Kandalepas PC et al., 2013]. A 
homologue of BACE-1, BACE-2, has been identified with a 64% homology in 
the amino acid sequence, but this enzyme is poorly expressed in neurons 
[Bennett BD et al., 2000]. 
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BACE-1 knock-out mice show a significant reduction in Aβ production but 
also complex neurochemical and behavioural phenotypes [Harrison SM et 
al., 2003]. This suggests that the BACE-2 homologue is not able to 
compensate for the BACE-1 absence, but also that BACE-1 inhibitors 
research as AD therapeutics should be done carefully to avoid side effects 
related to its physiological functions block.  
Since several studies have highlighted the importance of BACE-1 and APP 
co-localization and trafficking, interfering with the recycling of BACE1 may 
provide a novel approach to inhibit Aβ production [Agostinho P et al., 2015; 
Chia PZ et al., 2011]. 
- γ-secretase: this enzyme is responsible for the production of Aβ in the case 
of an amyloidogenic processing, while it produces P3 fragment in the case of 
a non-amyloidogenic processing. γ-secretase is composed by a complex of 
four proteins: Presenilin (PSEN) 1 or 2, Nicastrin (NCT, a type I trans-
membrane glycoprotein), the anterior pharynx defective (APH)-1a or APH-
1b, and PSEN enhancer (PEN)-2. These four proteins are requested for the 
functionality of the enzyme [Takasugi N et al., 2003]. 
APP cleavage by γ-secretase can produce Aβ peptides with different amino 
acid length. In the majority of the cells Aβ1-37, 38, 39 and 42 are present in 
low amounts (5-20% of total Aβ), while the main species is Aβ1-40 (50% of 
total Aβ).  
 
1.2.3 β-AMYLOID PEPTIDE 
 
According to ACH, β-amyloid generation is the first crucial event of AD 
pathogenesis. In 1984 Glenner and Wong isolated and purified this 4.2 kDa 
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peptide, hypothesizing it as a derivate of a longer precursor protein [Glenner 
GG et al., 1984].  
In physiological conditions, the ratio between Aβ42 and Aβ40 fractions is 1:10. 
The shift of this ratio is the first step of senile plaques formation and initiation 
of all the pathological AD characteristic events [Mawuenyega KG et al., 
2010]. 
The toxicity resulting from the increase in Aβ42 levels is due to its greater 
tendency to aggregation compared to Aβ40. In fact, all Aβ monomers are 
soluble and harmless, but after aggregation they become neurotoxic and 
cause a reduction in the peptide clearance itself [Kumar S et al., 2011]. 
It has been reported that Aβ42 oligomers accelerate further monomers 
aggregation to form toxic oligomers and fibrils. Furthermore, Aβ40 seems able 
to inhibit Aβ42 oligomerization by blocking it in stable tetrameric forms [Irie K 
et al., 2005; Murray MM et al., 2009]. 
The study of Aβ aggregation allowed to identify monomeric Aβ structure that 
is composed by α helix and/or disordered structures. The conformational 
changes that lead to βsheets formation, typical of disordered proteins, promote 
Aβ oligomers formation.  
Kinetic studies demonstrated that Aβ monomers misfolding anticipate 
oligomerization and constitutes the core for fibrils growth.  
The process for fibrils formation can be divided in two steps: a nucleation 
phase and an elongation phase. 
The nucleation phase involves Aβ42 monomers self-association, a process 
that is thermodynamically unfavoured.  
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Then follows a rapid enhancement phase in which oligomers are converted to 
proto-fibrils and finally mature fibrils.  
Fibrils formation can be kinetically represented by a sigmoid with an initial 
latent phase followed by a rapid growth and a final plateau [Kumar S et al., 
2011] (Figure 1.6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Polymerization model of Aβ: kinetic curve of fibrils formation (green) and the same 
kinetic curve with a shorter latency phase because of pre-formed seeds addition (red) 
(modified from [Kumar S et al., 2011]). 
 
1.2.3.1 Aβ oligomers 
Even though Aβ fibrils inside senile plaques have been proposed as the 
cause of AD for a long time, recent evidences suggest that intermediate 
oligomeric forms (AβOs) are the toxic factors [Verma M et al., 2015] 
(Figure 1.7).  
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Figure 1.7 AD-associated changes attributed to Aβ oligomers (modified from [Viola KL 
and Klein WL, 2015]). 
 
The levels of soluble AβOs in human brain seem to correlate better with 
the severity of the disease than amyloid plaques do. Moreover, fibril-free 
AβOs solutions are fundamental for memory loss, while fibrillary Aβ is not 
the active form affecting cognition [da Rocha-Souto B, et al., 2011; Brito-
Moreira J et al., 2017].  
The exact localization of AβOs is not fully clear, but there is convincing 
evidence of both intracellular and extracellular localizations. In particular, 
extracellular membrane-associated AβOs are observable at early stages 
of AD, but intraneuronal AβOs appear prior to extracellular plaques 
formation. It seems that there could be a dynamic exchange between the 
two spaces [Mroczko B et al., 2018].  
AβOs formation starts with alterations in the conformation of the monomer, 
resulting in low molecular weight (LMW) dimers and trimers that 
accumulate further monomers to form high molecular weight (HMW) 
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oligomers. These different conformations may be different also in their 
production’s pathway or toxicity [Ladiwala AR et al., 2012]. 
A specific neurotoxic function was attributed to the dodecamer called 
Aβ*56. Lesnè and colleagues found an inverse relationship between the 
level of Aβ*56 and memory performance in Tg2576 mice. They also 
demonstrated that injection of young rats with Aβ*56 purified from impaired 
mice was able to disrupt memory [Lesnè S et al., 2006]. Another study 
demonstrated that Aβ*56 interacts with NMDARs in cultured neurons, 
increasing intracellular calcium influx and activating phosphorylation and 
missorting of tau protein [Amar F et al., 2017].  
The toxicity of AβOs has been correlated with the direct or indirect action 
on specific receptors associated with intracellular cascades, with the 
formation of intramembrane pores with ionic channel functions, or with 
non-specific perturbation of both the intra- and extracellular membrane 
dynamics [Forloni G et al., 2016].  
Numerous candidates have been proposed as receptors for AβOs, and are 
summarized in Figure 1.8.  
 
 
 
 
 
 
 
 
Figure 1.8 Proposed receptors for AβOs (modified from [Mroczko B et al., 2018]). 
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1.2.4 sAPPα 
The sAPPα soluble fragment is a product of APP processing through the non-
amyloidogenic pathway, operated by the α-secretase enzyme. The role of this 
fragment has been investigated over the years in order to evaluate its 
physiological role in the brain and its contribution to neurodegeneration and 
AD pathology (Figure 1.9). 
 
Figure 1.9 Functions of sAPPα during three time-points of life: development, young adult, 
ageing/neurodegeneration (modified from [Corbett NJ and Hooper NM, 2018]). 
 
sAPPα has been shown to have a neuroprotective role in the adult brain and 
during ageing or neurodegeneration. In fact, it is able to promote neuronal 
growth and synaptogenesis [Mattson MP, 1997] and to reduce the production 
of Aβ by modulating the activity of BACE1 in cellular and in vivo models 
[Obregon D et al., 2012]. The viral gene transfer of sAPPα directly in the brain 
preserved synaptic loss, rescued memory impairment and decreased Aβ 
levels in a mouse model of AD [Fol R et al., 2016]. A link between sAPPα and 
tau has been estabilished both in vitro and in vivo: the protein was able to 
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decrease phosphorylated tau via glycogen synthase kinase 3β (GSK-3β) 
activity modulation [Deng J et al., 2015]. Several published data 
demonstrated that sAPPα production is stimulated by low cholesterol or 
inhibition of cholesterol biosynthesis [Kojro E et al., 2010]. The mechanisms 
of action of sAPPα in brain are still to be fully elucidated, but some hypotheses 
have been raised, as for example its involvement in NMDA receptors functions 
[Taylor CJ et al., 2008] or its binding to p75 neurotrophic receptor [Hasebe N 
et al., 2013]. 
A recent work demonstrated that sAPPα functions as ligand for the GABABR1a 
receptor to modulate synaptic transmission and plasticity [Rice H et al., 2019]. 
Besides these protective effects, too high levels of sAPPα can cause it to 
behave like a tumorigenic molecule [Nhan HS et al., 2015]. In addition, some 
studies suggested the importance of maintaining balanced levels of sAPPα 
during brain development as an excessive increase could be detrimental for 
synaptic plasticity functions [Pasciuto E et al., 2015]. This suggest that the 
timing, but also the amount of the protein, is critical at the synaptic level.  
 
1.2.5 sAPPβ 
 
The soluble fragment sAPPβ is the product of amyloidogenic processing 
operated by BACE-1. Although sAPPα and sAPPβ differ just from 16 amino 
acids, sAPPβ lacks most of the neuroprotective effects of sAPPα. The 
neuroprotective effects of sAPPβ against glucose deprivation, excitotoxicity, 
and Aβ peptide are 50- to 100-fold less potent [Furukawa et al, 1996]. In 
contrast with sAPPα, sAPPβ is not involved in LTP, suggesting that the last 16 
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C-terminal amino acids of sAPPα protein are involved in both neuroprotection 
and LTP [Taylor CJ et al., 2008].  
A recent study suggested that sAPPβ could be cleaved to generate an N-
terminal fragment. The N-terminal fragment can bind death receptor 6, 
activating caspase 6 which leads to further stimulation of axonal pruning and 
neuronal cell death [Nhan HS et al., 2015]. 
Overall, the functions that are related to the common domains of the two sAPP 
fragments are identical and are not affected by differences in the amino acidic 
sequence. This suggest that sAPPβ cannot be deleterious per se, and 
therapeutic strategies for AD that target Aβ cleaving enzymes should aim to 
modulate rather than inhibit Aβ generation [Chasseigneaux and Alliquant, 
2012].  
 
1.2.6 TAU PROTEIN 
 
Tau protein is a microtubule-associated protein, which is abundant in neurons 
of the central and peripheral nervous system of vertebrates. It is part of a family 
called MAP (microtubules-associated proteins) and was isolated and co-
purified for the first time in 1975 with tubulin, a component of microtubules, 
which are involved in maintaining neuronal morphology and play a 
fundamental role in cellular trafficking.  
The gene that encodes tau protein is located on chromosome 17, and in the 
human brain there are six different isoforms of the protein, generated by 
alternative splicing [Bakota L et al., 2016].  
Tau is a naturally unfolded protein with a high solubility under physiological 
conditions. To be susceptible to aggregation, tau must undergo a series of 
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post-translational modifications and conformational changes. In general, tau 
aggregation starts with its hyperphosphorylation, and when this happens the 
protein detaches from the microtubules and switches to a compact structure 
called “Alz50 state”. This aggregated state allows subsequent aggregation to 
form fibrillar structures. Furthermore, thanks to proteolytic cuts, a fragment 
called Tau-66 assembles into aggregates much faster than the native form. 
NFTs that originate at the end of this process are mostly formed by paired 
helical filaments (PHF-tau) [Lim S et al., 2014]. 
The formation of such aggregates is not typical of AD alone, but can be 
observed in other disorders that can be called “tauopathies”.  
It is now well known that Glicogen Synthase Kinase 3 (GSK-3) uncontrolled 
activation is involved in tau pathologic hyperphosphorylation (Figure 1.10).  
 
 
 
 
 
 
 
 
 
Figure 1.10 Structure of microtubules and phosphorylation sites of tau protein. Tau 
hyperphosphorylation by GSK3 causes the destabilization of microtubules, followed by the 
detachment of Tau and its self-aggregation (modified from [Barage SH et al., 2015]).  
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GSK-3 is over-expressed in AD patients’ brain and directly contributes to NFTs 
increase. For this reason, the enzyme has been studied as a specific 
pharmacological target for AD treatment [Gameiro I et al., 2017]. 
Abnormally phosphorylated tau was observed in selected subcortical areas 
long before its presence in the cerebral cortex, which could indicate that 
disease-like phosphorylation occurs already in early, preclinical disease states 
[Attems J et al., 2012]. In addition, tau is subjected to various other post-
translational modifications including O-glycosylation, ubiquitination, 
methylation and acetylation. Interestingly, tau acetylation at Lys174 has been 
recently identified as an early modification in brains from patients with AD, 
which slowed down tau turnover in a mouse model and promoted tau 
aggregation [Min SW et al., 2015].  
Figure 1.11 shows how the ACH can be influenced by tau pathologic features. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 The modified ACH where Aβ oligomers induce the synaptic changes, dendritic 
simplification and neuronal death via tau dependent and independent mechanisms (modified 
from [Bakota L and Brandt R, 2016]).  
46 
 
1.2.7 NEUROINFLAMMATION  
 
Neuroinflammation has been evident in AD patients since the disease was first 
described by Alois Alzheimer. Clusters of both reactive microglia and 
astrocytes migrate to and surround amyloid deposits in the brain of post-
mortem AD samples. 
Neuroinflammation in AD is considered as a double-edged sword where the 
immune cells of the brain exert beneficial effects by degrading Aβ deposits, as 
well as adverse effects by producing cytotoxic mediators that exacerbate Aβ 
deposition resulting in neuronal dysfunction [Bhaskar M, 2016].  
The two major players of the neuroinflammatory response in AD context are 
astrocytes and microglia (Figure 1.12).  
 
Figure 1.12 Possible role of microglia and astrocytes in AD pathology mediated by 
neuroinflammatory cytokines (modified from [Ahmad MH et al., 2019]). 
 
Microglia are the brain’s resident immune cells and are found throughout the 
brain, spinal cord, retina and optic nerves but mainly in the hippocampus and 
substantia nigra.  
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During AD progression, microglia respond to various stimuli, including amyloid 
beta peptides and NFTs [Czeh M et al., 2011]. 
It is the delicate balance between the neurotoxic and neuroprotective features 
that determines the role of microglial cells in AD onset and progression. In their 
resting form, they act on neurogenesis, synaptic pruning and neuroprotection 
[Sierra A et al., 2010; Vinet J et al., 2012], but their prolonged over activation 
leads to an ineffective Aβ clearance, resulting in a pro-inflammatory state 
[Hickman SE et al., 2008]. Activated microglia produce and secrete several 
mediators that contribute to AD pathogenesis [Cai Z et al., 2014].  
Astrocytes located in the CNS support the endothelial cells of the blood-brain-
barrier (BBB), maintain ion balance, and provide nutrients to neurons [Morales 
I et al., 2014]. Like microglia, astrocytes release cytokines, ILs, NO, and other 
potential cytotoxic molecules after exposure to Aβ, thereby exacerbating the 
neuroinflammatory response. Astrocytes damage and dysfunctions between 
astrocytes and the surrounding neurons can destroy the synaptic homeostasis, 
and initiate the cascade for neuronal injury [Avila-Muñoz E and Arias C, 
2014]. Above all, During AD pathology, astrocytes start to express BACE-1, 
thus acquiring Aβ producing ability [Rossner S et al., 2005].  
With the fact that Aβ accumulation is a potent glial activator, astrocytic and 
microglial activation could be an early event in the pathologic process, 
occurring even in the absence of Aβ deposition. A possible mechanism for 
activated astrocytes and microglia during AD pathology is described in Table 
1.2 [Ahmad MH et al., 2019].  
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Table 1.2 The impact of microglia and astrocytes in AD pathogenesis mediated by pro-
inflammatory cytokines (modified from [Ahmad MH et al., 2019]). 
 
1.2.8 OXIDATIVE STRESS 
 
In the brain, the free energy necessary to drive most cellular reactions derives 
from aerobic glucose oxidation. Oxidative stress is associated with increased 
production of reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) such as O2-, H2O2, NO, HO-, ONOO-, and the major contributors of this 
overproduction are mitochondria. Under normal conditions, ROS levels are 
regulated by antioxidant enzymes such as superoxide dismutase (SOD), 
catalase and glutathione peroxidase (GPX), and transcription factors as Nrf2, 
which stimulates the transcription of cytoprotective genes and antioxidant 
enzymes and proteins [Denzer I et al., 2016].  
In AD, the balance between ROS production and antioxidant defence is 
impaired, and there is evidence that mitochondrial damage, resulting in ROS 
overproduction, contributes to the early stage of AD prior to the onset of 
symptoms and Aβ pathology [Uttara B et al., 2009].  
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Several data demonstrate that in addition to mitochondrial ROS production, 
abnormal homeostasis of bioactive metals including iron (Fe), copper (Cu), 
zinc (Zn), magnesium (Mg), manganese (Mn) and aluminium (Al) could be 
involved in free radical production and oxidative stress influencing Aβ and Tau 
aggregation [Greenough MA et al., 2013; Wang P and Wang ZY, 2016]. 
There is a tight connection between protein misfolding, aggregation, and metal 
ion homeostasis. For example, Zn affects APP processing by binding to the 
protein, and Al, Fe, Zn, and Cu directly bind Aβ promoting its aggregation 
[Lammich S et al., 1999; Tougu V et al., 2008; Mantyh PW et al., 1993]. 
Similarly, the redox metals could stimulate Tau phosphorylation, its 
detachment from microtubules and NFTs deposition [Sayre LM et al., 2000]. 
In addition, a direct binding of Aβ with Fe or Cu has been shown to generate 
H2O2, contributing to oxidative stress increase and extra-mitochondrial ROS 
production [Huang X et al., 1999]. Another source of ROS production directly 
mediated by Aβ involves microglia activated in the brain in response to 
extracellular amyloid deposition. 
Furthermore, evidences in animal models of AD and humans suggested a 
direct relationship between oxidative stress, Aβ deposition and Tau 
phosphorylation, where pTau affects the activity of mitochondrial complex I, 
contributing to Aβ-mediated dysfunction and ROS production [Mondragon-
Rodriguez S et al., 2013].  
All these data suggest that altered mitochondria, oxidative stress, impaired 
antioxidant defence, production of Aβ and pTau, which ultimately influence 
mitochondrial dynamics and ROS production, could lead to a “vicious cycle” 
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that with time exacerbates the pathologic process, leading to neuronal loss, as 
illustrated in Figure 1.13 [Tönnies E and Trushina E, 2017].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13 Multiple cellular pathways and systems are affected by ROS, exacerbating ROS 
production, accelerating cellular damage, and leading to synaptic dysfunction (modified from 
[Tönnies E and Trushina E, 2017]). 
 
1.2.9 IN VITRO MODELS TO STUDY AD PATHOGENESIS 
Thanks to research progresses during the past years, several 2D and 3D cellular 
models have been proposed to study AD, combining standard culture methods 
with new technological platforms such as microfluidic systems and scaffolds 
[Ranjan VD et al., 2018]. 
AD in vitro models are usually obtained by AD-related genes transfection or 
treatment with synthetic compounds such as Aβ peptides. Among different types 
of cell cultures useful for this aim there are: 
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- Cell lines or primary neurons 
- Induced pluripotent stem cells (iPSCs)  
- 3D culture platforms 
Cell lines, such as neuroblastoma SH-SY5Y cells, or primary neurons are the 
most common in vitro approach for analysing mechanisms underlying AD. Even 
though this approach is cheap and easy to carry out, there are some limitations, 
as the cultured cells are susceptible to variations in genetic or physiologic 
features that do not allow accurate reproducibility and disease modelling 
[Horvath et al., 2016]. In addition, the use of rodent cultures is limited by their 
differences in pathological pathways compared to human cells.  
The discovery of iPSCs in 2006 opened up a new frontier in in vitro research and 
neurodegenerative disease modelling [Takahashi and Yamanaka, 2006], 
converting adult human cells into pluripotent stem cells that can be potentially 
differenciated in every cell type. This technology overcame the limits of the use 
of murine cells and tumor-derived cell lines, but it raised also ethical concerns of 
the use of human embryonic stem cells (hESCs).  
A number of 2D Alzheimer’s disease models have been developed using iPSCs 
technology, and are listed in Table 1.3. 
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Table 1.3 A list of some 2D cellular models of different AD forms, developed using iPSCs 
techniques, with their features of disease modelling (modified from [Ranjan VD et al., 2018]). 
 
Despite their advantages, some limitations of iPSCs are to be considered, such 
as their heterogeneity, the variability in differentiation protocols used by different 
groups but also the inability of mimicking mature neurons and form complex 
neuronal networks present in in vivo conditions [Arber et al., 2017; Jorfi et al., 
2017]. 
3D cultures that can host both cell lines and iPSCs, offer different advantages 
over 2D approaches, especially in terms of cell adhesion, communication, 
proliferation and mechanotrasduction. Realizing 3D microenvironment is of vital 
importance for neurodegeneration modelling, allowing cell-to-cell interactions (i.e 
neurons-glial cells or neurons-neurons) and spatial configuration of cellular 
networks [Ko KR and Frampton JP, 2016]. The main 3D AD models are explant 
cultures, self-assembled aggregates, scaffold cultures and microfluidic organ-on-
chip cultures [Ranjan VD et al., 2018], presented in Figure 1.14. 
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Figure 1.14 Four technologies for 3D AD modelling: explant culture, self-assembled aggregates, 
scaffolds and microfluidic organ-on-chip system.  
 
1.2.10 MOUSE MODELS TO STUDY AD PATHOGENESIS 
 
Mouse models continue to play a pivotal role in AD research, taking advantage 
of their low cost, small size, high birth rate and easy maintenance.  
Given the lack of an etiology of idiopathic AD, the majority of animal models 
have relied on the utilization of genetic mutations associated with FAD, with 
the rationale that the events downstream of the initial trigger are quite similar. 
Although no single mouse model recapitulates all of the aspects of the disease, 
each model can be useful for the analysis of one or two components of the 
disease [LaFerla FM and Green KN, 2012].  
It has been observed that the higher the number of mutations, the faster is Aβ 
production and accumulation [Cavanaugh SE, 2014]. 
Since 1995, several models overexpressing APP with FAD-related mutations 
have been developed, such as the Tg2576, the APP23, and the PDAPP lines. 
All these models overexpress APP with consequent overproduction of Aβ40 
and Aβ42, and show human AD particular features such as amyloid plaques, 
gliosis, synaptic damage, LTP and memory impairment, with an average onset 
of symptoms between 9 and 12 months of age [Puzzo D et al., 2015].  
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The onset of the AD phenotype occurs earlier (from 3-4 months of age) in 
double Tg mice where the mutated APP is co-expressed with mutated PS1 or 
PS2 (M146L or M146V variants) [Trinchese S et al., 2004]. However, these 
mice do not show some aspects of the disease such as neuronal loss and tau 
deposition.  
Oddo and collegues generated mice harbouring 3 different mutations, the 
3xTg-AD model (APPSwe, PS1 M146V, tauP301L) [Oddo S et al., 2003], with 
Aβ pathology that precedes tau pathology with NFTs formation, LTP and 
memory impairment, and neuroinflammation.  
There is also a 5xTg model (APP Swedish, Florida and London mutations, and 
PS1 M146L/L286V mutations) which presents, above other AD signs, neuronal 
loss in the cortical area [Jawhar S et al., 2012]. 
An overview of the progression of AD features in commonly used mouse 
models is represented in Figure 1.15. 
 
 
 
 
 
 
 
 
 
Figure 1.15 Onset and progression of AD features in three Tg mouse models (single APP 
Tg2576, double APP/PS1, triple 3xTg) and in a physiological model of ageing (modified from 
[Puzzo D et al., 2015]). 
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Finally, a list of advantages and limitations of in vivo and in vitro AD models is 
described in Table 1.4, underlyning that none of the proposed approaches is 
able by itself to recapitulate AD pathological picture. 
 
 
 
 
 
 
 
 
 
Table 1.4 Advantages and limitations of in vitro and in vivo AD modelling approaches (modified 
from [Ranjan VD et al., 2018]). 
 
 
1.3 AD treatment strategies 
Nowadays, the available treatments for AD are symptomatic, and can only 
delay the need for the patient to be placed in a nursery home. In addition, the 
last FDA approved New Chemical Entity (NCE) for AD treatment, Memantine, 
dates back to 2003, as most of the “disease-modifing drugs” under study are 
still in clinical phase or failed the experimentation [Atri A, 2011; Small GW et 
al., 2015]. 
 
 
56 
 
1.3.1 CURRENT THERAPIES 
 
Current drugs for AD treatment act on the main nervous transmission systems 
that appear altered in the disease, the cholinergic and glutamatergic systems. 
To that, is generally added a support therapy with antidepressants and 
antipsychotics.  
The most prescribed symptomatic treatment is based on acetylcholinesterase 
(AchE) inhibitors: tacrine, donepezil, rivastigmine and galantamine. These 
molecules reduce Ach degradation inhibiting its degrading enzyme. Ach 
increase in the synapses leads to cholinergic stimulation in the post-synaptic 
compartment and memory and learning improvement [Colović MB et al., 
2013].  
An excess of extracellular glutamate because of an increased release and 
decreased reuptake also characterizes AD, causing continuous stimulation of 
post-synaptic NMDA receptors [Revett TJ et al., 2013]. Memantine is a non-
competitive antagonist of NMDA receptor and acts blocking its open 
conformation. Memantine treatment showed an improvement of learning, 
psychiatric symptoms and the general clinical features of the patient [Anand 
R et al., 2014]. 
 
1.3.2 NEW THERAPEUTIC TARGETS 
 
The scientific confirmation of the value of the ACH evidenced new possible 
therapeutic targets. One of these consists in increasing the non-amyloidogenic 
processing of APP. For example, BACE1 inhibitors as Verubecestat (MK-
8931), showed sAPPβ, Aβ40 and Aβ42 reduction in the brain and CSF of 
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treated monkeys and rats, and reached the clinical phase after promising 
results obtained also in human patients [Kennedy ME et al., 2016], but 
unfortunately the trial was stopped due to lack of efficacy.  
The possible strategy to inhibit γ-secretase is limited by important side effects 
because of cross-interaction of the drug with other enzymes. In particular, the 
inhibitor Semagacestat showed plasmatic Aβ reduction together with some 
side effects on gastrointestinal tract and immune system [Doody RS et al., 
2015]. 
Nevertheless, it was observed that some NSAF are able to counteract Aβ42 
production inhibiting γ-secretase with minor side effects [Tayeb HO et al., 
2012]. 
Also tau protein is directly involved in AD pathogenesis, and several studies 
focused on its hyper phosphorylation prevention. This abnormal modification 
is catalysed in part by GSK-3β.  
GSK-3β over-expression in mice causes tau hyper phosphorylation, while 
treatment with litium, a specific GSK-3β inhibitor, attenuates tau 
phosphorylation and blocks tau-induced neurodegeneration [Engel T Goñi-
Oliver P et al., 2006]. 
Recently, a new compound able to inhibit GSK-3β and to induce Nuclear factor 
erythroid 2–related factor 2 (NRF2) has been tested. NRF2 is a transcription 
factor involved in anti-oxidant response and protects from oxidative damage. 
The tested compound showed an interesting role in neuroprotection of in vitro 
oxidative stress and AD models [Gameiro I et al., 2017].  
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1.3.2.1 The multi-targeted approach 
As AD is a complex and multifactorial disease, in the last few years the 
“one-molecule, one-target” paradigm has been exceeded by the new 
“multi-targeted” approach. This strategy can be based on two concepts: 
- The Multi-target Directed Ligand (MTDL) approach, that aims to find 
a compound or a hybrid that is effective in treating complex diseases 
interacting with the multiple targets responsible for its pathogenesis 
[Cavalli A et al., 2008].  
- The Combination-drugs-multi-targets (CDMT) approach, that it a 
combination of different drugs that could act on different targets being 
complementary, or act on the same targets giving synergistic or additive 
effects.  
The MTDL strategy has now been incorporated in routine therapeutic drug 
design, and a considerable number of compounds have been described in 
the last 10 years, basing on this therapeutic approach [Oset-Gasque MJ 
and Marco-Contelles J, 2018].  
In fact, as an example, the limited success of AChE inhibitors is because 
by improving cognitive, behavioral, and functional impairments, they seem 
unable to address the molecular mechanisms that underlie the pathogenic 
processes [Cavalli A et al., 2008].  
Some of the published MTDL strategies are described below.  
Jeřábek and colleagues combined the structural features of the AChE 
inhibitor tacrine with that of resveratrol, which is known for its antioxidant 
and anti-neuroinflammatory activities. They found that hybrid compounds 
inhibited human AChE, effectively modulated Aβ self-aggregation in vitro, 
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and exerted anti-inflammatory and immuno-modulatory properties in 
neuronal and glial AD cell models [Jeřábek J et al., 2016].  
Another recent work reported the activity of hybrid compounds directed to 
AChE inhibition, nicotinic receptors stimulation and Aβ aggregation 
inhibition [Simoni E et al., 2017].  
Yan and colleagues fused donepezil and curcumin structures and tested 
their AChE inhibition, amyloid-β aggregation inhibition and antioxidant 
effect with great results [Yan J et al., 2017].  
Another compound developed under fusion of GSK-3β inhibitors and 
NRF2 inducers showed an interesting neuroprotective effect on 
inflammation, oxidative stress and neuronal death [Gameiro I et al., 
2017].  
Another growing approach consists of the development of BACE-1-
centered compounds with a more complex mechanism of action to target 
different AD-related pathways [Prati F et al., 2018]. 
Finally, some other multi-target agents have been discovered without the 
fusion of two specific structures, as Quinti and colleagues did on HD 
models. They identified a novel thiazole-containing compound with SIRT2 
inhibition and NRF2 induction properties, highlighting the potential 
combinatorial therapeutic effect of multi-targeted agents not only for HD, 
but also for other neurodegenerative diseases [Quinti L et al., 2016]. 
Several studies have also been developed under the CDMT hypothesis.  
As an example, there are some clinical trials where the combination 
therapy consists in AchE inhibitors and memantine administration 
[Matsunaga S et al., 2014]. Another study reported the beneficial role of 
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the combination of galantamine and cilostazol on cognition and daily living 
functions in AD patients with cerebrovascular disease [Hishikawa N et al., 
2017]. 
Moreover, a preclinical study on an AD mouse model revealed that the 
combination of octyl gallate and ferulic acid improved neurodegeneration 
and cognition [Mori T et al., 2017]. Another group reported that a 2-week 
leptin and pioglitazone acute combined treatment resulted in cognitive, 
synaptic and amyloid-related improvement in a transgenic mouse model 
[Fernandez Martos CM et al., 2016]. 
 
1.3.3 INNOVATIVE THERAPEUTIC STRATEGIES 
 
Several non-conventional approaches are actually under study to counteract 
AD progression, and among them, we can mention immune therapy, cell-
based therapy, and drug-delivery systems (DDS). 
 
1.3.3.1 Immune therapy 
 
Immune therapy is focused on Aβ clearance to prevent toxic oligomers 
accumulation. It consists in Aβ peptide or part of it exposure, to stimulate 
immune response (active immunization), or alternatively to administer a 
specific monoclonal antibody against Aβ (passive immunization) [Evin G, 
2016]. However, this approach has actually strong limitations; for example, 
the monoclonal antibody CAD106, used in a phase III clinical trial, showed 
serious side effects in 24.5% of patients and his approval was discontinued 
[Vandenberghe R et al., 2016]. 
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1.3.3.2 Cell-based therapy 
 
Cell-based therapies consists in implantation of new cells in damaged 
brain areas, to support resident neurons with neurotrophic factors and to 
create new neuronal networks. Stem cells are undifferentiated cells able 
to divide and originate several cellular subtypes. 
Different types of stem cells are under study for this application, such as 
embryonal stem cells (ESC), mesenchymal stem cells (MSC), induced 
pluripotent stem cells (iPSC) and neural stem/progenitor cells (NPSC).  
In animal models, stem cells were able to reduce the astrogliosis and the 
pro-inflammatory microglia in favour of anti-inflammatory microglia and 
nonreactive astrocytes, thus inhibiting the amyloid cascade through a 
more efficient Aβ degradation. Moreover, these effects resulted in 
enhanced synaptogenesis, neuronal repair and increased neurotrophic 
factors secretion [Li XY et al., 2015; Choi SS et al., 2016; Shen Z et al., 
2017].  
Bone marrow-derived MSC transplant in an AD mouse model promoted 
functional recovery and trophic factors production, which induced survival 
and regeneration of host neurons [Huang B et al., 2012].  
Adult mouse NSC transplant in the hippocampus of AD transgenic mice 
ameliorated the migration and differentiation of endogenous NSC into 
different brain cell types, and led to lifespan and memory functions 
improvement [Yamasaki TR et al., 2007]. 
However, cell-based therapies are source of concerns because of immune 
rejection and tumor development. iPSC, obtained by somatic cells re-
programming, constitute a valid alternative in this sense. They have not 
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immunological complications, but as the ESC, there is a risk of 
tumorigenesis in in vivo transplant [Jung YW et al., 2012]. 
ESC-derived NPC implantation in an AD mouse model ameliorated 
cognitive functions and preserved neuronal phenotype. In addition, 40% of 
ESC showed a cholinergic phenotype after transplant, and no tumor 
formation, indicating that this approach could be safer [Moghadam FH et 
al., 2009]. 
Several clinical trials have been recently developed and two of them 
reached completion. Nine trials are still ongoing taking advantage of the 
use of different types of stem cells, assessing safety, MRI and CSF 
parameters [Wang SM et al., 2019]. A completed phase I study 
demonstrated the short-term and long-term safety of hippocampal 
intracranial injection of HUC-MSCs in patients with amyloid pathology 
[Kim HJ et al., 2015].  
 
1.4 Sirtuins  
Sirtuins (SIRTs) are a family of NAD-dependent enzymes homologues to Sir2 
protein, identified for the first time in yeast. MAR1 gene (Mating-type Regulator 
1) was identified in Saccaromyces Cerevisiae and subsequently renamed 
Silent Information Regulator 2 (Sir2) due to its ability to silence target genes 
[Klar AJ et al., 1979]. The first studies on S. Cerevisiae discovered that the 
presence of a supplementary copy of Sir2 gene increased survival by 50%, 
whereas its deletion significantly reduced it [Kaeberlein M et al., 1999]. Sir2 
promotes yeast longevity suppressing toxic extra-chromosomal rDNA circles 
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(ERCs) formation [Sinclair DA et al., 1997]. Subsequent studies 
demonstrated that Sir2 homologues of other species can also regulate 
survival.  
Seven SIRTs, named SIRT1-7, have been identified in mammals, and are 
classified as Class III Histone Deacetylases (HDACs). Every SIRT is 
characterized by a conserved 275 amino acids catalytic core, with a C-terminal 
and a N-terminal domain of variable length, differentiating the members of the 
protein family (Figure 1.16).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.16 Structural representation of mammalian SIRTs, with the catalytic domain (CD) in 
green (modified from [Hou X et al., 2016]). 
 
1.4.1 FUNCTIONS AND LOCALIZATION OF SIRTUINS 
 
The main activity of SIRTs is the deacetylase one, where there is the removal 
of an acetyl group from the N-ε-lysine residues of the substrate. Landry and 
colleagues first described the mechanism of this catalytic reaction in 2000, and 
demonstrated that lysine deacetylation is coupled with the formation of a 
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product, the O-Acetyl-ADP ribose (OAADPr), and a nicotinamide (NAM) 
molecule [Landry J et al., 2000] (Figure 1.17). 
Some SIRTs, like SIRT4 and SIRT6, have also a mono-ADP-
ribosyltransferasic activity, where an ADP-ribose molecule is transferred from 
a NAD+ to a substrate protein, producing a NAM molecule and a mono-ADP-
ribosylated protein [Sauve AA et al., 2006].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.17 Protein deacetylation reaction of SIRTs. Since cells cannot afford to lose NAD+ 
after each sirtuin reaction, they operate an enzymatic mechanism to reuse NAM to re-generate 
NAD+ (modified from [Anamika et al., 2019]). 
 
Since SIRTs are NAD-dependent enzymes, there is a tight correlation between 
their enzymatic activity and the energetic and metabolic state of the cell. NAM 
can operate, at high concentrations, a negative feedback on SIRTs activity by 
binding in a non-competitive manner, while the OAADPr seems to be a signal 
mediator in the cell [Michan S and Sinclair D, 2007]. 
SIRT1, SIRT2 and SIRT3 have strong deacetylase activity, which is weaker 
for SIRT4, SIRT5 and SIRT6. In addition, SIRT4 and SIRT6 have the mono-
65 
 
ADP-ribosyltransferasic activity. SIRT7 activity is still under study [Lalla R and 
Donmez G, 2013].  
The function of SIRTs reflects their sub-cellular localization.  
SIRT1 is predominantly localized in the nucleus, where it deacetylates H3 and 
H4 histones and transcription factors. In an oxidative stress condition, a 
possible translocation of SIRT1 from the nucleus to the cytoplasm has been 
reported [Pfister JA et al., 2008].  
SIRT2 resides predominantly in the cytoplasm, where is associated to 
microtubules and deacetylates α-tubulin to regulate microtubules dynamics. 
When the nuclear membrane disrupts during mitosis, SIRT2 is able to migrate 
in the nucleus and deacetylate H4 histone favouring chromatin condensation 
[Vaquero A et al., 2006].  
SIRT3, SIRT4 and SIRT5 are mitochondrial sirtuins and have an important role 
in cellular energetic metabolism and oxidative stress response. 
SIRT6 and SIRT7, like SIRT1, are nuclear proteins. In particular, SIRT6 is 
associated to heterochromatin, while SIRT7 is localized in the nucleolus, 
where it is involved in RNA polymerase I activation and DNA-association 
[Pfister JA et al., 2008]. 
In addition, other non-histone target proteins have been identified, which are 
substrate of SIRTs activity, as p53, NF-κB and FOXOs [Jęśko H et al., 2017] 
(Table 1.5).  
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Table 1.5 Localization and main targets of SIRTs (modified from [Mohamad Nasir NF et al., 
2018]). 
 
Different works highlighted the involvement of SIRT1 and SIRT2 in AD, with 
mRNA or protein expression decrease and increase, respectively, observed in 
AD human brains (Fig. 1.18). This led to stimulation of a lot of research for 
potential therapeutic strategies targeting these two proteins, while the 
involvement of other members of the family, with exception of SIRT3, is still 
poorly elucidated. 
 
                 
Figure 1.18 Changes in human brain levels of various sirtuins in the course of AD. 1 mRNA 
expression. 2 Negative (SIRT1, SIRT3) and positive correlation (SIRT5) of hippocampal 
immunoreactivity with pathological staging (modified from [Jęśko H et al., 2017]). 
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1.4.2 SIRT1  
 
SIRT1 human gene is located on chromosome 10. The protein is abundantly 
expressed in adipose tissue, liver, skeletal muscles and pancreas. In the brain, 
SIRT1 is present at high neuronal level in cerebral cortex, hippocampus, 
hypothalamus and cerebellum [Ramadori G et al., 2008]. Among all 
mammalian sirtuins, SIRT1 has been the most extensively studied due to its 
beneficial roles in energy metabolism by mediating caloric restriction (CR), 
arising the hope of extending human lifespan. SIRT1 is implicated in the 
regulation of multiple biological phenomena, including DNA damage repair, 
mitochondrial biogenesis, insulin secretion, stress response, apoptosis and 
genome stability (Figure 1.19).  
In the white adipose tissue, SIRT1 promotes lipolysis and fatty acids 
mobilization with fasting state, and suppresses nuclear peroxisome 
proliferator-activated receptor gamma (PPAR-γ) activity, thus decreasing 
adipogenesis [Picard F et al., 2004].  
In the liver, SIRT1 controls glucose production, fatty acids oxidation and 
cholesterol levels. During fasting, SIRT1 stimulates gluconeogenesis and 
suppresses glycolysis [Purushotham A et al., 2009]. The main targets of 
SIRT1 activity in the liver are PGC-1α, PPAR-γ, and LXRα, all involved in 
glucose and lipids metabolism.  
SIRT1 is considered a pro-survival factor because it mediates p53 
deacetylation preventing its transcriptional activity, and counteracts apoptosis 
in response to oxidative stress and DNA damage. Another SIRT1 target is NF-
κB whose deacetylation reduces inflammatory responses.  
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Besides blocking apoptosis, SIRT1 increases cell survival through regulation 
of FOXOs transcription factors [Michan and Sinclair, 2007]. SIRT1 
deacetylates FOXO1, promoting the transcription of target genes involved in 
gluconeogenesis [Donmez G and Outeiro TF, 2013].  
 
Figure 1.19 SIRT1 plays different roles in different molecular pathways including neuronal 
protection, inflammation, stress resistance, mitochondrial biogenesis, fatty acid oxidation and 
mobilization, insulin secretion, glucose production and lipid homeostasis (modified from 
[Donmez G and Outeiro TF, 2013]). 
 
1.4.2.1 SIRT1 in neurodegeneration and AD 
 
SIRT1 is highly expressed in those brain regions susceptible to 
neurodegeneration processes (basal ganglia, hippocampus and prefrontal 
cortex), and is predominantly present in neurons [Donmez G. and Outeiro 
TF, 2013].  
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There are many evidences that reported a role of SIRT1 in 
neurodegeneration processes related to AD (Fig. 1.20).  
It has been observed a reduction in SIRT1 mRNA and protein levels with 
progression of AD stages, a condition that was also mimicked on SHSY5Y 
neuroblastoma cells treated with Aβ peptide [Julien C et al., 2009; 
Lattanzio F et al., 2016]. 
 
Figure 1.20 Some of the molecular mechanisms of SIRT1 in Alzheimer’s disease and 
consequences of reduced SIRT1-dependent effects due to AD progression (modified 
from [Jesko H, et al., 2017]).  
 
The first studies on CR verified that SIRT1 over-expression reduced AD 
pathology [Imai S and Guarente L, 2010], and SIRT1 pharmacological 
activation with resveratrol reduced Aβ-induced cell death and decreased 
cognitive impairment in a mouse model of FAD [Porquet D et al., 2014].  
SIRT1 shifted the balance between amyloidogenic and non-amyloidogenic 
APP metabolism up-regulating the α-secretase ADAM10 and down-
regulating the expression of the β-secretase BACE1 possibly through 
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inhibition of NF-κB and activation of the retinoic acid receptors [Tippman 
F et al., 2009; Gao R et al., 2015; Lee HR et al., 2014]. 
Another study demonstrated that treadmill exercise inhibited Aβ 
production via SIRT1 activation in AD mice, and favoured the non-
amyloidogenic pathway [Koo JH et al., 2017]. In vitro SIRT1 over-
expression reduced Aβ oligomerization and oxidative stress [Wang J et 
al., 2010], while its activation with resveratrol in a cellular AD model was 
able to reduce astrocytes and pro-inflammatory mediators such as Nfkb-
p65 [Scuderi C et al., 2014]. An influence on NF-κB signaling has also 
been reported upon SIRT1 activation and over-expression obtaining a 
reduction of microglia-mediated Aβ toxicity [Chen J et al., 2005]. 
Moreover, PARP1 (which is overexpressed in AD, and may lead to NAD+ 
depletion and SIRT1 activity decrease) inhibition activated SIRT1 
expression in the presence of Aβ42 oligomers, and upregulated α-
secretase pathway [Wencel PL et al., 2018]. By deacetylation and 
activation of Peroxisome Proliferator-activated Receptor Gamma Co-
activator 1-alpha (PGC-1α), SIRT1 also promoted mitochondrial 
biogenesis and prevented mitochondrial dysfunction in AD [Donmez G, 
2012; Koo JH et al., 2017].  
Besides Aβ pathology, SIRT1 may act also on tau pathology directly 
deacetylating the protein. After deacetylation by SIRT1, tau may be more 
susceptible to ubiquitin ligases and can be degraded into multiple 
peptides, diminishing the formation of NFTs and suppressing the spread 
of tau-induced pathology in vivo [Min SW et al., 2010; Min SW et al., 
2018]. SIRT1 and tau also share upstream regulators such as AMPK and 
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microRNA-132, supporting the inverse correlation between SIRT1 levels 
in AD brain and abnormal tau deposit [Julien C et al., 2009; Salminen A 
et al., 2012; Kim HS et al., 2015]. 
SIRT1/retinoic acid receptor β pathway is also able to activate Notch 
cleavage, mediating neuroprotection, neurogenesis, synaptic plasticity, 
learning and memory functionality [Costa RM et al., 2005; Bonda DJ et 
al., 2011]. 
Other possible SIRT1 molecular partners involved in AD could be the 
FOXO transcription factors, that are able to modulate protein turnover and 
oxidative stress [Perez FP et al., 2014]. FOXO1 level is altered with AD 
progression, and FOXO3a could be the mediator of Aβ-induced inhibition 
of the neuroprotective PI3K/Akt signaling [Gòmez Ravetti M et al., 2010; 
Akhter R et al., 2014]. 
Another recent study also highlighted the critical role of SIRT1 in the BBB 
permeability/leakage. In this study, the age-dependent modification of 
SIRT1 expression, its knockdown or overexpression, affected BBB 
integrity, thus proposing SIRT1 as a promising target for reducing BBB 
hyperpermeability associated with ageing or neurodegenerative disorders 
[Stamatovic S et al., 2018].  
1.4.3 SIRT2 
SIRT2 human gene is located on chromosome 19. The protein is preferentially 
cytosolic, co-localizes with microtubules and is responsible of α-tubulin 
deacetylation [North BJ et al., 2003]. SIRT2 transiently shuttles to the nucleus 
during the G2/M transition of the cell cycle, where it has a strong preference 
for histone H4 lysine 16, thereby regulating chromosomal condensation during 
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mitosis [Inoue T et al., 2007]. Despite this target preference, SIRT2 interacts 
with and regulates numerous histone and non-histone protein substrates, and 
the variety of endogenous targets is correlated with the different biological 
functions modulated by this deacetylase [de Oliveira RM et al., 2012] (Figure 
1.21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.21 A list of selected protein targets of SIRT2 in different organs, and the involved 
metabolic pathways (modified from [Gomes P et al., 2015]).  
 
SIRT2 is expressed in a wide range of tissues and organs and has been 
detected in metabolically relevant tissues, including the brain, muscle, liver, 
testes, pancreas, kidney and adipose tissue [Wang F et al., 2007; Kim HS et 
al., 2011; Maxwell MM et al., 2011]. In these tissues, SIRT2 exerts its function 
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on cell cycle regulation, energy metabolism, oxidative stress and inflammation, 
among others.  
Some of the non-histone targets of SIRT2 are p65, FOXO3 and FOXO1 and 
NRF2.  
Numerous evidences implied a role for SIRT2 in pathological processes such 
as tumorigenesis, where there are still contradictory results about its 
tumorigenic or tumor-suppressor functions [Chen J et al., 2013; Wang F et 
al., 2007]. 
With respect to SIRT1, whose beneficial role is well established, the implication 
of SIRT2 in pathological and protective functions is less clear, raising the 
question of whether activation or inhibition of SIRT2 is beneficial or detrimental 
under specific circumstances.  
 
1.4.3.1 SIRT2 in neurodegeneration and AD 
SIRT2 is highly expressed in the brain, especially in oligodendrocytes, glial 
cells and post-mitotic neurons, and is involved in numerous cerebral 
functions. In neurons and oligodendrocytes, SIRT2 is localized in the 
cytosol. At neuronal level, its expression can be detected in all neurites 
and growth cones. Among SIRT2 functions in the brain there are the 
alteration of cones and neurites growth dynamics (acting on acetylated-α-
tubulin), and oligodendrocytes arborization and differentiation 
[Pandithage R et al., 2008]. Several published data demonstrated an 
association between SIRT2 activity and neurodegenerative processes and 
ageing [Maxwell MM,et al., 2011], giving rise to a growing interest in the 
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use of SIRT2 inhibitors on models of AD and other disorders [Donmez G 
and Outeiro TF, 2012].  
A link between SIRT2 and AD pathology has been provided by genetic 
studies, which demonstrated an association between the SNP rs10410544 
in SIRT2 gene and AD susceptibility in a case-control study on a 
Caucasian population, a result that was confirmed in a meta-analysis too 
[Polito L et al., 2013; Wei W et al., 2014].  
SIRT2 was associated with the aggregation of amyloidogenic proteins 
such as α-synuclein and huntingtin [Outeiro TF et al., 2007; Luthi-Carter 
R et al., 2010] that share some of their characteristics with Aβ.  
In addition, SIRT2 was indirectly associated with neurodegenerative 
processes such as inflammation, apoptosis, microtubules destabilization, 
autophagy and oxidative stress [De Oliveira RM et al., 2012].  
The work from Biella et al demonstrated that SIRT2 specific inhibition was 
able to stimulate non-amyloidogenic pathway, suppress the amyloidogenic 
one, and improve cognitive function in two transgenic mouse models 
(3xTg-AD and APP23) [Biella et al., 2016]. 
Microtubules instability and altered autophagy are also two important 
mechanisms that result affected by SIRT2 activity in AD. Silva and 
colleagues demonstrated that in AD patient’s brain there is mitochondrial 
dysfunction, that leads to SIRT2 over-activation and consequently to 
microtubules disruption and autophagic-lysosomal pathway (ALP) 
impairment. Through SIRT2 inhibition they propose an approach to 
stabilize microtubules and improve autophagic traffick through tubulin 
acetylation, preventing ALP dysfunction and consequent toxicity given by 
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accumulation of Aβ and tau protein aggregates (Figure 1.22). Increased 
acetylated tubulin/α-tubulin ratio was also reported in samples of AD brains 
[Silva DF et al., 2017]. 
Another study pointed out that SIRT2 inhibition-dependent α-tubulin 
acetylation, a process that is linked to more stable microtubules, improves 
microtubules dynamics increasing tau/tubulin binding and consequently 
decreasing its accumulation and aggregation [Esteves AR et al., 2018]. 
 
 
 
 
 
 
 
 
 
Figure 1.22 The proposed mechanism of SIRT2-dependent microtubule acetylation and 
its regulation. A) Healthy neuron in basal conditions: microtubules stabilization is reached 
in a dynamic manner through SIRT2-dependent acetylation and tau binding. Autophagic 
vacuoles (AVs) are transported to lysosomes side for digestion and other cargo proteins 
are transported along microtubules bidirectionally; B) AD neuron when mitochondrial 
metabolism fails: ROS production and SIRT2 over-activation lead to microtubules 
disruption, tau dissociates and is prone to phosphorylation and aggregation. AVs are not 
transported and accumulate in the cell, favouring Aβ release and aggregation into 
oligomers. Autophagic flux impairment and metabolic disregulation lead to caspases 
activation and cell death. SIRT2 inhibition with AK1 could partially reverse some of these 
features (modified from [Silva DF et al., 2016]). 
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Of notice, in the context of oxidative stress that characterizes AD, SIRT2 
was also reported as deacetylase of NRF2, reducing its cellular and 
nuclear levels. This NRF2 reduction is associated with a decrease in 
transcription of its target gene Fpn1, which leads to a reduction in iron 
efflux from the cell, increasing intracellular iron level. An excessive 
intracellular iron is associated with oxidative stress and cellular damage 
[Yang X et al., 2017]. 
Another molecular player that is influenced by SIRT2 inhibition is SREBP-
2, involved in sterol biosynthesis at neuronal level, and whose nuclear 
translocation seems to be inhibited by tubulin acetylation, conferring 
neuroprotection [Luthi-Carter R et al., 2010]. 
Wang and colleagues demonstrated that SIRT2 is required for LPS-
induced neuroinflammation by microglial activation, and SIRT2 inhibition 
rescued this process also preventing nuclear traslocation of NF-κB and 
TNFα and IL-6 levels [Wang B et al., 2016]. 
 Given all the evidences of SIRT2 contribution to neurodegeneration, in 
particular for HD and PD models, there is rising interest in elucidating the 
effects and possible mechanisms through which SIRT2 influence AD 
pathology.  
 
1.4.4 SIRT1/SIRT2 MODULATORS AND THEIR APPLICATION TO 
NEURODEGENERATION 
The greater knowledge of the functions of SIRT1 and SIRT2 and their 
implication in gene expression, cellular metabolism, inflammation and 
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neuroprotection, has pushed the scientific community to search for molecules 
able to modify their activity. The use of SIRT modulators have broadened the 
knowledge of the molecular and biological functions of these proteins, and 
identified new lead compounds for the treatment of different pathological 
conditions. 
1.4.4.1 SIRT1 activators 
Most of the Sirtuin Activating Compounds (STACs) act on SIRT1.  
Their action is to decrease the Km of SIRT1 catalytic reaction. 
STACs bind the SIRT1-peptide complex on an allosteric site on the 
catalytic domain, increasing the enzyme’s affinity for the acetylated 
substrate [Milne JC et al., 2007]. 
The first generation of STACs is represented by polyphenolic 
metabolites [Howitz KT et al., 2003]. The most potent natural STAC 
is resveratrol (RSV) (Figure 1.23), a polyphenolic compound able to 
produce a 10-fold increase in SIRT1 activity. RSV is present in red 
wine, and was already known for its antioxidative properties on 
human health [Bhat KPL et al., 2001]. 
 
 
 
 
Figure 1.23 The chemical structure of resveratrol (modified from [Smith JJ et 
al., 2009]).  
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RSV and other STACs can mimic CR, increasing survival [Wood JG 
et al., 2004], and its beneficial effect was recently confirmed in the 
context of senile dementias and AD [Sawda C et al., 2017]. 
The second generation of STACs is composed of synthetic 
molecules with an imidazole-derived structure: some of these 
compounds are SRT1720, SRT1460, SRT2104 and SRT2183. 
Despite the similar mechanism of action to natural compounds, 
synthetic STACs are much more potent. SRT1720 is a potent and 
selective SIRT1 activator, with an EC₅₀ = 0.16 μM (Figure 1.24), that 
showed beneficial effects against oxidative stress, insulin-resistance 
[Milne JC et al., 2007], and neurodegeneration. 
 
 
Figure 1.24 The chemical structure of SRT1720 (modified from [Smith JJ, et al., 
2009]). 
 
SRT1720 also preserved mitochondrial biogenesis [Hansen LW et 
al., 2016], reduced oxidative damage in interstitial fibrosis models 
[Ren Y et al., 2017], and showed a protective effect against age-
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related disorders in mice fed both a high-fat and a standard diet 
[Minor RK et al., 2011; Mitchell SJ et al., 2014]. 
In neurological context, this modulator showed neuroprotection 
during in vivo cerebral oxidative stress [Gueguen C et al., 2014], 
significantly improved outcomes after spinal cord injury acting on 
inflammation [Chen H et al., 2017], and reversed ROS excess, 
inflammation and endothelial dysfunction in aged mice [Gano LB et 
al., 2014]. 
Another new STAC with promising proof-of-concept efficacy data is 
SRT2104 (Figure 1.25), which reached fourteen clinical trials [Dai H 
et al., 2018]. SRT2104 was well tolerated in humans and produced 
beneficial effects on serum cholesterol, LDL levels and triglycerides, 
both in healthy volunteers and diabetic patients [Libri V et al., 2012; 
Baksi A et al., 2014]. Another clinical trial demonstrated a beneficial 
effect of SRT2104 administration in patients with moderate-to-severe 
psoriasis [Krueger JG et al., 2015]. 
 
 
 
 
 
Figure 1.25 The chemical structure of SRT2104 (modified from [Dai H et al., 
2018]). 
 
SRT2104 
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SRT2104 is also under study at preclinical level, and demonstrated 
interesting properties.  
Mercken and collegues demonstrated that SRT2104 extends 
survival of male mice on a standard diet, improving motor 
coordination and insulin sensitivity, increasing mitochondrial content 
and decreasing inflammation. In the same study, SRT2104 short-
term treatment preserved bone and muscle mass in a model of 
atrophy [Mercken EM et al., 2014].  
Another recent study demonstrated the beneficial effect of SRT2104 
hippocampal injection on stress-induced depressive-like behaviors 
and microglial phenotype switch in mice [Duan C et al, 2020]. 
 
SRT2104 was also tested in neurodegeneration context, where it 
was demonstrated that it penetrates the BBB, attenuates brain 
atrophy, improves motor function, and extends survival in a mouse 
model of HD [Jiang M et al., 2014]. 
A summary of STACs effects in ageing and age-related disorders is 
presented in Figure 1.26. 
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Figure 1.26 Effects of SIRT1 activation by RSV, SRT1720 and SRT2104 on 
ageing and neurodegenerative diseases. Stars indicate ongoing studies 
(modified from [Hubbard and Sinclair, 2014]) 
 
1.4.4.2 SIRT2 inhibitors 
Several studies highlighted that SIRT2, whose cellular levels are 
altered in senile dementias, promotes neurodegeneration. Its 
pharmacological inhibition antagonised this pathological process, 
conferring neuroprotection.  
SIRT2 inhibition has been investigated in AD models. Rat primary 
astrocytes treated with AGK2 had a reduction in their activation and 
pro-inflammatory mediators’ production [Scuderi C et al., 2014].  
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AGK2 is a SIRT2 reversible, potent inhibitor (IC₅₀ = 3.5 µM) (Figure 
1.27), able to protect SIRT2-overexpressing SHSY5Y cells from 
oxidative damage induced by rotenone and diquat toxins [Singh P et 
al., 2017].  
 
Figure 1.27 The chemical structure of the SIRT2 inhibitor AGK-2. 
 
AGK2 treatment protected neuronal cultures and reduced microglial 
activation in PD models with dopaminergic degeneration and 
microglial infiltration [Harrison IF et al., 2018].  
In cellular and invertebrate HD models, AGK2 treatment down-
regulated genes involved in sterol biosynthesis, leading to 
neuroprotection [Luthi-Carter R et al., 2010]. 
Taylor and colleagues observed that sulfobenzoic acid derivates 
exerted high SIRT2 inhibition and screened such derivates in order 
to select a new, potent, selective and brain-permeable SIRT2 
inhibitor.  
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The compound named AK7 (Figure 1.28) was developed based on 
the structure of its analogue AK1 [Spires-Jones TL et al., 2012] and 
was able to satisfy those requirements.  
 
 
 
 
 
Figure 1.28 The chemical structure of the SIRT2 inhibitor AK7 (top), a dose-
response curve (A) and a three-dimensional model for AK7 and SIRT2 interaction 
(modified from [Chen X et al., 2015]). 
 
Our group investigated AK7 application in two AD models (3xTg-AD 
and APP23 mice), and demonstrated that AK7 administration 
recovered their cognitive deficit and acted on APP processing 
increasing the neuroprotective fragment sAPPα and decreasing 
sAPPβ [Biella G et al., 2016].  
Silva and colleagues investigated SIRT2 inhibition with the 
compound AK1 in AD context demonstrating protection against 
microtubule disruption and autophagy dysfunction [Silva DF et al., 
2017]. 
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Treatment of an in vitro model of HD with AK7 showed 
neuroprotection, reducing the aggregation and number of 
polyglutamine neuronal inclusions and cholesterol levels [Taylor DM 
et al., 2011].  
In a mouse model of HD, AK7 was able to ameliorate motor deficits, 
extend survival and reduce cerebral atrophy [Chopra V et al., 2012].  
Positive results have been obtained also on PD models, where AK7 
reduced in vitro α-synuclein toxicity and in vivo MPTP-induced 
neuronal loss [Chen X et al., 2015]. Other studies demonstrated 
neuroprotection by AK7 treatment on a rotenone-induced PD rat 
model and on MPTP-treated mice, acting on aging-related 
neurochemical and behavioural deficits and dysfunction of redox 
network [Wang X et al., 2015; Guan Q et al., 2016].  
 
1.4.5 THE ROLE OF OTHER SIRTs IN NEURODEGENERATION AND AD 
Besides SIRT1 and SIRT2, whose role in neurodegenerative diseases is the 
most studied, other members of the protein family are now a target of interest.  
In fact, all SIRTs are present in the brain in a highly regulated pattern and are 
able to influence the course of ageing and age-related disorders [Wątroba M 
and Szukiewicz D, 2016].  
The expression of SIRT3-SIRT7 undergoes changes in the ageing brain and 
during AD pathology [Jęśko H et al., 2017].  
SIRT5 is induced in activated microglia of AD brains [Lutz MI et al., 2014], 
and overexpression of APP and PS1 has led to a reduction in SIRT3 mRNA 
and protein in a mouse model [Yang W et al., 2015].  
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It has been found that short-term treatment with Aβ42 oligomers stimulated 
SIRT4 expression and a prolonged treatment influenced all mitochondrial 
SIRTs (SIRT3, SIRT4, SIRT5), suggesting a complex link between SIRTs and 
Aβ/APP pathology [Cieslik M et al., 2015].  
SIRT6 activity declines with age and AD, with a concomitant accumulation of 
DNA damage. Furthermore, brain-specific SIRT6-KO mice have behavioral 
and learning impairments and hyperphosphorylated tau, possibly through 
increased activation of GSK3α/β [Kaluski S et al., 2017].  
The most relevant results in AD context were recently produced on SIRT3. 
A natural SIRT3 activator named Honokiol exerted antioxidant activity, 
mitochondrial energy regulation and decreased Aβ levels in APP/PS1 CHO 
cells [Ramesh S et al., 2018]. 
Another study showed that SIRT3 has a role in hippocampal synaptic plasticity 
and adaptations to intermittent fasting in a mouse model of AD [Liu Y et al., 
2019]. 
Li and colleagues demonstrated that SIRT3 could be involved in tau protein 
acetylation and consequent accumulation [Li S et al., 2019].  
The rising interest in SIRTs involvement in neurodegenerative diseases 
stimulates the search for new, specific, brain-permeable small 
inhibitors/activatos, an objective that for most of the members of this protein 
family is still challenging. 
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1.5       Drug-delivery Systems (DDS) 
 
DDS are a useful solution for those molecules that have promising 
therapeutic potentialities but poor pharmacokinetic paramters or the 
impossibility to cross the BBB. 
DDS could increase brain bioavailability of new compounds giving a 
chance to AD treatment [Choonara YE et al., 2016].  
Among all DDS, three main categories can be mentioned in relation to the 
mechanism that allows the drug release from a polymeric system: release 
controlled by chemical reaction, solvent-mediated activation, and diffusion-
dependent release. 
Another interesting type of delivery system is the one based on 
nanoparticles (NPs) as carriers for active compounds (NPDDS). NPs are 
able to cross the BBB and can be functionalized to release the drug in the 
target site [Nguyen KT et al., 2017]. 
Repeated intraperitoneal injection of small nanoparticles carrying 
phosphatidic acid/cardiolipin reduced brain Aβ level in APP/PSEN1 mice 
[Ordóñez-Gutiérrez et al., 2015].  
NPDDS also constitute an interesting approach for delivery of already 
approved symptomatic drugs, such as rivastigmine [Leszek J et al., 
2017]. 
Besides their interesting potential, nanotechnologies have some 
limitations related to the cost/benefit ratio and processability of NPDDS, 
generally neglected factors [Wen MM et al., 2017]. 
In addition, the most effective NPs formulations for the transport of drugs 
in brain accumulate significantly in other regions of the body, such as liver, 
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spleen and kidney, before being eliminated. It is important to design 
nanoformulations that only after reaching the brain are activated to release 
the drug [Li W et al., 2015] instead of doing it elsewhere in the body 
[Saraiva C et al., 2016]. 
In the last decades, bioengineering developed new sophisticated DDS, the 
injectable hydrogels, which have mechanical features similar to brain 
tissue [Khaing Z et al., 2014]. These materials can be injected in the brain 
in liquid form and can gelate in situ. Their biocompatibility avoids 
inflammatory reactions, and their biodegradability makes it possible to 
eliminate them without requiring additional surgery [Pakulska MM et al., 
2012]. Thus, injectable hydrogels are promising as DDS in the CNS and 
could offer new therapeutic possibilities for AD treatment. 
 
1.5.1 HYDROGELS AS DDS  
 
Hydrogels are three-dimensional hydrophilic networks able to absorb great 
water or biological fluids volumes without dissolving in it. The presence of 
chemical or physical networks, indeed, makes these materials insoluble 
[Peppas NA et al., 2000]. This feature is important as hydrogels mimic human 
tissues and are highly biocompatible [Kopecek J et al., 2007].  
Hydrogels can be ideally composed by any hydrophilic polymer, so they exist 
in a wide range of chemical compositions and mechanical properties. They can 
be classified according to different characteristics, such as the ionic charge of 
the side groups, the physical structure, the method of preparation and the 
reversible or irreversible nature of the cross-linking. Moreover, it is possible to 
formulate hydrogels in different physical forms, such as micro particles, NPs, 
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plates and films, peculiarities that make them suitable for applications in 
different fields. 
In the biomedical field, they have been used as: 
- systems for the delivery of bioactive molecules [Hoare et al., 2008] 
- vehicles for cell-based therapies [Munarin F et al., 2012] 
- tools for the creation of 3D models of pathologies [Choi SH et al., 2014] 
- scaffolds in regenerative medicine [O'Loughlin A et al., 2013] 
- supports for stem cell growth and differentiation [Ou L et al., 2011] and for 
tissue engineering [Billiet T et al., 2012]. 
Hydrogels can be classified by their preparation method, in omopolymeric, co-
polymeric, multipolymeric, and interpenetrated (IPNs).  
IPNs hydrogels are of particular interest because of the co-existence of two 
polymers that are physically independent. In IPN hydrogels there is the co-
existence of a reticulated matrix polymer (main matrix) with a second polymer 
which can be dispersed within the meshes of the main matrix or cross-linked 
to form a secondary matrix. The formation of the IPN polymeric network occurs 
when a pre-polymerized hydrogel is immersed in a solution of monomers, a 
polymerization initiator and an agent that promotes the second network (cross-
linker). In the absence of the cross-linker, the linear polymers do not cross-
link, but remain trapped in the main matrix, generating semi-interpenetrated 
hydrogels (semi-IPNs), as illustrated in Figure 1.29.  
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Figure 1.29 IPN and semi-IPN hydrogel formation (modified from [Hoare TR et al., 2008]) 
 
The interest in these structures is due to the possibility of combining the 
favorable properties of each component to produce a new system with 
properties that often differ from those of the single polymer [Zoratto N et al., 
2018]. 
Semi-IPNs hydrogels are more efficient in preserving release kinetics at 
varying pH and temperature. They also possess many of the benefits of IPNs 
hydrogels, such as pore size control, the ability to slowly release an active 
molecule and good mechanical properties [Hoare TR et al., 2008]. 
 
1.5.1.1 Hydrogels for CNS application 
 
As mentioned above, the main applications of hydrogels are injectable 
devices. Exogenous materials that are supposed to be implanted under 
the skin, unfortunately, can evoque an undesired response by the host 
tissue, like inflammation, tumorigenesis and immune response. Therefore, 
the essential requirement for such materials is the bioavailability, a feature 
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that completely characterizes hydrogels, in addition to other peculiar 
properties including minimal irritation following in vivo application, 
possibility of loading drugs with different hydrophilicity and size, possibility 
of adjusting the release kinetics by modulating the pore size of the network.  
Furthermore, the study of the polymers used for the production of 
injectable hydrogels has led to the development of biodegradable systems, 
which do not require further surgery for the removal after the complete 
release of the drug [Cho CS et al., 1999]. 
CNS targeting therapies have some peculiar limitations, such as the 
possibility that the active molecule, systemically administered, does not 
reach efficiently the target tissue because of the presence of the BBB. In 
fact, in physiological conditions BBB does not allow passive diffusion of 
molecules and immune cells from the blood to the brain. 
Further critical elements are the skull which makes any intervention 
extremely invasive, the mechanical properties of the brain that do not allow 
the use of rigid scaffolds, the cicatrisation of the glia that prevent the 
correct tissue regeneration and the accurate endogenous immune 
mechanisms.  
Tunesi and colleagues have extensively analysed the rheological 
properties of collagen/PEG semi-IPNs injectable hydrogels, in cellular and 
murine neurodegeneration models. Their results highlighted the in situ 
gelation, the neuronal viability preservation, cell line proliferation 
maintenance, and the absence of inflammatory reaction after 
subcutaneous injection. In addition, no inflammation or tissue damage was 
detected after intracranial injection [Tunesi M et al., 2013]. 
91 
 
Li and colleagues, after having identified the neuroprotective potential of 
activin B in PD, overcame the limitations related to its short half-life 
developing an injectable and thermo-sensible hydrogel as vehicle for a 
prolonged release. Stereotactic injection of such hydrogel in a PD in vivo 
model revealed an increase in tyrosine hydroxylase, neuroinflammation 
reduction and cognitive improvement [Li J et al., 2016]. 
Intracranial injectable hydrogels are also included among the innovative 
therapeutic strategies for neuro-regeneration following traumatic spinal 
cord injury [Kumar P et al., 2015]. Injecting a thermo-sensible hydrogel 
into a clinically relevant spinal cord injury model promoted remodelling of 
the extracellular matrix, eliminating cystic cavities. Hydrogels could 
potentially be used, therefore, as a form of natural filling of defects and 
body cavities [Hong LTA et al., 2017]. 
Finally, in a recent study, an IPN chitosan hydrogel was used for prolonged 
local administration of a chemotherapeutic agent and a 
radiopharmaceutical in an in vitro glioblastoma model. The results showed 
a reduction in tumor size and an increase in the survival of the treated cells 
compared to the control group [Puente P et al., 2018]. 
Injectable hydrogels are an excellent vehicle for the delivery of active 
molecules in brain and an innovative therapeutic strategy for many CNS 
diseases.  
One promising approach for a local and minimally-invasive brain drug 
delivery was the epi-cortical positioning of a scaffold containing a 
hyaluronan-metilcellulose hydrogel. This approach allowed CNS delivery 
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of EGF without tissue damage and good results in the stroke-injured 
mouse brain [Cooke MJ et al., 2011]. 
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2. Aim of the study 
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Although our knowledge of AD pathology has increased enormously in recent 
years, we do not yet have effective therapies for its treatment. Given the high 
number of people affected by AD throughout the world, a prevalence destined 
to rise according to estimates, the development of therapies capable of 
modifying the course of the disease remains a very urgent need. In fact, the 
available therapies for AD are still symptomatic and do not arrest the 
progression of the pathology.  
Over the years, new molecular players are emerging, involved in a 
neuroprotective or neurodegenerative sense in pathogenetic mechanisms 
linked to AD, such as inflammation, oxidative stress, aggregation of toxic 
proteins, synaptic deficits, and others. 
In this context, an interesting role also emerged for Sirtuins (SIRTs), enzymes 
with deacetylase activity that regulate a high number of cellular processes, 
such as energetic metabolism, epigenetic mechanisms and cell cycle. 
Numerous works highlighted the involvement of SIRTs in neurodegenerative 
processes, particularly because both epigenetic and metabolic deregulation 
rise with ageing, and can promote the onset and progression of 
neurodegeneration. SIRT1 and SIRT2 are the most studied in 
neurodegenerative disorders, where SIRT1 has been associated with 
neuroprotective properties, while SIRT2 seems to be involved in 
neurodegenerative mechanisms.  
Active research on small molecules able to modulate the activity of these 
enzymes has led to studies aimed at activating SIRT1 or inhibiting SIRT2 in 
models of AD, demonstrating a protective effect of these two approaches. 
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It has now been established that AD is a very complex multifactorial pathology, 
and it is interesting to notice that therapeutic strategies aimed at a single 
molecular target, such as AchE inhibitors or BACE inhibitors, have proved to 
be ineffective as disease-modifying drugs. The multi-targeted therapeutic 
approach, in which a single or a combination of drugs is able to target different 
molecular players of a disease to obtain an enhanced therapeutic effect, is 
currently of particular importance, and studies on this strategy are steadily 
growing. 
The work presented in this thesis aims to study a possible multi-target 
approach involving SIRT1 and SIRT2, on AD in vitro and in vivo models. The 
rationale is that, starting from positive data for the sole activation of SIRT1 and 
the sole inhibition of SIRT2, we could combine these two modulations at the 
same time. This can potentially allow us to act on different molecular pathways 
and pathologic features that can be linked to the activity of one or both 
enzymes (APP-derived metabolites, inflammatory and antioxidative pathways) 
and attack the pathology from multiple points, converging on a pro-cognitive 
general effect obtained with the union of the two approaches. 
The characterization of this new strategy was achieved through the 
development of the following points: 
• The first part of the work will focus on an AD cellular model, the H4-sw 
neuroglioma cell line expressing human Swedish APP. The aim is to 
evaluate the feasibility of a combined treatment with SIRT1 activators 
SRT1720 or SRT2104 and SIRT2 inhibitor AK7 in terms of potential 
cytotoxicity, and to explore the effects on APP metabolism, a 
characteristic parameter of the selected model. In particular, the focus 
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of the experiments will be to evaluate a possible effect on sAPPα 
production and Aβ levels, following the molecular hypothesis of a role 
of SIRT1/2 in non-amyloidogenic processing stimulation and Aβ 
production decrease. 
• The second part of the work will target the single and the double 
treatment with SIRT1 activator SRT2104 and SIRT2 inhibitor AK7 on a 
transgenic AD mouse model, the 3xTg-AD. The main purpose is to 
achieve cognitive improvement of 6-months old mice receiving the 
single and the combined treatment following an acute protocol of two 
weeks. After behavioural assessment, biochemical analyses will be 
performed to define the effect on sAPPα production, Aβ oligomers, 
inflammation markers CD11b and GFAP, oxidative stress response 
proteins NRF2 and SOD1, and synaptic density marker Synaptophysin, 
in order to detect some changes in AD-related molecular pathways. As 
both SIRT1 and SIRT2 are involved with different extent in 
neurodegenerative features, the effects seen upon single treatments 
will clarify the contribution of each SIRT to the potential cognitive effect 
obtained combining SIRT1 and SIRT2 modulation.  
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3. Materials and methods 
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3.1 In vitro experiments 
 
3.1.1 H4-SW CELLS 
 
For in vitro experiments we used H4 human neuroglioma cell line harbouring 
a plasmid containing human mutated APP (Swedish mutation KM595/596NL). 
The over-expression of mutated APP makes H4-sw cells able to produce high 
amounts of Aβ in culture medium.  
Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with foetal bovine serum to a final concentration of 10%, 2mM 
L-glutamine, 100 U/mL penicillin and 100μg/mL streptomycin. For stable 
transfection maintenance, 300 µg/mL Hygromycin B and 10 µg/mL Blasticidin 
S were freshly added to plated cells. 
Cells were incubated at 37°C in 5% CO2 humified atmosphere and were split 
two times per week from sub confluent flasks. In details: after washing with 
PBS to remove any trace of serum, cells were incubated with 500μL of 
trypsin/EDTA solution (0.005% trypsin and 0.02% EDTA in PBS) for 3-5 min 
at 37°C. After inhibiting trypsin with DMEM, the cells were collected and 
centrifuged. The supernatant was discarded and fresh medium was added to 
dilute the pellet at the appropriate cell concentration. For the experiments, cells 
were counted with a Burker chamber and seeded in the appropriate multi-well 
at the desired density: 
- 96-well plate: 8000 cells/well 
- 6-well plate: 120000 cells/well 
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3.1.2 COMPOUNDS AND CELL TREATMENTS 
 
To obtain the inhibition of SIRT2 cells were exposed to the specific inhibitor 
AK7 (Sigma-Aldrich) at 20 µM for 24 hours. AK7 is a brain-permeable selective 
SIRT2 inhibitor with an IC50= 15.5 µM. 
To obtain the activation of SIRT1 cells were exposed to the potent activator 
SRT1720 (EC50= 160 nM; Cayman Chemicals) at 0.5 µM, or SRT2104 
(MedChem Express; EC50 = µM range) at 3 µM, for 24 hours.  
All the compounds were purchased in powder form and dissolved in DMSO to 
obtain a stock solution. Working dilutions were made in fresh complete culture 
medium and added directly to the corresponding well.  
 
3.1.3 RNA INTERFERENCE 
 
To reach SIRT2 silencing in H4-sw cells, we used a specific siRNA (Silencer® 
Select siRNA – Ambion®) and a commercial scrambled sequence as negative 
control siRNA.  
Cells were transfected using Lipofectamine™ 3000 (Invitrogen) as transfection 
agent. In detail: cells were plated on 6-well plates and let reach almost 80% 
confluence. The medium was replaced with antibiotic-free medium 1 hour 
before transfection. After mix preparation according to manufacturer’s 
instructions, the siRNA-Lipofectamine complex was added to the 
corresponding wells. 5 hours post transfection, the medium was replaced 
again to avoid liposomes excessive toxicity. Cells were incubated for 48 hours 
to reach effective gene silencing, then culture media were collected and cells 
were lysed for biochemical tests.  
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3.1.4 MTS VIABILITY ASSAY 
 
Cellular viability of H4-sw cells was evaluated using the CellTiter 96® 
AQueous One Solution Cell Proliferation Assay (Promega). 
Briefly, cells were plated on 96-well plates, treated with SIRTs modulators for 
24 hours, and finally the medium was replaced with fresh medium containing 
1:10 MTS solution. After 3 hours of incubation, absorbance was read with 
Tecan Infinite® M200 instrument at 490 nm.  
Results were expressed as % cellular viability vs control.  
 
3.1.5 PROTEIN EXTRACTION FROM CELLS AND CULTURE MEDIA 
 
Proteins for Western blotting and ELISA analyses were extracted as follows. 
Proteins released in the culture medium were obtained with media 
centrifugation at 21000 rcf for 5 minutes at 4°C, and then the supernatant was 
frozen at -20°C until use.  
For whole cell lysates, H4-sw were washed with cold PBS 1X and lysed on ice 
with a scraper using a pH 7.4 Ice Cold Lysis Buffer (50mM Tris/HCl, 150mM 
NaCl, 0.5mM EDTA and 1% Triton X-100) with 1% broad-range Proteases 
Inhibitor Cocktail (Sigma-Aldrich). Lysed cells were centrifuged at 21000 g for 
5 minutes at 4°C. Pellets were discarded and supernatants were stored at -
20°C. Small aliquots were taken for protein quantification by Pierce™ BCA 
Protein Assay Kit (Thermo Scientific).  
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3.1.6 SDS-PAGE AND WESTERN BLOTTING 
 
Equal amounts of proteins (10-20 µg depending on the protein of interest) from 
cell lysates were denatured by boiling in SDS sample buffer (125mM Tris-HCl 
pH 6.8, SDS 1%, glycerol 10% and bromophenol blue 0.006%) added with 50 
mM DTT at 95°C for 5 minutes. For secreted proteins, equal volumes of 
medium were processed in the same way and normalized to BCA protein 
content of the corresponding cell lysate.  
Proteins were separated on 8% poly-acrylamide gels using a molecular weight 
marker (Biorad). Electrophoresis was carried out in 1X Tris Glycine-based 
Running Buffer, at 180 V. Proteins were then transferred to a nitrocellulose 
membrane in 1X Transfer Buffer for about 2 hours at 300 mA. The membrane 
was blocked for 1 hour in 5% non-fat dry milk or Bovine Serum Albumin (BSA) 
dissolved in Tris-Buffer Saline supplemented with 0.1% Tween 20 (TBS-T). 
After blocking, membranes were incubated overnight with the specific primary 
antibody diluted in 5% non-fat dry milk/TBS-T solution at 4°C, with gentle 
shaking. The following primary antibodies were used: 2C11 (not commercial 
IgG2a for full length APP, from Dr. Alessio Colombo), 22C11 (Millipore 
MAB348), 6E10 (Biolegend 803001), SIRT1 (Abcam ab32441), SIRT2 
(Sigma-Aldrich S8447), α-tubulin (Abcam ab7291).  
The following day, membranes were washed three times for 10 minutes in 
TBS-T and incubated with the appropriate secondary HRP-conjugated Ig 
antibody for 1h at room temperature with gentle shaking. Membranes were 
then washed again with TBS-T as described above and covered with ECL 
substrate reagent (Millipore) for 3min. At the end, membranes were exposed 
to ChemiDoc™ Imaging System (BioRad) for signal detection. 
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Quantitative densitometric analyses were performed on digitalized images of 
immunoblots and band intensities were measured using ImageJ software. The 
obtained values were normalized to the corresponding α-tubulin band intensity 
or to the protein concentration of the sample in the case of secreted proteins.  
 
3.1.7 Enzyme-Linked Immunosorbent Assay (ELISA) 
 
β-amyloid peptides and sAPPβ fragment were assessed in the conditioned 
culture media of H4-sw cells, using Human Amyloid β(1-40)/β(1-42) Assay Kit 
and Human sAPPβ Assay Kit (IBL) according to the manufacturer instructions.  
Briefly, media were appropriately diluted and added to the pre-coated plate for 
antigen capture. After overnight incubation and several washing steps, the 
secondary antibody was added to the samples and the colorimetric reaction 
was detected with Tecan Infinite® M200 (450 nm) after adding TMB substrate. 
Obtained values, expressed in pg/ml, were finally normalized on BCA protein 
content of every sample. 
 
3.1.8 TOTAL RNA EXTRACTION 
 
Total RNA extraction from H4-sw cells was performed with Maxwell® 16 LEV 
simplyRNA Cell Kit (Promega). According to the manufacturer instructions, 
cells were seeded on 6-well plates and processed for automated RNA 
extraction after loading into the Maxwell® 16 instrument (Promega). The eluted 
RNA was quantified with NanoDrop 1000 (Thermo Scientific) and stored at -
80°C in small aliquots.  
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3.1.9 QUANTITATIVE REAL TIME PCR 
 
A total of 500 ng RNA from treated H4-sw samples were reverse transcribed 
into cDNA in a 20 μL reaction mixture using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). 
RT-PCR assay run on the Applied Biosystem 7300 RT-PCR System. RT-PCR 
was prepared using 80 ng of cDNA, 2x TaqMan® Master Mix and 20x 
TaqMan® gene expression assays. The reference gene used for the 
experiment was human β-actin. The fluorescence emitted after each cycle was 
measured and plotted (in log scale) against the cycle number. The raw data 
(threshold cycle CT) were used for the analysis of mRNA expression. The 
relative expression of each gene was calculated by the ΔΔCt method 
according to the following formula: 
Amount of target= 2 -∆∆CT  
∆∆Ct = [(Cttarget gene-Ctreference gene)Q - (Cttarget gene-Ctreference gene)CB]  
Q= Sample (treatment condition) and CB= Calibrator (control condition).  
All samples run in triplicate in the same 96-well plate. 
 
3.2 In vivo experiments 
 
3.2.1 3xTg-AD MOUSE MODEL 
 
Homozygous 3xTg-AD mice were generated from a C57BL/6-129SV mixed 
background. A PSEN1 mutant (M146V) mouse embryo was transfected with 
two expression plasmids, one containing a cDNA encoding the AD linked 
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Swedish double mutation of APP (K595M/N596L) and the other a cDNA 
encoding a tau mutation (P301L) that causes frontotemporal lobar dementia, 
both under the control of the Thy-1 promoter. Originally developed 3xTg-AD 
mice display both plaques and NFTs. Aβ deposition is progressive, with 
massive intracellular immunoreactivity detected as early as three to four 
months of age. Extracellular Aβ deposits appear visibly by twelve months. 
Hyperphosphorylated tau and NFTs occur later, by 12 to 15 months. Cognitive 
impairment, gliosis, LTP and synaptic plasticity deficiency appear at an early 
stage (4-6 months of age) [Oddo S et al, 2003; Billings LM et al, 2005; 
Stover KL et al., 2015].  
Treatments were performed on 6 months old animals, while phenotypic 
characterization was conducted on multiple time-points (6,12,18 and 22 
months). As 3xTg-AD mice and Non-Tg (NTg) mice had the same genetic 
background but were not littermates, high attention was paid in housing all the 
animals in the same room and subjecting them to the same environmental 
conditions and manipulations.  
Procedures involving animals and their care were conducted in conformity with 
the institutional guidelines at the Istituto di Ricerche Farmacologiche Mario 
Negri IRCCS, in compliance with national and international laws and policies.  
Mice were housed in a SPF animal facility, at 23°C room temperature, with 
food and water ad libitum and a 12 hours light/dark cycle. 
 
3.2.2 SIRT2 INHIBITOR ADMINISTRATION PROTOCOL 
 
AK7 (Sigma Aldrich, code SML0152) is a SIRT2 selective reversible inhibitor, 
and it is a brain-permeable sulfobenzoic acid derivate, with IC50= 15.5 µM. 
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AK7 powder was dissolved in DMSO to obtain the stock solution, and stored 
at -80°C.  
Mice received an intraperitoneal injection twice daily (AK7 half-life= 2 h). 
For treated group, AK7 was diluted at a dose of 20 mg/kg in a vehicle 
composed by β-hydroxypropyl-cyclodextrin (Sigma Aldrich) 10% in sterile 
water.  
Control group received the vehicle solution alone. 
 
3.2.3 SIRT1 ACTIVATOR ADMINISTRATION PROTOCOL 
 
SRT2104 (MedChem Express; EC50 = µM range) is a SIRT1 selective and 
brain-permeable activator.  
SRT2104 powder was dissolved in DMSO with warming and sonication to 
obtain a stock solution, and stored at -80°C.  
Mice received an oral gavage once daily. 
For treated group, SRT2104 was diluted at a dose of 100 mg/kg in a vehicle 
composed by β-hydroxypropyl-cyclodextrin (Sigma Aldrich) 10% in sterile 
water.  
Control group received the vehicle solution alone. 
 
3.2.4 EXPERIMENTAL TIMELINE 
 
Sex and age balanced 3xTg-AD mice were divided in two groups of treatment 
(8 mice per group) and subjected to the following experimental timelines. 
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In AK7 experiment, mice were treated with AK7 or vehicle twice daily for 15 
days. Before sacrifice, mice were assessed for cognitive impairment with 
Novel Object Recognition Test (NORT) (Figure 3.1). 
 
 
 
 
Figure 3.1 Timeline for AK7 experiment on 3xTg-AD mice 
 
In SRT2104 experiment, mice were treated with SRT2104 or vehicle for 15 
days once daily. Before sacrifice, mice were assessed for cognitive impairment 
with NORT (Figure 3.2). 
 
 
 
 
Figure 3.2 Timeline for SRT2104 experiment on 3xTg-AD mice 
 
107 
 
For combined treatment, mice were treated with the combination of AK7 and 
SRT2104 or with vehicle, for 15 days. Before sacrifice mice were tested for 
cognitive impairment with NORT (Figure 3.3) 
 
 
 
 
 
Figure 3.3 Timeline for AK7 and SRT2104 combined treatment experiment on 3xTg-AD mice 
 
All mice involved in the experiments were genotyped and monitored for 
excessive stress behaviour and changes in body weight during the experiment. 
Mice were weighed on day 1, day 7 and day 15 of treatment.  
3.2.5 BEHAVIOURAL TEST (NORT) 
 
 
 
 
 
Figure 3.4 Schematic representation of NORT protocol 
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Mice were tested in an open-square grey arena (40 x 40), 30 cm high (Figure 
3.4).  
The following objects were used for the test: a black plastic cylinder, a glass 
vial with a white cup, a metal cube, and a holed black plastic cone.  
The protocol started with a habituation trial during which the animals were 
placed in the empty arena in the absence of any specific stimulus for 5 minutes, 
and their movements were videorecorded in terms of distance travelled within 
the arena, and average speed, using the Ethovision XT software.  
The next day, mice were placed in the same arena containing two identical 
objects (training phase) placed at opposite corners of the arena. Exploration 
time was recorded in a 10 minutes trial. Sniffing, touching and stretching the 
head toward the object at a distance not more than 2 cm were considered as 
object investigation. 
The third day, mice were placed again in the arena containing one familiar 
object from the training phase, and a novel object, different from the familiar 
one. Time spent exploring the two objects was videorecorded in a 10 minutes 
trial and analysed by an investigator blinded to the treatment assigned to the 
mouse.  
Memory was expressed as a discrimination index (DI) with the following 
formula: 
 
The positions of the objects were randomly changed for each animal and both 
the arena and the objects were cleaned with ethanol diluted in water between 
trials.  
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Total exploration times in the training and in the test days were calculated for 
each mouse, in order to verify any significant difference between the two 
groups in the exploration activity.  
An NTg mice group was included in each trial to obtain the baseline physiologic 
cognitive performance value.  
 
3.2.6 TISSUES PREPARATION FOR BIOCHEMICAL ANALYSES 
 
The day after behavioural assessment, mice received the last dose of the 
treatment and were sacrificed 4 hours later by decapitation after a mild 
anaesthesia. Brains were removed from the skull and laid on an ice chilled 
dish. Hippocampi were dissected from the brain and fresh frozen on dry ice.  
Ice-cold Lysis buffer pH 7.4 (50 mM Tris/HCl, 150 mM NaCl, 0.5 mM EDTA 
and 1% Triton X-100) was prepared and 2% of broad-range Proteases Inhibitor 
Cocktail (Sigma-Aldrich) was added. Tissues were homogenized by a Teflon-
on-glass homogenizer with 500 µL of lysis buffer. Lysates were then passed 
through a 29-gauge needle to disrupt DNA, and were then cleared by 
centrifugation at 21000 rcf for 5 minutes at 4°C. Supernatants were collected 
and stored at -80°C, and small aliquots were taken for protein quantification by 
BCA assay. 
Soluble fractions were prepared by clearing the total homogenate by 
centrifugation at 21000 rcf for 5 minutes at 4°C, and then ultracentrifugating 
the resulting supernatant at 100000 rcf for 1h. The obtained supernatants were 
taken as the soluble protein extract and protein concentrations were 
determined. 
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Where histology was required, one brain hemisphere was collected and post-
fixed in 4% paraformaldehyde overnight, dehydrated for 24h in 30% sucrose 
in PBS 1X, and frozen in N-pentane for histology analyses. 30μm-thick coronal 
sections were cut from post-fixed brains using a cryostat and placed in 24-well 
plates containing PBS 1X. 
 
3.2.7 SDS-PAGE AND WESTERN BLOTTING 
 
20 µg of proteins from brain homogenates and soluble fractions were 
denatured by boiling in SDS sample buffer added with 50 mM DTT at 95°C for 
5min. Proteins were separated on 8% or 12% poly-acrylamide gels (depending 
on the protein of interest). Electrophoresis and immunoblotting protocols were 
carried out as described in 3.1.6 paragraph.  
The following primary antibodies were used: 2C11 (not commercial IgG2a for 
full length APP, from Dr. Alessio Colombo), 22C11 (Millipore MAB348), 6E10 
(Biolegend 803001), SIRT1 (Sigma-Aldrich S5196), SIRT2 (Sigma-Aldrich 
S8447), α-tubulin (Abcam ab7291), GFAP (Millipore MAB3402), CD11b 
(Abcam ab75476), SOD1 (StressMarq SPC-206), Synaptophysin (SYSY 
101002), NRF2 (Abcam ab137550).  
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3.2.8 IMMUNOHISTOCHEMISTRY 
 
Free-floating sections were incubated in 0.6% H2O2 solution in PBS 1X for 10 
minutes to inactivate endogenous peroxidases. After washing in PBS 1X, the 
slices were blocked for 1h in 0.1% Triton x-100, 3% normal goat serum with 
gentle shaking, then the slices were incubated overnight at 4°C with the 
specific primary antibody with gentle shaking. The following primary antibodies 
were used: 6E10 (Biolegend 803001), AT8 (Thermo Fisher MN1020). 
The next day after washing the slices with PBS 1X, the sections were 
incubated with biotinylated secondary antibody for 1h at room temperature. At 
the end of this incubation, another washing step was carried out with TBS 1X, 
and then 1% avidin-biotin horseradish peroxidase complex in TBS 1X 
(Vectastain ABC HRP kit – Vector Laboratories) was added for 1h. Peroxidase 
activity was determined by reaction with a solution containing 
diaminobenzidine (DAB). The sections were washed with TBS 1X and 
mounted on gelatinated slides, dried, dehydrated and covered with mounting 
medium.  
 
3.3 Statistical analysis 
 
All the analyses reported in this chapter were processed with GraphPad 
Prism® V. 7.0 software.  
For the in vitro analyses, Kruskal-Wallis with Dunn’s post hoc test was used to 
compare groups of cellular viability, mRNA, SIRTs silencing and ELISA 
assays, Mann-Whitney test was used for H4-sw characterization, one-way 
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ANOVA followed by Tukey’s post hoc test was used for APP metabolism 
Western blotting analyses. 
For the in vivo analyses, Student’s t test or Mann-Whitney test were used for 
3xTg-AD characterization, one way or two way ANOVA with Tukey’s post hoc 
test were used for behavioural data and body weights, whereas Student’s t test 
was used for Western blotting protein analyses.  
Before applying the parametric statistics, D’Agostino-Pearson normality test 
was performed as recommended by GraphPad Prism® V. 7.0 software, to 
check for normal distributions of experimental groups.  
Data shown in the graphs correspond to the value of each experimental group 
(mean ± SEM) with respect to the correspondent control group. 
Two-tailed levels of significance were used in all the above analyses and 
p<0.05 was the cut-off for statistical significance. 
 
3.4 Hydrogels for controlled release of SIRTs modulators 
3.4.1 IN VIVO BIOCOMPATIBILITY OF HYDROGELS: AIR POUCH MODEL 
An air pouch is obtained by subcutaneous injection of sterile air into the back 
of a mouse, and mimics the synovial cavity providing an environment 
permeable to circulating inflammatory cells. 
We used this model to test the inflammatory potential of hydrogel biomaterials. 
Two hydrogels, kindly provided from Politecnico di Milano, were tested: 
1) Collagen 1.2 mg/mL + Low Molecular Weight Hyaluronic Acid (LMWHA) 2.5 
mg/mL (pH 7.0)  
2) Collagen 1.8 mg/mL + PEG2000 0.6 mg/mL (pH 7.0)  
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The hydrogels were prepared, loaded in a 1 mL syringe, and left at 37 °C for 1 
hour to obtain solidification prior to the injection in the air-pouch animal model. 
The extent of inflammatory response reflected the amount of inflammatory 
cells in the air-pouch after the injection of the tested compound (LPS was used 
as positive control, sterile saline as negative control). 
The experiment was conducted on CD-1 male mice.  
• Day 1 – air pouch formation: 5 mL of sterile air were injected subcutaneously 
on the back of the mouse, forming an air pouch. 
• Day 4 – air pouch maintenance: 5 mL of sterile air were re-injected inside 
the first air pouch.  
• Day 5 – positive stimulus and test biomaterials injection: positive control 
group received 0.5 µg LPS injection, negative control group received 1 mL 
sterile saline injection, and test groups received 1 mL of the hydrogel.  
• After 4 hours, LPS injected mice were sacrificed, 1 mL saline was injected 
into the air-pouch and the exudate was collected. 
• After 24 hours, exudates were collected from saline and biomaterial-injected 
mice. 
• Exudates were diluted and cells were counted with a Burker chamber using 
Trypan Blue dye.  
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3.4.2 IN VITRO CONTROLLED-RELEASE: HYDROGEL COMPOSITION 
 
The selected hydrogel for in vitro experiments was a type I collagen (COLL) 
and PEG2000-based semi-IPN polymeric system. 
The COLL 2.4 mg/mL stock solution was prepared as follows: 
- 80% Bovine Collagen 3 mg/mL (Sigma-Aldrich) 
- 10% PBS 10x (Phosphate Buffered Saline Solution, Sigma-Aldrich) 
- 10% NaOH 0.1 N 
The PEG2000 2.4 mg/mL stock solution was prepared dissolving the polymer 
in saline and autoclaving for 20 minutes at 121°C.  
The final hydrogel composition was COLL 1.8 mg/mL and PEG2000 0.6 
mg/mL obtained mixing three parts (v/v) of COLL stock solution with one part 
(v/v) of PEG2000 stock solution in PBS 1X.  
All the process was done on ice to prevent hydrogel polymerization during 
preparation. Ultimately, a final 500 µL mix was dispensed in 48-well plates and 
incubated at 37°C for polymerization. After 1 hour, 750 µL of supernatant (PBS 
1X) was added to polymerized hydrogels. 
 
3.4.3 UV-VIS SPECTROPHOTOMETRY: MODULATORS DETECTION AND 
STANDARD CURVE SETTING 
 
UV-VIS spectrophotometry was used to quantify SIRTs modulators 
concentration in solution at a specific absorbance wavelength (λₘₐₓ). The 
absorbance peak for SRT1720, AK7 and another SIRT2 inhibitor, AGK2 
(Sigma-Aldrich code A8231; IC50=3.5 µM), was investigated with an 
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explorative analysis (λ range = 209.6-800 nm) of the compound in PBS 1X 
solution using a UV-VIS spectrophotometer with a quartz cuvette. The solution 
was analysed in parallel with a negative control containing DMSO instead of 
the compound. 
To avoid interference given by the natural degradation of the hydrogel, the 
same explorative analysis was performed with supernatants (PBS 1X) derived 
by control hydrogels.  
To obtain the linear range between concentration of the compound and 
absorbance value at the corresponding peak, several modulator solutions with 
known concentration in PBS 1X were prepared. All the solutions were then 
analysed with Tecan Infinite® M200 at the maximum absorbance wavelength 
of the compound. 
The analysis was done in triplicate and the absorbance values were elaborated 
after subtraction of the blank (DMSO in PBS 1X) value. 
 
3.4.4 HYDROGEL-MEDIATED RELEASE STUDY AND DATA ANALYSIS 
 
For each sample, a 500 µL mix of hydrogel containing SIRTs modulator or 
DMSO (control) was prepared in triplicate in a 48-well plate, with 750 µL PBS 
1X as supernatant (Table 3.1). 
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Hydrogel solution components for 
COLL 1,8 mg/mL + PEG2000 0,6 
mg/mL final concentrations 
Volumes (μL) for each sample (total 
volume 555,56 μL) 
COLL 2.4 mg/mL 375 
PEG2000 1.8 mg/mL 125 
PBS 1X + compound/ DMSO 55.56 
 
Table 3.1 Hydrogel composition for each sample. 
 
The compound was loaded into the hydrogel in three increasing concentrations 
to assess the possibility of a load-dipendent release kinetic. Hydrogels covered 
with supernatant were placed on an orbital shaker (35 rpm) at 37°C.  
At selected time points (from 1 hour up to 7 days from hydrogels incubation), 
the supernatant was collected and replaced with 750 μl of fresh PBS 1X. 
Collected supernatants were analysed with Tecan Infinite® M200 at the 
maximum absorbance wavelength of the compound. 
The concentration of the compound was measured interpolating the obtained 
absorbance values, after blank subtraction, with the corresponding standard 
curves. The amount of modulators released in the supernatant at each time 
point was obtained by summing the concentrations acquired from the analysis 
of the supernatants taken at earlier time points.  
Once the concentration of the compoud was obtained, we calculated the 
released moles. 
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Finally, the percentage of modulator released as a function of time was 
calculated with the following formula:  
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4. Results: SIRT1 activation and 
SIRT2 inhibition in in vitro and in 
vivo AD models 
 
 
 
 
 
 
 
 
 
 
 
 
119 
 
Introduction 
Despite the continuous effort to find an effective therapeutic strategy for AD, 
still no therapy able to modify the course of the disease has been discovered.  
In recent years, the concept of multi-target therapy has increasingly 
developed, stimulating the research of hybrids or combination of drugs that 
can modify different molecular mechanisms of AD pathogenesis, obtaining 
cognitive improvement. In fact, AD presents a complex set of 
neuropathological alterations such as Aβ and aggregation and toxicity, 
neuroinflammation, synaptopathy, oxidative stress, and others, which makes 
it suitable for a multi-target intervention.  
In this perspective, the aim of the work presented in this thesis was to try a 
multi-target approach on AD models, with a combination of drugs able to 
modulate SIRT1 and SIRT2. These two proteins, members of a deacetylase 
enzymes family, were reported as opposite players in neurodegeneration, with 
a marked neuroprotective role of SIRT1 and a neurodegenerative one of 
SIRT2.  
As these two enzymes have different preferential localizations and different 
molecular targets, our hypothesis was that the contemporary activation of 
SIRT1 and inhibition of SIRT2 on AD models could provide a new strategy to 
attack the pathology from different but converging points, obtaining cognitive 
improvement. 
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Specific aims 
In the first part of the work, the combined treatment was tested on the H4-sw 
cellular AD model to assess the cytotoxicity and impact on APP metabolism, 
as these cells are a suitable model to assess APP production and processing.  
Starting from previous evidences of our laboratory on in vivo SIRT2 inhibition, 
a SIRT1 activator and SIRT2 inhibitor were given both alone and in 
combination to 6-month old 3xTg-AD mice, following an acute 2-weeks 
protocol. AD mice were characterized for cognitive impairment and specific 
pathological alterations, such as neuroinflammation, synaptic and antioxidant 
deficiency and Aβ toxic oligomers presence. All those parameters were re-
assessed on treated mice to verify cognitive deficit rescue, in order to 
characterize the pathway-specific contribution of the two SIRTs moduations to 
the overall cognitive effect, and to what extent each SIRT could be involved in 
the pathology. 
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4.1 In vitro results 
4.1.1 H4-SW CELLS  
H4-sw cell line was previously developed in our laboratory with the aim to 
create a cellular system suitable for APP production and processing analyses. 
Despite its limits due to immortalized neuroglioma origin, this cellular model is 
able to offer an indication of treatments effects on APP parameters and has 
been already used in literature [Czvitkovich S et al., 2011; Colombo A et al., 
2008; Colombo A et al., 2013; Shin J et al., 2010]. As in vitro experiments 
were aimed at preliminary evaluation of combined treatment feasibility, we 
decided to use this available and easy to use cellular tool.  
In order to characterize our in vitro model, we first verified the presence of the 
Swedish double mutation KM595/596NL, and then evaluated full-length APP 
(flAPP) over-expression in H4-sw cells, with respect to H4 native cells. We 
confirmed that H4-sw cells had a high over-expression of APP (Fig. 4.1), while 
in H4 native cells endogenous APP protein level was poorly detectable.  
 
Figure 4.1 A) PCR analysis to confirm the presence of the APP-Sw mutation in H4-sw cells. 
H4 native cells were used as negative control. B) Western blotting analysis of whole cell 
lysates from H4 and H4-sw cells, assessing flAPP protein level with 2C11 antibody, normalized 
with α-tubulin (right). Results are reported as Mean±SEM (n=4; Mann-Whitney test, * p<0.05). 
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Before treating H4-sw cells with SIRT1 activator and SIRT2 inhibitor, we also 
verified the basal expression of the two SIRTs in this model, in order to 
elucidate if the over-expression of APP-sw could interfere with expression of 
our targets of interest [Shin et al., 2010]. Figure 4.2 shows a representative 
Western blotting where SIRT2 is significantly increased in H4-sw cells, while 
SIRT1 expression level has a not significant trend towards a decrease, 
suggesting the lack of a link between APP-sw presence and SIRT1 protein 
level, even if the specific cellular model or the small sample size of the 
experiment could have contributed to this result.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Representative Western blotting analysis of three independent experiments on 
whole cell lysates from H4 and H4-sw cells, assessing SIRT1 and SIRT2 protein levels, 
normalized to α-tubulin. Results are reported as Mean±SEM (n=3; Mann-Whitney test, * 
p<0.05; SIRT1 p=0.1, SIRT2 p=0.045).  
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4.1.2 EVALUATION OF CYTOCOMPATIBILITY OF SIRT1 AND SIRT2 
MODULATION IN H4-SW CELLS 
 
In order to proceed with the combined treatment on SIRT1 and SIRT2, it was 
necessary to assess its potential cytotoxicity, so we did viability assays after 
the single and the double treatment and determined the proper concentration 
for in vitro experiments. 
AK7 is a brain-permeable and selective SIRT2 inhibitor, whose structure was 
derived from its analogue AK1. The concentration range of AK7 for cellular 
treatments was selected referring to available literature [Chen X et al., 2015; 
Wang X et al., 2015].  
The analysis of cellular viability with increasing concentrations of the SIRT2 
inhibitor AK7 showed that the modulator is not toxic in the 10-20 μM 
concentration range (AK7 IC50= 12.5 μM) (Fig. 4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 MTS assay on H4-sw cells treated for 24 hours with increasing concentrations of 
the SIRT2 inhibitor AK7. CTRL= DMSO. Results are reported as Mean±SEM (n=4; Kruskal-
Wallis and Dunn’s post hoc test).  
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For the SIRT1 activator SRT1720, we did the analysis of cellular viability with 
increasing concentrations of the compound in the 0.3-2 µM range (EC50= 0.16 
µM), as our previous experiments and literature data showed that this was the 
efficacy concentration interval for in vitro treatments [Nishida K et al., 2018; 
Minor RK et al., 2011]. In H4-sw cells, starting from 2 µM, SRT1720 leads to 
significant cytotoxicity (Fig. 4.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 MTS assay on H4-sw cells treated for 24 hours with increasing concentrations of 
the SIRT1 activator SRT1720. CTRL= DMSO. Results are reported as Mean±SEM (n=4; 
Kruskal-Wallis and Dunn’s post hoc test, * p<0.05).  
 
Next, we decided to combine the higher non-toxic dose of AK7 (20 µM) with 
increasing concentrations of SRT1720, which was the one that showed slight 
toxicity in the considered range. Analysis of cellular viability after 24 hours 
treatment revealed that the higher concentration that does not produce 
significant cellular mortality is 20 µM AK7 and 0.5 µM SRT1720 (Fig. 4.5). 
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Figure 4.5 MTS assay on H4-sw cells treated for 24 hours with 20 μM AK7 together with 
increasing concentrations of SRT1720. CTRL= DMSO. Results are reported as Mean±SEM 
(n=4; Kruskal-Wallis and Dunn’s post hoc test, * p<0.05, ****p<0.0001). 
 
4.1.3 EFFECT OF THE DOUBLE TREATMENT ON flAPP AND sAPPα 
LEVEL 
H4-sw cells have a high amyloidogenic APP metabolism and Aβ production 
[Colombo et al., 2008].  
We decided to analyse if our single or double treatments could exert an effect 
both on the production of flAPP protein and on its proteolytic processing 
fragments. Western blotting analysis on flAPP showed no change between 
untreated and treated cells, both with one or two combined modulators (Fig. 
4.6), suggesting that SIRT1 activation and SIRT2 inhibition don’t affect APP 
expression.  
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Figure 4.6 Representative Western blotting analysis on H4-sw cells treated for 24 hours with 
20 μM AK7, 0.5 μM SRT1720, and the combination of the two modulators, assessing flAPP 
protein level with 2C11 antibody, normalized to α-tubulin. CTRL= DMSO. Results are reported 
as Mean±SEM (n=6; One-way ANOVA and Tukey’s post-hoc test).  
 
After we verified that our treatment did not affect flAPP production, we 
analysed its metabolism by assessing the total pool of soluble fragments 
(sAPPα and sAPPβ) released in H4-sw conditioned media. Western blotting 
analysis on cell supernatants after the single and the combined treatments 
showed a significant increase of total sAPP protein (Fig. 4.7). 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Representative Western blotting analysis on conditioned media from H4-sw cells 
treated for 24 hours with 20 μM AK7, 0.5 μM SRT1720, and the combination of the two 
modulators, assessing sAPP protein level with 22C11 antibody, normalized to the total protein 
content of the sample. CTRL= DMSO. Results are reported as Mean±SEM (n=6; One-way 
ANOVA and Tukey’s post-hoc test; CTRL vs SRT1720 *p=0.03, CTRL vs AK7 *p=0.011, CTRL 
vs AK7+SRT1720 *p=0.047).  
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As the total pool of soluble APP increased but no indication was given on 
specific proteolytic pathway involvement, we proceeded with the analysis of 
the sAPPα fragment, to assess if sAPP increase could be related to the non-
amyloidogenic processing activation. Both AK7 and SRT1720 produced a 
significant increment of this neuroprotective protein. Moreover, with the double 
treatment we obtained a larger increase of sAPPα (Fig. 4.8) with respect to 
single modulators, suggesting that we could observe an additive effect of the 
two modulations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Representative Western blotting analysis on conditioned media from H4-sw cells 
treated for 24 hours with 20 μM AK7, 0.5 μM SRT1720, and the combination of the two 
modulators, assessing sAPPα with 6E10 antibody, normalized to the total protein content of 
the samples. CTRL= DMSO. Results are reported as Mean±SEM (n=6; One-way ANOVA and 
Tukey’s post-hoc test; *p<0.05, **p<0.01, ***p<0.001; CTRL vs SRT1720 *p=0.036, CTRL vs 
AK7 **p=0.0068, CTRL vs AK7+SRT1720 ***p=0.0004, SRT1720 vs AK7+SRT1720 
*p=0.010, AK7 vs AK7+SRT1720 *p=0.049).  
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We checked if sAPPα increase could be due to enhanced α-secretase 
(ADAM10) mRNA, as this fragment is the result of α-secretase activity, but the 
Real Time PCR result unespectedly showed that the treatments were 
uneffective on ADAM10 gene expression (Fig. 4.9), a result that is also in 
contrast with some literature data. In this case too, the data could suggest the 
hypothesis of a model-dependent effect or an effect on ADAM10 activity and 
membrane availability rather than on its mRNA level. 
 
 
 
 
 
 
 
 
 
Figure 4.9 ADAM10 mRNA levels in H4-sw cells treated for 24 hours with 20 μM AK7, 0.5 μM 
SRT1720, and the combination of the two modulators, assessed by quantitative Real time 
PCR. CTRL= DMSO. Data were calculated with the 2-ΔΔCt method, using β-actin as reference 
endogenous gene. Results are reported as Mean±SEM (n=4; Kruskal-Wallis and Dunn’s post 
hoc test).  
 
4.1.4 SIRT2 SILENCING: EFFECT ON sAPPα 
In order to deepen the relationship between sAPPα increase and SIRT2 
modulation and to verify AK7 specificity whose in vitro data are less 
represented in literature, we decided to analyse sAPPα parameter after 
transient small interfering RNA silencing (siRNA) of SIRT2 to replicate AK7 
effect. 
C T
R L
S R
T 1
7 2
0
A K
7
A K
7 +
S R
T 1
7 2
0
0 .0
0 .5
1 .0
1 .5
 
A
D
A
M
1
0
 e
x
p
re
s
s
io
n
 (
2
-∆
∆
C
t )
129 
 
SIRT2 silencing produced an increase in the neuroprotective sAPPα fragment, 
in accordance with SIRT2 pharmacological inhibition with AK7 (Fig. 4.10). 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 A) Representative Western blotting analysis on H4-sw cells treated for 48 hours 
with SIRT2 siRNA or a negative control siRNA (Scr siRNA=scrambled sequence with no match 
in human gene database), assessing SIRT2 protein level, normalized to α-tubulin. B) sAPPα 
protein analysis on H4-sw conditioned media, after 48 hours treatment with SIRT2 siRNA. 
Results are reported as Mean±SEM (n=4; Kruskal-Wallis and Dunn’s post hoc test; Mann-
Whitney test; *p<0.05; sAPPα *p=0.028). 
 
 
4.1.5 EFFECT OF SIRT1/2 MODULATION ON AMYLOIDOGENIC 
PROCESSING: sAPPβ, Aβ40 AND Aβ42 
The total sAPP increase in treated cells correlated with neuroprotective sAPPα 
increase. To draw a complete picture of APP processing, we focused our 
analyses also on the amyloidogenic pathway by assessing sAPPβ fragment 
and β-amyloid peptides (Aβ40 and Aβ42) generation. 
The double treatment produced a significant decrease of sAPPβ level, while 
the single treatments did not affect this β-secretase cleavage product. The 
same effect was evident for Aβ40 peptide (Fig. 4.11). 
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Figure 4.11 sAPPβ (A) and Aβ40 (B) ELISA assay on conditioned media from H4-sw cells 
treated for 24 hours with 20 μM AK7, 0.5 μM SRT1720, and the combination of the two 
modulators. CTRL= DMSO. Data were normalized to the total protein content of the sample. 
Results are reported as Mean±SEM (n=4; Kruskal-Wallis and Dunn’s post hoc test, *p<0.05; 
sAPPβ CTRL vs AK7+SRT1720 *p=0.0306, Aβ40 CTRL vs AK7+SRT1720 *p=0.021). 
 
The same experiment was performed with another SIRT1 activator, SRT2104, 
which is brain-permeable and has been subsequently introduced for in vivo 
treatments in the following part of the thesis. SRT2104 cytocompatibility in H4-
sw cells was previously assessed both for single and combined treatment 
(data not shown). 
In this case too, the double treatment decreased both sAPPβ and Aβ40, a 
change that was not significant in the case of single modulations (Fig. 4.12). 
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Figure 4.12 sAPPβ (A) and Aβ40 (B) ELISA assay on conditioned media from H4-sw cells 
treated for 24 hours with 20 μM AK7, 3 μM SRT2104, and the combination of the two 
modulators. Data were normalized to the total protein content of the sample. CTRL= DMSO. 
Results are reported as Mean±SEM (n=4; Kruskal-Wallis and Dunn’s post hoc test, *p<0.05; 
sAPPβ CTRL vs AK7+SRT1720 *p=0.039, Aβ40 CTRL vs AK7+SRT1720 *p=0.048). 
 
The results obtained on sAPPβ and Aβ40 suggest that the combination of the 
two treatments is necessary to produce a significant change of these 
parameters.  
We examined the effect of the treatment on Aβ42 peptide too, and the result 
was surprisingly in contrast with the previous one. In particular, the presence 
of AK7 in both the single and the double treatment conditions produced a 
significant increase in Aβ42 levels. The experiment was replicated twice, and 
performed with SRT2104 activator too, as for Aβ40 (Fig. 4.13). 
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Figure 4.13 Aβ42 ELISA assay on conditioned media from H4-sw cells treated for 24 hours 
with A) 20 μM AK7, 0.5 μM SRT1720, AK7+SRT1720 and B) 20 μM AK7, 3 μM SRT2104, 
AK7+SRT2104. Data were normalized to the total protein content of the sample. CTRL= 
DMSO. Results are reported as Mean±SEM (n=4; Kruskal-Wallis and Dunn’s post hoc test, 
*p>0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
 
Interestingly, Aβ42 level in the double-treated cells was lower than that 
observed on AK7-treated cells, suggesting that the presence of the SIRT1 
activator could interfere with this unexpected increase of Aβ42.  
To check if this AK7 effect was dependent on its action on SIRT2, Aβ42 assay 
was repeated with conditioned media from H4-sw cells treated either with the 
inhibitor AK7 or with SIRT2 siRNA. The result showed that only AK7 was able 
to increase Aβ42, while SIRT2 siRNA did not affect its level. This suggests that 
the elevated Aβ42 monomer fraction is  due to a direct interaction between 
AK7 molecule and Aβ forms, which could interfere with the ELISA assay result 
without SIRT2 involvement (Fig. 4.14).  
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Figure 4.14 Aβ42 ELISA assay on conditioned media from H4-sw cells treated either with 
SIRT2 siRNA and control siRNA (left), or with AK7 and DMSO as control (right). Data were 
normalized to the total protein content of the sample. Results are reported as Mean±SEM 
(n=4; Mann-Whitney test, **p<0.01 AK7 vs Ctrl DMSO). 
 
Different hypotheses can be formulated on this result. The first can be a side 
effect of the molecule, which could lead to reconsideration of its potential 
clinical use, even if we demonstrated that such effect was not dependent on 
SIRT2 inhibition, therefore such unspecific mechanism would still be unknown. 
We formulated another possible hypothesis that considers AK7 reacting with 
oligomeric Aβ42 through a chemical, SIRT2-independent mechanism, directly 
acting on oligomers that form in cell culture medium [Reed MN et al., 2011; 
Walsh DM et al., 2002] of H4-sw cells. We hypothesized a dissolving effect 
on oligomers leading to monomeric fraction increase, but further studies are 
needed to explore this hypothesis, as for now we found some literature 
considerations to support our idea (see Discussion section). 
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In vitro results: general conclusions 
The data obtained from our in vitro experiments demonstrated that the 
approach of combining the inhibition of SIRT2 with activation of SIRT1 is 
feasible, as it did not negatively influence the viability of the selected H4-sw 
cellular model. The main aim of this section was to obtain some indications of 
the beneficial effect of the treatment on APP proteolytic processing. We 
demonstrated that the double treatment is able to modulate the non-
amyloidogenic processing through increase of sAPPα protein fragment, known 
for its neuroprotective properties. Moreover, the combined modulation of 
SIRT1/2 showed a greater effect compared to single treatments. The 
assessment of amyloidogenic processing supported the use of the 
combination too, as the single treatments were not effective on both sAPPβ 
and Aβ40 peptide, while the double treatment decreased those two 
parameters. However, some contradictory results emerged, as the 
assessment of Aβ42 revealed a paradoxical increase with SIRT2 inhibitor 
treatment, an effect that we hypothesized to be related to an antiaggregant 
property, but that could also constitute a potential side effect of the molecule 
that needs careful investigation.  
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4.2 In vivo results 
4.2.1 3xTg-AD MICE PATHOLOGICAL PHENOTYPING 
For in vivo experiments, we selected 3xTg-AD mice between 6 and 7 months 
of age, balancing experimental groups for sex, age and weight. The selected 
age could allow to treat early-stage AD mice, harbouring a cognitive deficit and 
neuropathological alterations in a pre-plaque status, where the pathology is 
mainly related to intraneuronal Aβ accumulation and oligomers toxicity, thus 
mimicking an early intervention strategy in humans . 
At this age, mice present a significant cognitive deficit, measured by NORT, 
where the mean discrimination index (DI) of NTg mice (see Materials and 
Methods 3.2.5) is between 0.3 and 0.4, while the mean discrimination index of 
3xTg-AD mice is close to zero (Fig. 4.15). 
A phenotypic characterization of these mice showed that both extracellular and 
intraneuronal Aβ are detectable in hippocampus, while a very low detectability 
was obtained in the cortex, so we decided to focus our neuropathological 
analyses on brain samples of hippocampal origin. 
This feature is partially in line with what has been described by other research 
groups that characterized the temporal and regional progression of pathology 
in 3xTg-AD model [Oddo S et al., 2006; Belfiore R et al., 2018]. With respect 
to what was reported previously [Mastrangelo and Bowers, 2008] in the 
original model characterization, there is some temporal delay in the 
development of the pathology, as pointed out by Belfiore and colleagues 
[Belfiore R et al., 2018]. 
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Figure 4.15 Discrimination Index of 3xTg-AD and NTg mice at 6 months of age, measured by 
the Novel Object Recognition Test (NORT). Results are reported as Mean±SEM (n=8; 
Student’s t test, **p=0.0011). 
 
Prior to plaques formation, Aβ accumulates intracellularly mostly at 
hippocampal level, at the age of 6 months. 
Mice show Aβ senile plaques deposition starting from 12 months of age, 
detectable in hippocampus but not in cortex (Fig. 4.16). 
 
 
Figure 4.16 Immunohistochemistry for Aβ plaques using 6E10 antibody on coronal 30 µm-
thick brain sections from 3xTg-AD mice. The panel shows the temporal profile of intracellular 
Aβ at 6 months and plaques deposition from 12 to 22 months of age. 
 
Some immunoreactivity for NFTs is detectable in the hippocampus from 19 
months of age, while 6-months old 3xTg-AD mice do not show the presence 
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of PHF-tau (Fig. 4.17), accordingly to literature data about a  late development 
of tau tangles in transgenic AD mice [Belfiore R et al., 2018]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 Immunohistochemistry for tau tangles (PHF tau) using AT8 antibody on coronal 
30 µm-thick brain sections from 3xTg-AD at 19 and 6 months of age. The panel shows 
magnifications of the hippocampal regions, highlighting some signal at the age of 19 months 
but not at 6 months. The white arrows point to positive hippocampal neurons that accumulate 
phospho-tau in their soma. 
 
 
Then, we evaluated the detectability of hippocampal soluble Aβ oligomers in 
samples from 3xTg-AD mice with the widely used human Aβ antibody 6E10. 
This commercial antibody has been used for AβO detection by other groups 
[Amar F et al., 2017] despite some concerns could be raised on its potential 
cross-reactivity with mouse tissue samples due to its mouse IgG nature, as 
well as on its inability to detect all the Aβ forms [Hunter S and Brayne C, 
2017].  
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We were able to detect a high molecular weight signal at 55 kDa, absent in 
NTg hippocampus, possibly representing Aβ*56 form, which is an oligomeric 
form related to the presence of cognitive impairment [Lesnè S et al., 2006; 
Billings LM et al., 2007]. A low molecular weight signal was visible near 15 
kDa, which could represent a smaller aggregate form. Other specific signals 
were not detectable with this method (Fig. 4.18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Western blotting analysis on hippocampal soluble fractions of 3xTg-AD and NTg 
mice at 6 months, assessing Aβ soluble oligomers with 6E10 antibody. One clear specific 
signal was detected, possibly representing a high-molecular weight aggregate form (55 kDa). 
Another weaker signal was present near 15 kDa, corresponding to the expected molecular 
weight of a trimeric aggregate. Other signals were attributable to unspecific binding.  
 
At hippocampal level, 3xTg-AD mice show also an increase in 
neuroinflammation markers GFAP and CD11b, and a decrease in the 
presynaptic marker Synaptophysin. We also assessed the level of NRF2, a 
master regulator of oxidative stress response, and detected a trend towards 
the decrease of this transcription factor (Fig. 4.19). 
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Figure 4.19 Western blotting analysis on hippocampal lysates of 3xTg-AD and NTg mice at 6 
months, assessing (A) CD11b, (B) GFAP, (C) Synaptophysin and (D) NRF2. Data were 
normalized to α-tubulin and are presented as Mean±SEM (n=4; Mann-Whitney test, *p<0.05; 
A *p=0.050, B *p=0.028, C *p=0.04, D p=0.0571).  
 
We also assessed the basal expression of SIRT1 and SIRT2 in our model. As 
shown in Figure 4.20, SIRT1 expression was not different between 3xTg-AD 
and NTg mice. Differently, hippocampal SIRT2 basal expression in 3xTg-AD 
mice is higher than NTg mice. This corroborates our rationale of inhibiting 
SIRT2 for pathological phenotype improvement, while it seems that in our 
experimental model we are not in the condition of a SIRT1 deficiency and the 
treatment should boost its neuroprotective activity. 
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Figure 4.20 Western blotting analysis on hippocampal lysates of 3xTg-AD and NTg mice at 6 
months, assessing SIRT1 and SIRT2. Data were normalized to α-tubulin and are presented 
as Mean±SEM (n=4; Mann-Whitney test *p>0.05; SIRT2 NTg vs 3xTg-AD *p=0.029).  
 
All the characterization results suggest that our 3xTg-AD mice have a group of 
neuropathological alterations including neuroinflammation and an indication of 
synaptic deficit, which with the presence of high intracellular Aβ and oligomers 
could contribute to cognitive impairment establishment and memory loss.  
 
4.2.2 EFFECT OF SIRT2 INHIBITION AND SIRT1 ACTIVATION ON 3xTg-
AD COGNITIVE PERFORMANCE 
As already demonstrated by Biella et al. in 2016, 2 weeks treatment of 3xTg-
AD mice at 6-8 months with AK7 leads to cognitive deficit improvement. In 
addition, AK7-treated mice had an increased non-amyloidogenic and 
decreased amyloidogenic APP processing, in the hippocampus. We replicated 
the NORT behavioural data on 6 months-old mice (8 mice per group) in order 
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to assess the reproducibility of the protocol and move on with the combined 
treatment approach.  
First, we verified that AK7 treatment was well tolerated, as assessed by body 
weight monitoring during the experiment (Fig. 4.21). Body weight was not 
significantly different between treated and untreated mice. 
 
 
 
 
 
 
 
 
 
 
Figure 4.21 Body weight monitoring of 3xTg-AD mice treated with AK7 or vehicle, assessed 
on day 1 and day 15. Data are presented as Mean±SEM (n=8; Two-way ANOVA and Tukey’s 
post hoc test; p>0.05).  
 
 
We decided to treat 3xTg-AD mice only, as we focused our objective on closely 
detecting an improvement of the pathologic phenotype dependent on mutated 
human transgenes expression, favouring this aspect over the assessment of 
an effect on the healthy mouse phenotype. Our decision was also supported 
by the fact that SIRT2 inhibition with AK7 did not show pro-cognitive effect on 
NTg mice [Biella G et al., 2016]. However, it could be possible that SIRT1 
treatment or the combined one boost cognitive functions in NTg mice too, as 
in our experimental set-up we are masking the contribution given by genotype 
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to our treatment effects. This could be a limit of our experimet’s design, and a 
complete assessment on both a treatment- and genotype-dependent basis 
should be taken into consideration for future experiments. 
Treated and untreated 3xTg-AD mice, together with a NTg control group taken 
for baseline measurement, were tested for cognitive impairment with the 
NORT as described in Methods.  
Total exploration time of the training and testing phases was calculated and 
was not significantly different among groups (Fig. 4.22).  
 
 
 
 
 
 
 
 
 
 
Figure 4.22 Total exploration time of training and testing phases for each experimenttal group. 
Data are presented as Mean±SEM (n=8; One-way ANOVA and Tukey’s post hoc test; p>0.05; 
NTg vs 3xTg-AD Vehicle p=0.115 for Training, p=0.08 for Test).  
 
The % of investigation on the familiar and the novel object during the test 
phase was calculated. As shown in Figure 4.23, the vehicle-treated 3xTg mice 
did not show a difference in the % of investigation between the familiar and the 
novel object, suggesting no preference for a specific object. The AK7-treated 
mice, instead, spent more time exploring the novel object, as NTg mice did. 
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Figure 4.23 % of investigation on the familiar and the novel object for each experimental 
group, during the test phase. Data are presented as Mean±SEM (n=8; Repeated measures 
Two-way ANOVA and Tukey’s post hoc test; *p<0.05, **p<0.001).  
 
AK7 treatment produced the recovery of memory deficit in 3xTg-AD mice (DI 
3xTg AK7 vs. DI 3xTg vehicle *p<0.05) (Fig. 4.24), that had a mean DI similar 
to NTg mice. 
 
 
 
 
 
 
 
 
 
Figure 4.24 Discrimination Index of 3xTg-AD mice treated with AK7 or vehicle, measured by 
the Novel Object Recognition Test (NORT). Results are reported as Mean±SEM (n=8; One-
way ANOVA and Tukey’s post hoc test, NTg vs 3xTg-AD Vehicle ***p<0.001, 3xTg-AD Vehicle 
vs 3xTg-AD AK7 *p=0.0114). 
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We selected another group of 6-months old 3xTg-AD mice to be treated with 
the SIRT1 activator SRT2104, for two weeks, by oral gavage (8 mice per 
group).  
SIRT1 activator administration was well tolerated, as assessed by body weight 
monitoring during the treatment (Fig. 4.25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.25 Body weight monitoring of 3xTg-AD mice treated with SRT2104 or vehicle, 
assessed on day 1 and day 15. Data are presented as Mean±SEM (n=8; Two-way ANOVA 
and Tukey’s post hoc test, p>0.05).  
 
As we did for AK7 experiment, we assessed cognitive performance with 
NORT, together with the NTg control group. Again, total exploration time of the 
training and testing phases was not significantly different between groups (Fig. 
4.26).  
It is worth to notice a substantial difference in exploration times between this 
experiment and the one in Figure 4.22. In fact, AK7 treatment resulted in total 
exploration times below 15 seconds, while Figure 4.26 shows longer 
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explorative activity both in training and testing phase of SRT2104 treatment. 
As an explanation for the oscillations between the experiments and 
experimental groups, one point to clarify is that these animals do not show long 
exploratory activity as a characteristic of the 129SV strain, which is quite 
sensitive to anxious situations [van Bogaert MJ et al., 2006]. In general, the 
exploratory activity presents some variability depending on the animals, the 
treatment protocol, the operator and the handling. In the AK7 experiment, 
which was the first of the set, a handling factor could have influenced the 
propensity of the animals to move and explore, a factor that with operator 
training and further experiments became less evident. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26 Total exploration time of training and test phases for each experimental group. 
Data are presented as Mean±SEM (n=8; One-way ANOVA and Tukey’s post hoc test; p>0.05).  
 
As shown in Figure 4.27, vehicle-treated 3xTg mice did not show a difference 
in the % of investigation between the familiar and the novel object, while 
SRT2104-treated and NTg mice spent more time exploring the novel object. 
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Figure 4.27 % of investigation on the familiar and the novel object for each experimental 
group, during the test phase. Data are presented as Mean±SEM (n=8; Repeated measures 
Two-way ANOVA and Tukey’s post hoc test; ****p<0.0001). 
 
Like SIRT2 inhibition, SIRT1 activation was able to recover cognitive deficit of 
3xTg-AD mice (DI 3xTg SRT2104 vs. DI 3xTg vehicle **p<0.01), as shown by 
DI calculation in Figure 4.28, where the mean DI of SRT2104-treated mice was 
tendent to that of NTg group. 
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Figure 4.28 Discrimination Index of 3xTg-AD mice treated with SRT2104 or vehicle, measured 
by the Novel Object Recognition Test (NORT). Results are reported as Mean±SEM (n=8; One-
way ANOVA and Tukey’s post hoc test, NTg vs 3xTg-AD Vehicle ***p<0.001, 3xTg-AD Vehicle 
vs 3xTg-AD AK7 **p=0.002). 
 
Considering the behavioural results presented above, the two single 
treatments on SIRT1 and SIRT2 were able to favour cognitive damage 
recovery of 3xTg-AD mice, so we decided to move on with our overall objective 
combining these two approaches. We treated 6 months-old 3xTg-AD mice with 
intraperitoneal SIRT2 inhibitor and oral SIRT1 activator, for 2 weeks. 
Before the experiment, we performed a preliminary evaluation of the stress 
related to the procedure and of DMSO potential toxicity. Mice’s general health 
status and body weight were constantly monitored during a one-week trial with 
vehicle containing DMSO both for intraperitoneal and oral dosing, and were 
not affected by the double treatment (data not shown).  
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As we did for the single treatments, during AK7/SRT2104 protocol we 
monitored mice’s general health state and body weight (Fig. 4.29). No 
difference in body weight was evident. 
 
 
 
 
 
 
 
 
 
 
Figure 4.29 Body weight monitoring of 3xTg-AD mice treated with AK7+SRT2104 or vehicle, 
assessed on day 1 and day 15. Data are presented as Mean±SEM (n=8; Two-way ANOVA 
and Tukey’s post hoc test, p>0.05).  
 
Animals were subjected to NORT protocol for cognitive assessment, following 
the same timeline of the previous experiments.  
Total exploration time of the training and testing phases was calculated and 
was not significantly different among groups (Fig. 4.30). 
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Figure 4.30 Total exploration time of training and testing phases for each experimental group. 
Data are presented as Mean±SEM (n=8; One-way ANOVA and Tukey’s post hoc test; p>0.05).  
 
 
As shown in Figure 4.31, the vehicle-treated 3xTg mice showed no significant 
difference in the % of investigation between the familiar and the novel object, 
while AK7/SRT2104-treated mice spent more time exploring the novel object. 
 
 
 
 
 
 
 
 
 
 
Figure 4.31 % of investigation on the familiar and the novel object for each experimental 
group, during the test phase. Data are presented as Mean±SEM (n=8; Repeated measures 
Two-way ANOVA and Tukey’s post hoc test; ****p<0.0001). 
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The double treatment significantly improved the cognitive performance of 
3xTg-AD mice (DI 3xTg AK7+SRT2104 vs. DI 3xTg vehicle ****p<0.0001), 
which had a mean DI comparable to that of NTg mice (Fig. 4.32).  
 
 
 
 
 
 
 
 
 
 
Figure 4.32 Discrimination Index of 3xTg mice treated with AK7+SRT2104 or vehicle, 
measured by the Novel Object Recognition Test (NORT). Results are reported as Mean±SEM 
(n=8; One-way ANOVA and Tukey’s post hoc test, **p<0.0015, ****p<0.0001). 
 
This result confirms that when AK7 and SRT2104 modulators are given in 
combination are still able to lead to complete cognitive deficit recovery. 
 
4.2.3 EFFECT OF SIRT2 INHIBITION AND SIRT1 ACTIVATION ON AD-
RELEVANT NEUROPATHOLOGIC PATHWAYS 
 
AK7 treatment acted on APP metabolism in vivo, leading to sAPPβ decrease 
and sAPPα increase, as previously reported [Biella G et al., 2016] and 
suggested by in vitro data obtained in this thesis. Starting from this point, we 
checked sAPPα level in SRT2104 treated mice too, and we detected a 
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significant increase of this protein in hippocampus (Fig. 4.33A). sAPPα level 
resulted significantly increased also in double-treated mice (Fig. 4.33B).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.33 Representative Western blotting analysis on hippocampal soluble fractions of 
3xTg-AD mice treated with SRT2104 (A) or AK7+SRT2104 (B), assessing sAPPα protein 
normalized to α-tubulin. Data are presented as Mean±SEM (n=8; Student’s t test, *p<0.05; 
Vehicle vs SRT2104 p=0.0168, Vehicle vs AK7+SRT2104 p=0.04).  
 
As mentioned previously we were able to identify, in hippocampal soluble 
fractions of 3xTg-AD mice, a 55 kDa SDS-resistant form of Aβ, that we assume 
to be the called Aβ*56, whose presence was correlated to cognitive deficits 
[Lesnè S et al., 2006; Cheng IH et al., 2007; Amar F et al., 2017].  
We performed Western blotting on hippocampal soluble fractions from treated 
3xTg-AD mice and assessed the level of the 55 kDa Aβ. The results in Figure 
4.34A-B show that AK7 treatment significantly reduced 55 kDa Aβ, with 
respect to the vehicle-treated group, while SIRT1 activation with SRT2104 was 
ineffective on this Aβ aggregate.  
Again, in double-treated mice there was a significant reduction of 55 kDa Aβ 
(Fig. 4.34C), reflecting the result obtained with single modulations. 
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Figure 4.34 Representative Western blotting analysis on 55 kDa Aβ aggregates, assessed 
with 6E10 antibody in the hippocampus of 3xTg-AD mice treated with AK7 (A), SRT2104 (B) 
or the combination of the two modulators (C). Target proteins were normalized to β-actin. The 
stars point to unspecific bands. Data are presented as Mean±SEM (n=8; Student’s t test, 
*p<0.05; Vehicle vs AK7 p=0.0186, Vehicle vs AK7+SRT2104 p=0.0113).  
 
This result could support the hypothesis that AK7 exerts its effect on Aβ 
aggregation, reducing oligomers fraction and contributing to cognitive 
recovery.  
At this point, we decided to move beyond the investigation of APP metabolism 
and shift our attention to other relevant pathways of AD neuropathology, such 
as neuroinflammation, oxidative stress and synaptic physiology.  
First, we evaluated GFAP and CD11b as neuroinflammation markers of 
astrocytes and microglia, respectively. These two markers were over-
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expressed in the hippocampus of 6-months old 3xTg-AD mice, as shown in 
4.2.1 section.  
Western blotting analysis revealed that both GFAP and CD11b were reduced 
by SRT2104 treatment (Fig. 4.35A-B), while no significant change was 
detected in mice treated with AK7 (Fig. 4.35C-D).  
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Figure 4.35 Representative Western blotting analysis on GFAP and CD11b, assessed in the 
hippocampus of 3xTg-AD mice treated with SRT2104 (A-B), or AK7 (C-D). Target proteins 
were normalized to α-tubulin. Data are presented as Mean±SEM (n=8; Student’s t test, 
*p<0.05, **p<0.01; CD11b Vehicle vs SRT2104 *p=0.048, GFAP Vehicle vs SRT2104 
**p=0.0038).  
 
The reduction of neuroinflammation markers was confirmed in double-treated 
mice, where SRT2104 and AK7 were given together. In fact, both GFAP and 
CD11b were significantly reduced (Fig. 4.36). 
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Figure 4.36 Representative Western blotting analysis on (A) GFAP and (B) CD11b, assessed 
in the hippocampus of 3xTg-AD mice treated with SRT2104 together with AK7. Target proteins 
were normalized to α-tubulin. Data are presented as Mean±SEM (n=8; Student’s t test, 
*p<0.05; GFAP *p=0.0343, CD11b p=0.042).  
 
As previously shown (Fig. 4.19) Synaptophysin hippocampal level was 
significantly reduced in 3xTg-AD mice at the age of 6 months. We found that 
SIRT1 activation with SRT2104 was able to significantly increase 
Synaptophysin level (Fig. 4.37A), while no effect was seen with SIRT2 
inhibition (Fig. 4.37B). 
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Figure 4.37 Representative Western blotting analysis on Synaptophysin, assessed in the 
hippocampus of 3xTg-AD mice treated with SRT2104 (A) or AK7 (B). Target proteins were 
normalized to α-tubulin. Data are presented as Mean±SEM (n=8; Student’s t test, *p<0.05; 
Vehicle vs SRT2104 *p=0.021).  
 
This positive modulation was confirmed in double-treated mice, where 
SRT2104 and AK7 were administered together (Fig. 4.38). 
 
 
 
 
 
 
 
 
 
Figure 4.38 Representative Western blotting analysis on Synaptophysin, assessed in the 
hippocampus of 3xTg-AD mice treated with SRT2104 together with AK7. Target proteins were 
normalized to α-tubulin. Data are presented as Mean±SEM (n=8; Student’s t test, *p=0.0363).  
 
 
A clear connection has been established between APP protein misfolding, 
aggregation and ROS production [Mondragon-Rodriguez S et al., 2013]. 
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Provided that, we evaluated the hippocampal level of two antioxidant proteins: 
the transcription factor NRF2, whose levels were slightly reduced in 3xTg-AD 
mice, and the enzyme SOD1, an important player of the antioxidant machinery 
that was reported to be connected to NRF2 pathway [Park EI and Rho HM, 
2002; Mota SI et al., 2015]. NRF2 defects were also correlated to AD 
pathology and SIRT1/2 activities [Xue F et al., 2016; Yang X et al., 2017]. 
Western blotting analysis revealed that SIRT1 activation significantly 
increased both NRF2 and SOD1 (Fig. 4.39A), while SIRT2 inhibition did not 
affect the level of the two proteins (Fig. 4.39B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.39A Representative Western blotting analysis on SOD1 and NRF2, assessed in the 
hippocampus of 3xTg-AD mice treated with SRT2104. Target proteins were normalized to α-
tubulin. Data are presented as Mean±SEM (n=8; Student’s t test, *p<0.05; SOD1 Vehicle vs 
SRT2104 p=0.037, NRF2 Vehicle vs SRT2104 p=0.035).  
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Figure 4.39B Representative Western blotting analysis on SOD1 and NRF2, assessed in the 
hippocampus of 3xTg-AD mice treated with AK7. Target proteins were normalized to α-tubulin. 
Data are presented as Mean±SEM (n=8; Student’s t test, *p<0.05; NRF2 Vehicle vs AK7 
p=0.056).  
 
 
The combined treatment with SRT2104 and AK7 confirmed a significant 
increase of both hippocampal SOD1 and NRF2 (Fig. 4.40). 
 
 
 
 
 
 
 
 
 
159 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.40 Representative Western blotting analysis of (A) SOD1 and (B) NRF2, assessed 
in the hippocampus of 3xTg-AD mice treated with SRT2104 together with AK7. Target proteins 
were normalized to α-tubulin. Data are presented as Mean±SEM (n=8; Student’s t test, 
**p<0.01; SOD1 Vehicle vs AK7+SRT2104 p=0.0072, NRF2 Vehicle vs AK7+SRT2104 
p=0.0051).  
 
 
In vivo results: general conclusions 
Overall, in vivo results are supportive of our hypothesis about the beneficial 
effect of SIRT1/2 modulation both at cognitive and biochemical level. NORT 
behavioural assay resulted in a recovery of the cognitive impairment measured 
on 3xTg-AD mice through the visual recognition task. All treatments led to 
improved cognitive performance, and biochemical results defined the 
contribution of each of the two modulations to the effects on different molecular 
targets. While both SIRT1 activation and SIRT2 inhibition seem involved in the 
increase of sAPPα, as already demonstrated in cellular experiments, SIRT1 
activation could be more active on antioxidative response stimulation, synaptic 
density and neuroinflammation, while SIRT2 inhibition could affect mostly 
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amyloid-related parameters with milder effect on other pathways, at least in 
these experimental conditions. The use of the combined treatment could not 
only ensure cognitive recovery, but also integrate some disease-modifying 
molecular effects that are dependent by the single modulations and could 
influence each other’s. A direct comparison between the single and the double 
treatments is mandatory to evaluate whether the extent of the cognitive and 
biochemical effect could be synergic or not, in parallel with a more complete 
drawing of the cognitive picture, measulrable through multiple memory tasks 
and multiple time-points of testing. 
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5. Results: in vitro set-up of a 
hydrogel-based controlled release 
system for SIRTs modulators 
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Introduction  
Although SIRTs modulators, including those used in this work, have interesting 
pharmacological properties in AD models, there are limits to their 
administration in complex systems, including in vivo models of pathology. 
These limits are mainly the inability to pass through the BBB by passive 
diffusion or their rapid clearance, or even both. For these reasons, we 
considered the characterization of a hydrogel matrix loaded with SIRTs 
modulators, in search of a controlled release delivery system of these 
neuroactive molecules. For this preliminary study, we considered the SIRT2 
inhibitor AK7 because it possesses one of the aforementioned limitations. 
Despite the brain permeability and SIRT2 selectivity, AK7 has a short half-life 
(2 h) and IC50 of 15.5 µM that makes it moderately potent. Thus, it could be 
considered for a controlled release from the periphery to the CNS using the 
hydrogel, avoiding repeated administrations, but also a direct CNS prolonged 
administration to minimize periphery loss [Li J and Mooney DJ, 2016]. In 
parallel with AK7, we decided to include in the analysis another well 
documented SIRT2 inhibitor, called AGK2, that we used in previous work 
[Villalba JM and Alcaín FJ, 2012; Biella G et al., 2016]. This choice was 
supported by the fact that AK7 showed some paradoxical results during in vitro 
experiments on Aβ42 that cannot completely exclude a potential side effect. In 
addition, AGK2 has an IC50 of 3.5 µM, thus suggesting better potency. As a 
limit, AGK2 is not brain-permeable, which makes it a good candidate for a 
controlled-release system directly in the target site (CNS).  
A controlled release of SIRT1 activator was evaluated too, using SRT1720 as 
candidate instead of SRT2104, both because of its higher potency (EC50 
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ranging in nM interval respect to EC50 in µM range for SRT2104) and its 
inability to cross the blood-brain barrier, supporting the use of the hydrogel for 
controlled CNS release.  
For controlled release, fundamental characteristics of the selected polymeric 
system are injectability, biocompatibility and biodegradability. 
Injectable hydrogels are excellent vehicles for the specific site release of drugs 
(drug delivery) in the CNS as they can be implanted with minimally invasive 
techniques. In fact, these materials can be injected in liquid form and gelate in 
situ. Biocompatibility avoids post implantation inflammatory reactions, while 
biodegradability, finally, makes it possible to eliminate it from the organism 
without requiring additional surgical intervention [Pakulska MM et al., 2012]. 
These preliminary tests will allow having an idea about the potentiality of using 
hydrogel-based systems for the administration of SIRTs modulators with 
pharmacokinetic and chemical characteristics varying case by case. 
 
Specific aims 
In this part of the work, a hydrogel matrix was selected basing on the in vivo 
biocompatibility and SIRTs modulators capability to gelate inside the 
formulation.  
Next, a SIRT1 activator and a SIRT2 inhibitor were analysed by 
spectrophotometric technique to obtain a maximum absorbance peak (λₘₐₓ), 
and their release kinetic from the hydrogel matrix was assessed. 
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5.1 Hydrogel in vivo biocompatibility and matrix selection 
To test the potential release system for SIRTs modulators, we initially 
considered two different semi-synthetic semi-IPN hydrogels, and tested their 
inflammatory potential after peripheral implantation in the air-pouch model 
described in Materials and Methods section 3.4.1: 
1) Collagen 1.2 mg/mL + Low Molecular Weight Hyaluronic Acid (LMWHA) 2.5 
mg/mL (pH 7.0)  
2) Collagen 1.8 mg/mL + PEG2000 0.6 mg/mL (pH 7.0)  
After the injection of LPS, saline or the two biomaterials in the air pouch, the 
exudates were collected, and inflammatory cells were counted. The count 
revealed that neither of the two hydrogels produced a significant inflammatory 
reaction at the site of injection, suggesting that in vivo implantation of these 
biomaterials could be safe (Fig. 5.1). 
 
 
 
 
 
 
 
 
Figure 5.1 Cell count in the exudates collected from air pouches containing LPS, saline, 
COLL+LMWHA hydrogel, and COLL+PEG hydrogel. Data are presented as Mean±SEM (n=5, 
One-way ANOVA and Tukey’s post hoc test; ****p<0.0001). 
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Of the two available hydrogels, we chose the COLL+PEG2000 formulation.  
In fact, in a preliminary test SRT1720, AK7 and AGK2 compounds were loaded 
into both hydrogels, but the COLL+HA hydrogel was not able to gelate after 1 
hour incubation. We hypothesized that the cause could be an interference of 
DMSO with the hydrogel components. On the other hand, COLL+PEG2000 
biomaterial easily gelated after loading and incubation with all modulators.  
 
5.2 Spectrophotometric analysis of SIRTs modulators 
Known concentrations of SRT1720, AGK2 and AK7 were analysed by an 
explorative assay (λ range = 209.6-800 nm) with an UV-Vis 
spectrophotometer, looking for an absorbance peak of the molecule.  
The manufacturer indicated the absorbance peak of SRT1720, and we 
confirmed this parameter, detecting a maximum absorbance peak at 244 nm 
(λₘₐₓ) (Fig. 5.2). 
 
 
Figure 5.2 Spectrophotometric analysis of a 25 µM solution of SRT1720 in PBS 1X vs blank 
(PBS 1X with DMSO in equivalent volume). The maximum absorbance peak at 244 nm is A ≈ 
0,820. 
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The λₘₐₓ of AGK2 was unknown, so two different concentrations of the 
modulator were prepared from DMSO stock solutions. Dilutions in PBS 1X or 
H2O were prepared in ratios that not affect solubility in an aqueous solvent, 
which is essential for spectrophotometric analysis. 
Two peaks were detected, at 233 nm and 359 nm (Fig. 5.3). 
The λₘₐₓ=359 nm was selected for AGK2 quantification analysis, and PBS 1X 
was chosen as supernatant as the peak intensity (pink and green lines) was 
higher than that obtained with H2O (blue and yellow lines). The peak intensity 
was also proportional to the concentration of the modulator. 
 
 
 
 
 
 
 
Figure 5.3 Spectrophotometric analysis of 100 µM AGK2 in PBS 1X (pink) and in H₂O (green) 
or 75 µM AGK2 in PBS 1X (blue) and in H₂O (yellow) vs blank (PBS 1X and H₂O with DMSO 
in equivalent volume). The maximum absorbance peak at 359 nm for PBS 1X solutions is A ≈ 
1.210 for 100 µM AGK2 and A ≈ 0.880 for 75 µM AGK2. 
 
The same spectrophotometer scan was performed with AK7, as no information 
was available regarding the presence of a chromophore in its chemical 
structure. Unfortunately, no peak was detectable for this molecule, suggesting 
that AK7 need another type of analytical technique for quantification (Fig. 5.4). 
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Figure 5.4 Spectrophotometric analysis of 40 µM AK7 in PBS 1X vs blank (PBS 1X with DMSO 
in equivalent volume). No peak was detectable, using both a quartz (yellow) or a plastic (green) 
cuvette. 
 
The hydrogelic matrix where SIRTs modulator are to be loaded is 
biodegradable, and for this reason, any interference in spectrophotometric 
readings due to gel components leakage was investigated. 
The analysis of supernatants from unloaded COLL+PEG2000 hydrogels, after 
24 - 48 - 72 hours of incubation, revealed no peaks at the λₘₐₓ of SRT1720 
and AGK2 (Fig. 5.5). 
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Figure 5.5 Spectrophotometric analysis of unloaded hydrogel supernatants collected at 24, 
48 and 72 hours. No peak was detectable at the absorbance wavelength of AGK2 and 
SRT1720 (359 nm and 244 nm, respectively). 
 
After the determination of the λₘₐₓ for AGK2 and SRT1720, we verified the 
linear correlation between their concentration and the absorbance.  
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We obtained two calibration curves (Fig. 5.6) to use in the release kinetic study 
to extrapolate the unknown concentrations of modulators released at 
increasing time points.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Concentration-absorbance correlation for (A) AGK2 and (B) SRT1720, assessed 
by spectrophotometric analysis at the absorbance λₘₐₓ (Linear regression; n=3 for each point). 
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5.3 Release kinetic study 
 
As described in Materials and Methods section 3.4.4, the supernatants from 
AGK2- and SRT1720-loaded hydrogels were collected at different time points 
and analysed to determine the concentration of the released SIRTs modulator.  
 
• SRT1720 
30, 60 and 90 µM SRT1720, corresponding to 15-30-45 nmol, were loaded in 
the hydrogel of COLL 1.6 mg / mL + PEG2000 0.6 mg / mL. After each time 
point, the supernatant was replaced with fresh PBS 1X and the amount of 
released modulator was calculated by adding the amounts acquired from the 
supernatants taken from previous time points. 
SRT1720 was released at decreasing rate with time (Fig. 5.7). Moreover, there 
was a correlation between the modulator’s released nanomoles and the initial 
load (15-30-45 nmol). Independently from the starting hydrogel loading, the % 
of released modulator over time was the same. After 168 h from hydrogel 
loading, the % of released SRT1720 was 92.8% ± 5.2% of total loading (Fig. 
5.8). 
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Figure 5.7 Spectrophotometric analysis of supernatants collected from hydrogels loaded with 
15 (blue), 30 (green), 45 (red) nmol SRT1720. The graph represents the released nmol over 
time (0-168 hours). (Nonlinear regression, curve fit; n=4). 
 
 
 
 
 
 
 
 
 
Figure 5.8 Spectrophotometric analysis of supernatants collected from hydrogels loaded with 
15 (blue), 30 (green), 45 (red) nmol SRT1720. The graph represents the % SRT1720 released 
by the hydrogel over time, with respect to the total loading. (Nonlinear regression, curve fit; 
n=4). 
 
The release mechanism of SRT1720 was then studied taking in consideration 
four different kinetic models: zero order, first order, Korsmeyer-Peppas and 
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quadratic. The rate constants (k) and the determination coefficients (R2) were 
obtained through linear regression (best fitting).  
The zero order and the first order models produced R2 values of 0.768 and 
0.81, respectively.  
The best correlation values (best fitting) were obtained with the quadratic 
kinetic model (R² = 0.925) and with the Korsmeyer-Peppas model (R² = 0.976), 
suggesting an active release mechanism from the hydrogelic matrix controlled 
by diffusion and little influenced by matrix swelling (Fig. 5.9). 
 
 
 
 
 
 
 
 
Figure 5.9 Korsmeyer-Peppas model: logaritmic transformation of SRT1720 cumulative 
release (Linear Regression; n=4). 
 
A summary of data elaboration is presented in the table below (Table 5.1). 
173 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1 Mathematical elaboration of recorded cumulative absorbance values. For each time 
point, mean values are reported in the table. % data are reported as the mean value of all the 
considered loading concentrations. 
 
In summary, these experiments have shown that the controlled release of the 
SIRT1 activator SRT1720 by a biocompatible collagen-based hydrogel is 
feasible. 
 
• AGK2 
AGK2 was loaded into the hydrogel of COLL 1.6 mg/mL + PEG2000 0.6 
mg/mL in three concentrations: 300-600-900 μM, corresponding to 150-300-
450 μmol of modulator. 
As in the case of SRT1720, the aim was to avoid obtaining a release not 
detectable by spectrophotometry. 
Unfortunately, the absorbance values recorded at each load concentration 
examined were close to zero (Fig. 5.10). 
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The result suggests that the molecule is not released from the matrix, and the 
reasons need further investigation. A hypothesis could be the presence of a 
sufficiently strong, maybe covalent, interaction between the molecule and the 
matrix components. 
 
 
 
 
 
 
 
 
Figure 5.10 Spectrophotometric analysis of supernatants collected from hydrogels loaded with 
150 (blue), 300 (green), 450 (red) μmol AGK2. (n=4). 
 
 
General conclusions 
The data presented in this last section are still preliminary, but supported the 
idea of the potential usefulness of hydrogels as DDS for SIRTs modulators, in 
accordance with available literature. Our results showed in vivo 
biocompatibility of a Type I collagen/PEG2000 semi-interpenetrated hydrogel, 
and its potential application to the characterization of SIRTs modulators 
controlled-release, based on the assumption that some of those compounds 
possess pharmacokinetic issues that require non-conventional 
administrations. Unfortunately, the optimization of such complex systems 
needs deep study, as only one of the chosen compounds, the SIRT1 activator 
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SRT1720, was suitable for controlled-release detection and analysis in our 
experimental conditions. This suggests that, despite the potentialities of 
hydrogel-based DDS, their use for SIRTs modulators loading and release is 
still far from the application to in vivo models and clinic, and needs further 
investigation. 
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6. Discussion and conclusions 
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AD is a frequent neurodegenerative pathology affecting the central nervous 
system, characterized by deterioration of memory and other cognitive 
processes. AD generally occurs in the elderly population, as its incidence 
doubles every 5 years after 65 years of age. This disease finds its 
pathophysiological basis in the progressive loss of some specific neuronal 
populations, which then causes typical symptoms such as memory 
impairment, linguistic and motor disorders, and behavioural changes [Herman 
L et al., 2017; Tree J et al., 2015].  
AD still lacks a precise pathogenic mechanism, and for most of the past years 
research has been based on the concept of ACH. This hypothesis focuses on 
the pivotal role of Aβ42 production and aggregation in determining senile 
plaques formation, causing neuronal damage, tau neurofibrillary tangles 
accumulation and finally, neuronal death and synaptic loss [Hardy JA et al., 
1992]. 
Although there are approved pharmacological treatments able to alleviate AD 
symptoms, there is an urgent need to improve the understanding of its 
pathogenesis to allow the development of therapies capable of modifying the 
course of the disease. In fact, no drug for the symptomatic treatment of AD has 
been approved by FDA since 2003, and compounds proposed as "disease-
modifying drugs" are still in the clinical phase with no certainty of their actual 
effectiveness, a fundamental aspect given the amount of failures obtained over 
the years [Small GW, et al., 2015]. 
Of relevance, several preclinical and clinical trials are progressing but with no 
success as “one-molecule-one-target” single therapies. Most of the AD drugs 
that failed have been developed against amyloid pathology, but it is now well 
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established that AD is more than an amyloid-centred pathology. In fact, it can 
be defined as a complex, multifactorial disease, in which several other 
pathologic processes are involved, and most of them still need to be identified. 
The major etiologic features leading to neuronal death can be summarised in 
four groups [Weinstein JD, 2018]:  
- Mitochondrial dysfunction that is linked to energetic metabolism impairment, 
ROS production and cerebrovascular hypoperfusion. 
- Abnormal protein deposits: in addition to Aβ protein, whose oligomeric 
aggregates are the most toxic species for neurons, some other proteins with 
amyloidogenic behaviour have been proposed in AD context (e.g. tau, α-
synuclein, TDP43). 
- Oxidative stress, where ROS are not neutralized and the oxidation-defence 
mechanisms are impaired. 
- Neuroinflammation, where overactivation of astrocytes and microglia leads 
to destructive inflammatory processes in a vicious cycle. 
In a context of such complexity, the research for an effective therapy for AD is 
increasingly moving to support the concept of both multi-targeted and 
combination therapies. While the former requires the development of a new 
drug or the implementation of an existing chemical entity able to affect different 
targets of the pathology, the latter takes advantage of existing molecules that 
can work in combination, giving synergistic, additive or complementary effects 
on pathologic or neuroprotective mechanisms. 
SIRTs are a rational target for AD combined therapy. In fact, they have been 
studied as therapeutic targets for neurodegenerative diseases, with many 
positive results but no strong indication supporting clinical trials. Drug 
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development of molecules able to modulate SIRTs activity delivered several 
data about their involvement in neurodegenerative pathologies, including AD. 
The SIRTs protein family is composed of seven mammalian members (SIRT1-
SIRT7), NAD-dependent enzymes with deacetylase activity and a fundamental 
role in gene expression regulation, cellular homeostasis, energetic 
metabolism, inflammation and senescence [Wątroba M et al., 2017].  
The interest in SIRTs is due to their involvement in molecular 
neurodegenerative processes. In fact, in the ageing population, metabolic 
impairment and epigenetic deregulation increase, and can influence the 
initiation or progression of neurodegeneration [Silberman DM, 2018]. 
SIRT1 and SIRT2 are the most interesting targets in this context, as they seem 
to possess opposite roles, neuroprotective for SIRT1 and neurodegenerative 
for SIRT2 [Donmez G and Outeiro TF, 2013]. 
SIRT1 over-expression or pharmacological activation with RSV resulted in 
reduced AD pathology, Aβ-induced cell death and cognitive impairment 
improvement in a mouse model [Imai S and Guarente L, 2010; Porquet D et 
al., 2014]. In addition, other studies demonstrated that SIRT1 activation via 
treadmill exercise and via CR favoured APP non-amyloidogenic pathway and 
reduced Aβ production [Koo JH et al., 2017; Wang J et al., 2010], and RSV 
treatment reduced reactive gliosis and pro-inflammatory mediators in vitro 
[Scuderi C et al., 2014]. By acting on PGC-1α and NF-κB, SIRT1 also 
promotes mitochondrial biogenesis and prevents mitochondrial dysfunction in 
AD [Donmez G, 2012; Gan L and Mucke L., 2008]. Moreover, SIRT1 
overexpression acted also on tau pathology promoting its degradation and 
reducing the spread of tau-induced pathology in vivo [Min SW et al., 2018]. 
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Some studies suggested that, possibly via NF-κB inhibition and activation of 
the retinoic acid receptors, SIRT1 could shift the balance between alpha and 
beta secretases expression and activity [Tippman F et al., 2009; Gao R et 
al., 2015; Lee HR et al., 2014]. 
Some data exist implicating SIRT2 changes in AD, while several data have 
suggested a neurodegenerative role of SIRT2 in ageing, PD and HD.  
SIRT2 high expression level was detected in brain cells of AD patients, and 
SIRT2 inhibition with the synthetic inhibitor AK1 led to microtubules 
stabilization, improved autophagy and Aβ oligomers elimination in AD models 
[Silva DF, et al., 2017]. In addition, the SIRT2 intronic SNP rs10410544 was 
associated with sporadic AD in two genetic studies [Polito L et al., 2013; Wei 
W et al., 2014].  
SIRT2 specific inhibition with the compound AK7 (a brain-permeable AK1 
analogue) resulted in neuroprotective effects both in PD and HD models, 
preventing α-synuclein and huntingtin toxicity and aggregation, and improving 
motor functions [Chen X et al., 2015; Chopra V et al., 2012]. 
A study from our laboratory demonstrated the efficacy of SIRT2 inhibition with 
AK7 in two AD mouse models, resulting in improved cognitive function and 
increased APP non-amyloidogenic processing [Biella G et al., 2016].  
Esteves and colleagues reported that α-tubulin acetylation dependent on 
SIRT2 inhibition improves microtubules stabilization and increases tau/tubulin 
binding decreasing tau detachment and aggregation [Esteves AR et al., 
2018].  
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Regarding inflammatory processes, Wang and colleagues demonstrated that 
SIRT2 is involved in microglial activation, and its inhibition rescued this 
process acting on NF-κB translocation cytokines levels [Wang B et al., 2016]. 
 
On this basis, SIRT1 activation coupled to SIRT2 inhibition could represent a 
still unexplored potential multi-target approach for AD neuropathology. 
 
The rationale of the work presented in this thesis is to combine SIRT1 and 
SIRT2 modulations, and better understand SIRT1/2 involvement in AD 
molecular mechanisms, eventually allowing us to act on different pathologic 
features dependent on one or both enzymes, under the hypothesis that 
attacking the pathology at different targets could improve the final 
neuroprotective effect.  
We started implementing this approach with an in vitro model, the H4-sw cells. 
H4-sw are human neuroglioma cells over-expressing the Swedish mutated 
APP gene (K595N/M596L), which makes these cells an ideal model for high 
Aβ peptides production and investigation of APP metabolism. We considered 
also the use of primary neurons from 3xTg-AD mice, but the problem with 
those primary cultures was that the transgenes are under the control of the 
Thy1.2 promoter that starts its activity only after postnatal day 6. Given this 
limitations we chose the H4-sw model for our preliminary analyses.  
Interestingly, in these cells we observed an increase of SIRT2 basal 
expression, as depicted by literature, while no SIRT1 reduction was detected. 
The reason for the absence of SIRT1 reduction could be model-dependent, or 
could be due to the small sample size taken into consideration. Another 
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hypothesis could be that SIRT1 expression is not affected by the APP-sw 
presence but its enzymatic activity instead is. Given this observation, it could 
be interesting to investigate a link between the APP-sw and imbalanced 
catalytic activity of SIRTs.  
First, we assessed the feasibility of the double treatment in vitro, assessing the 
potential cytotoxicity, as SIRTs targets are proteins and transcription factors 
with an important role in cellular physiology.  
The results showed that the single and double treatments were safe for our 
model, in a range of doses similar to those used in the literature [Nishida K et 
al., 2018; Minor RK et al., 2011; Chen X et al., 2015; Wang X et al., 2015]. 
After the optimization of the double treatment protocol, we decided to assess 
APP, and the effect of our treatment on its processing.  
While no effect of both the single and the double treatment was found on total 
APP production, we detected an increase in the soluble fragments pool, 
released by cells after APP cleavage. The increase of total sAPP showed no 
difference between the single and the double modulation. As total sAPP 
detection is not specific for single APP metabolic pathways, we focused our 
attention on the non-amyloidogenic one, assessing specifically sAPPα in 
conditioned media from treated cells. 
H4-sw cells showed a significant increase in sAPPα when treated with SIRT1 
activator or SIRT2 inhibitor. Moreover, when the two compounds were given 
in combination, the increase in sAPPα was higher, suggesting a possible 
synergic effect. 
An increase in sAPPα protein is actually considered an important goal for AD 
treatments, as this fragment shows neuroprotective properties able to 
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counteract neurodegeneration. It can promote neuronal growth and 
synaptogenesis, reduce Aβ production, and contrast synaptic loss when 
directly injected in brains of AD mouse models [Obregon D et al., 2012; Fol 
R et al., 2016]. 
A possible link between SIRT1-2 and sAPPα could be the fact that SIRT1 
activation or over-expression was already reported to increase APP non-
amyloidogenic processing [Koo JH et al., 2017; Qin W et al., 2006], while we 
previously demonstrated that SIRT2 inhibition led to increased sAPPα in vivo 
[Biella G et al., 2016], with a mechanism that is still unclear. 
Some published data demonstrated that sAPPα production is stimulated by 
low cholesterol or inhibition of cholesterol biosynthesis [Kojro E et al., 2010]. 
Since Taylor and colleagues reported that SIRT2 inhibition with AK7 was 
neuroprotective in HD models through reduced cholesterol levels [Taylor DM 
et al., 2011], an association between cholesterol, SIRT2 and APP processing 
could be a hypothesis also for AD.  
sAPPα increase was persistent after SIRT2 silencing, in agreement with AK7 
treatment, confirming that pharmacological SIRT2 inhibition led to specific 
biological effects. 
Another interesting point was that ADAM10 mRNA levels were unaltered by 
treatment, despite the increase in sAPPα that is the product of its secretase 
activity. A possible explanation for this result could be an increased activation 
or membrane trafficking of the secretase, rather than its over-expression. In 
fact, ADAM10 activity is also regulated by its intracellular trafficking, where the 
membrane localization is associated with its activation [Marcello E et al., 
2013]. Since some evidences point to an involvement of SIRTs in intracellular 
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trafficking, it could be interesting to undertake further studies on the SIRT1-2 
influence on ADAM10 membrane localization [Budayeva HG and Cristea IM, 
2016]. Another point could be also the choice of the model of study, that could 
produce some contradictory results, suggesting the need to move to more 
reliable models as neuronal cultures.  
As for the APP amyloidogenic processing, conditioned media from H4-sw 
treated cells were analysed for sAPPβ, Aβ40 and Aβ42. At this stage the brain-
permeable SRT1720 analogue called SRT2104, selected for subsequent in 
vivo treatments, was assessed in parallel for single and combined treatments. 
Both sAPPβ protein and Aβ40 peptide were significantly reduced by the double 
treatment condition only, supporting the importance of using both compounds 
to obtain significant molecular effects on this pathway. This result suggests 
that the double treatment could act on both APP processing pathways, with a 
greater weight on the non-amyloidogenic one. This is in accordance with the 
total sAPP increase measured in the double-treated condition that is not 
different from the single modulations, maybe because of the compensation 
between sAPPα increase and sAPPβ decrease. 
A paradoxical result emerged when we found Aβ42 levels were significantly 
increased in SIRT2 inhibition condition and double modulation, but not with 
SIRT1 activation. This result is clearly inconsistent with that obtained on Aβ40 
and sAPPβ, and we assumed a SIRT2-independent effect of the AK7 
compound. This hypothesis was confirmed by comparing Aβ42 levels after 
AK7 treatment or after SIRT2 silencing with specific siRNA. The unexpected 
Aβ42 increase was evident only after AK7 treatment, while with SIRT2 
silencing there was no effect, consistently with Aβ40 result. We tried to 
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formulate some hypotheses for this unexpected result. First, it must be taken 
into account that the characterization and potential clinical use of this molecule 
is in its infancy, so it is possible that some side or off-target effects could 
emerge upon its pre-clinical use in disease models. This observation highlights 
the attention to be paid to a more cautious use of these compounds. 
Another interesting hypothesis that we formulated was that AK7 directly 
interacts with Aβ42 in cell-conditioned medium. We support the concept that 
AK7 could act as a disaggregating or anti-aggregating compound on Aβ42 
oligomers, increasing the monomeric fraction that we detect in ELISA assay. 
Our theory is based on some evidences about the anti-aggregating effect of 
AK7, its analogue AK1 and other sulfobenzoic acid derivates, on poly-
glutamine aggregates [Chopra V, et al., 2012; Khanfar MA, et al., 2014].   
In addition, AK7 chemical structure has some similarities with compounds 
screened for their direct Aβ42 binding capability and anti-aggregating effect. 
Some of these similarities are the high hydrophobicity, the presence of 
aromatic groups and the presence of bromine substitution on one aromatic ring 
[McKoy AF et al., 2014]. Another point to be addressed is the discrepancy 
between Aβ40 and Aβ42 results. Since the two peptides have very different 
kinetic and propensity to aggregation [Qiu T et al., 2015; Zheng W et al., 
2017], it is reasonable to expect that a disaggregating effect in the short time-
frame of our cell model will occur preferentially on Aβ42 rather than on Aβ40.  
The perspective of an anti-aggregating effect, not attributable to the inhibition 
of SIRT2, could constitute an additional property of the molecule on an 
important target of the pathology. In fact, numerous efforts are underway to 
counteract the aggregation of toxic proteins in AD, since they seem directly 
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responsible for the major neuropathological damaging effects [Verma M et al., 
2015; Brito-Moreira J et al., 2017]. 
However, as mentioned previously, it is possible that the AK7 effect is simply 
model or assay-dependent, or even a side effect making this drug not safe, 
and specific analyses will be required to verify and confirm our hypothesis on 
its anti-aggregating properties. Some of those analyses could for example 
include an aggregation kinetic study of Aβ42 oligomers in the presence of AK7, 
or the measurement of other peptides downstream of the amyloidogenic 
processing, as C99 fragment, whose level should be unchanged if the 
antiaggregating hypothesis is supported. 
Overall, the in vitro data suggest that contemporary SIRT1 and SIRT2 
modulation is compatible with cellular viability and is effective in modulating 
APP metabolism improving the neuroprotective pathway through sAPPα 
increase and sAPPβ decrease, thus stimulating further analyses using this 
combined strategy. 
Taking advantage of the in vitro evidence, and to better explore the relevance 
of the combined SIRT1 activation and SIRT2 inhibition as multi-target 
approach, we moved to an in vivo mouse model of AD, the 3xTg-AD [Oddo S 
et al., 2003]. We decided to select mice at 6-7 months of age to mimic an early 
disease stage and approximate a clinical situation where patients are 
diagnosed for the first time with memory impairment and biomarkers 
alterations in biological fluids. 
At this age, 3xTg-AD mice have a marked cognitive deficit, without Aβ plaques 
and tau tangles, which appear after 12 and 18 months, respectively. Despite 
the absence of the two major pathological features, these animals have other 
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alterations that could contribute to the observed cognitive impairment. They 
consist primarily of accumulation of intracellular Aβ in the hippocampus, which 
was already associated with the onset of the early cognitive deficit in 3xTg-AD 
mice [Billings LM et al., 2005].  
Moreover, a 55 kDa Aβ species, that could represent a highly toxic oligomer 
much discussed in literature and called Aβ*56 [Chiang ACA et al., 2018; 
Lesnè SE et al., 2006; Billings LM et al., 2007; Amar F et al., 2017; Lesnè 
SE et al., 2013], was detected by 6E10 antibody in hippocampal soluble 
lysates of our 6 month-old 3xTg-AD mice. 6E10 is a commercial antibody 
widely used for human APP and Aβ species detection and reported for 
recognition of Aβ*56 too [Chiang ACA et al., 2018].  However, some limits in 
its use for this purpose may emerge due to potential cross-reactivity with 
mouse tissue samples as stated previously, and some other observations 
came on its inability to detect all Aβ forms [Hunter S and Brayne C, 2017].  
In addition, we detected an increased expression of the neuroinflammation 
markers GFAP and CD11b, a decrease in the synaptic marker Synaptophysin, 
and a decrease in NRF2, a master regulator of the antioxidant response. 
Moreover, in accordance with our in vitro results, these mice had increased 
protein expression of SIRT2, supporting the hypothesis that in a 
neurodegenerative condition there is an accumulation of this protein, and 
strengthening our rational to its inhibition. However, SIRT1 basal expression 
was apparently unaffected by the 3xTg-AD pathologic condition. This result is 
partially in contrast with the hypothesis of restoring a reduced SIRT1 level 
already associated with the human AD condition [Cao K et al., 2018]. 
Consequently, our treatment approach is likely to be considered as a boosting 
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of SIRT1 neuroprotective activity rather than a compensation of its deficiency, 
even if it cannot be excluded that we have a reduced activity of SIRT1 in a 
normal protein expression condition. Another point to be addressed is the early 
age of animals and their early neuropathological phenotype, which could be 
insufficient to trigger SIRT1 downregulation and so contributes to our result. In 
support of this observation, some literature data report a reduction of SIRT1 in 
old AD mice [Rodriguez-Ortiz CJ et al., 2014]. In addition, Bonda et al. made 
some considerations about the potential role of therapeutic SIRT1 upregulation 
for AD phenotype amelioration given its direct involvement in counteracting 
AD-related pathways [Bonda DJ et al., 2011]. 
The set of neuropathological features detected in these animals could 
therefore be responsible for the cognitive deficit at such an early age. 
Starting from this characterization and from the data already available from our 
previous work on the inhibition of SIRT2 [Biella G et al., 2016], we decided to 
inhibit SIRT2 and activate SIRT1, with the objective of assessing the effect of 
the combined treatment on 3xTg-AD memory deficit and molecular alterations. 
As mentioned previously, SIRT2 inhibition with AK7 gave positive results on 
3xTg-AD mice at 6-7 months of age, significantly increasing the non-
amyloidogenic pathway through an increase in sAPPα and producing a 
marked improvement of cognitive deficit measured with NORT [Biella G et al., 
2016].   
Starting from this point, we first of all replicated the AK7 behavioural data. As 
expected, AK7 treatment was well tolerated, as assessed by body weight 
monitoring, and led to a strong cognitive deficit improvement. In fact, the mean 
DI of AK7-treated mice was 0.29, a value not significantly different from that of 
189 
 
NTg mice (mean DI = 0.39) but clearly improved with respect to untreated 
3xTg-AD mice (mean DI = 0.02). 
Next, we developed a 2-week acute protocol for SIRT1 activation. We selected 
a brain-permeable analogue of SRT1720, SRT2104, and also member of the 
second generation of STACs. This compound showed promising results in 
models of atrophy, diabetes, psoriasis and HD, and reached the clinical trial 
phase several times [Mercken EM et al., 2014; Jiang M et al., 2014; Baksi 
A et al., 2014; Krueger JG et al., 2015]. 
3xTg-AD mice treated with SRT2104 had cognitive deficit recovery, as 
indicated by the DI (mean DI = 0.32) that was very close to that of NTg mice 
(mean DI = 0.36), while 3xTg-AD mice treated with vehicle had cognitive 
impairment (mean DI = -0.02).  
This result is in line with that reported by other groups, where SIRT1 over-
expression or pharmacological activation (e.g. by resveratrol) resulted in 
cognitive performance improvement of AD mouse models [Porquet D et al., 
2014; Corpas R et al., 2017].  
Given the promising results obtained with the single SIRT1 or SIRT2 
modulation, we moved to the main objective of the project, to modulate the two 
SIRTs in opposite directions. 
AK7 and SRT2104 were given to 3xTg-AD mice with the same doses and 
routes of administration of the single treatments, and body weight was 
monitored during the course of the experiment. A preliminary evaluation of 
vehicle/DMSO toxicity following a repeated treatment was also performed prior 
to the double treatment, with no evidence of detrimental effects (data not 
shown).  
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In fact, the double treatment was well tolerated and significantly improved 
cognitive performance, as the mean DI of 3xTg-AD treated mice and NTg 
group was the same (NTg mean DI = 0.38; double-treated 3xTg-AD mean DI 
= 0.37), with a complete reversion of the vehicle-treated 3xTg-AD mice 
cognitive impairment (mean DI = 0.03). One experimental limit to be 
considered is that we excluded NTg-treated group from our analyses, to focus 
the attention on the improvement of the transgenic phenotype both at 
behavioural and biochemical level, but further analyses on the possible effect 
on healthy animals should be performed to draw more complete conclusions. 
Another important limitation that deserves attention is related to the choice of 
the behavioural task analysed. In fact, we measured visual recognition 
memory without assessing other recognition memory experimental settings 
(such as those discriminating the encoding, storage and retrieval of memory) 
or other types of memory, such as the spatial one that requires other 
behavioural tests (e.g. Morris Water Maze, Barnes Maze or Y-maze). Thus, 
the concept of complete cognitive recovery should be approached with 
caution. Additionally, our 24 hours test setting is a long-term memory 
assessment that do not give any information about the influence of the 
treatment on different time-point memories, such as short-term memory, a limit 
that could be exceeded by multiple time point behavioural analysis. NORT 
cognitive assessment has supporting literature regarding hippocampal 
involvement in object recognition, but just as much literature exists about the 
difficult interpretation of NORT because of multiple brain regions involvement, 
chiefly the perirhinal cortex that seems highly involved in memory retrieval 
[Broadbent NJ et al, 2009; Cohen SJ and Stackman RW, 2015; Lueptow 
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LM, 2017]. This is a reason to foresee the analysis of biochemical parameters 
also in other brain areas involved in recognition memory, as the experiments 
presented below were focused on hippocampal samples only. 
As previously stated, we treated our 3xTg-AD mice in an early phase, when 
amyloid plaques are not evident but intracellular and oligomeric Aβ forms are 
detectable together with other pathologic alterations, as shown in the 3xTg-AD 
characterization results. Moreover, Aβ oligomers have been proposed as 
directly responsible for alterations such as synaptic damage and 
neuroinflammation [Mroczko B et al., 2018].  
Consequently, we tried to correlate the recovery in mice cognitive impairment 
with neuropathological changes of those markers that resulted altered in 3xTg-
AD mice at basal level.  
We already knew that SIRT2 inhibition with AK7 acted on APP processing in 
hippocampus of 3xTg-AD mice by increasing the non-amyloidogenic pathway, 
with higher levels of the neuroprotective fragment sAPPα and lower levels of 
sAPPβ [Biella G et al., 2016]. 
Therefore, we investigated sAPPα levels in hippocampus of SRT2104 and 
double-treated mice too, and results showed that both treatments significantly 
increased this APP protein fragment, in accordance with our in vitro data and 
with literature about SIRT1 activation. 
Another relevant parameter detected in hippocampal soluble fractions of 3xTg-
AD mice was the Aβ form having SDS-PAGE molecular weight of 55 kDa, 
which corresponds in size to a 12-mer. We hypothesize it to be the reported 
Aβ*56 toxic species found in Tg2576 AD mice and directly associated with 
memory loss [Lesnè S et al., 2006; Amar F et al., 2017]. Moreover, this band 
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was also detected in brain lysates from memory impaired 3xTg-AD mice 
[Billings LM et al., 2007]. We assessed the level of this oligomer after each 
treatment, and found that while SRT2104 alone did not affect its level, AK7 
administration significantly lowered it, and the double treatment condition 
maintained AK7 effect, showing again a significant decrease of 55 kDa Aβ.  
This result could align with the Aβ42 paradoxical effect seen on AK7-treated 
H4-sw cells and with our hypothesis of a direct effect of AK7 on Aβ aggregation 
dynamics.  
These data strengthen the potential of SIRT2 inhibition in counteracting Aβ-
related pathology, acting both on APP processing and on soluble aggregated 
forms of Aβ peptide that are generally considered the most toxic species 
[Verma M et al., 2015]. In fact, it is reasonable to assume that an increase in 
sAPPα production and a reduction in hippocampal Aβ oligomers could give a 
strong contribution to mice cognitive improvement.  
As stated in the Results section, despite its widespread use, the 6E10 antibody 
for AβO visualization could raise some doubts related to mouse cross-
reactivity, even if the absence of the 55kDa Aβ form in NTg mice could suggest 
that we are detecting some specific signal. To eliminate this doubt and verify 
the identification of Aβ*56 as an oligomeric species, we could select another 
Aβ oligomer-specific antibody instead of 6E10, such as 4G8, A11 or 82E1 
clones, in parallel to an optimized extraction protocol with varying detergent 
concentrations [Chiang ACA et al., 2018]. 
Another factor to discuss is the sole analysis of soluble fractions, which on one 
hand we decided to select as an amount of circulating soluble Aβ oligomers 
that can confer neurotoxicity is present [Hong W et al., 2018] and could also 
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constitute an interesting player in the pathogenesis of the AD early stages that 
we are analyzing. On the other hand, this choice may highlight a limitation of 
our experiments that could have been performed on the insoluble AβO-
containing pellets too, to assess both soluble and insoluble Aβ forms and draw 
a complete picture of the situation.  For future analyses, western blotting could 
be perfomed on hippocampal ultracentrifuged pellets solubilized in formic acid 
(FA) for detection of those insoluble AβO species, as well as other interesting 
insoluble fractions.  
Next, we assessed the effect of the treatments on neuroinflammation by 
measuring hippocampal levels of GFAP and CD11b, that were increased in 
3xTg-AD mice.  
Neuroinflammation is a major player in AD pathogenesis, as Aβ peptide is 
directly responsible for glial over-activation, which is considered an early event 
for AD neuronal damage and synaptic failure [Ahmad MH et al., 2019; Avila-
Muñoz E and Arias C, 2014]. 
We also measured the effect on the pre-synaptic marker Synaptophysin, 
whose basal level was decreased in 3xTg-AD mice, indicating an initial 
synaptic deficit.  
SRT2104 administration, but not AK7, significantly reduced GFAP and CD11b 
levels, and increased Synaptophysin in the hippocampus of 3xTg-AD mice. 
This result was confirmed in mice treated with the combination of AK7 and 
SRT2104, indicating that SIRT1 activation effects were maintained.  
Overall, one could hypothesize that decreased neuroinflammation markers 
lead directly to improved synaptic health that was evident through increased 
Synaptophysin level.  
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The absence of effects of AK7 on neuroinflammation markers is in accordance 
with our previous work on the same model [Biella G et al., 2016], even if some 
literature data point to a role of SIRT2 inhibition in reducing reactive gliosis in 
vitro [Scuderi C et al., 2014]. 
Another important feature of AD molecular pathology is oxidative stress and 
impaired antioxidant response, that are correlated with mitochondrial 
dysfunction and Aβ accumulation. Moreover, ROS production can itself 
stimulate aggregation of misfolded proteins, exacerbating the toxicity status of 
the neuron [Uttara B et al., 2009; Wang P and Wang ZY, 2016]. 
In our 3xTg-AD mice, we detected basal decreased levels of NRF2, a 
transcription factor regulating genes for the antioxidant response. Together 
with decreased transcription of its target genes, one important consequence 
of NRF2 reduction is a high intracellular iron level that can contribute to 
oxidative stress and cellular damage [Yang X et al., 2017]. Another work 
showed that the lack of NRF2 in an AD-NRF2 KO mouse model worsened 
APP and tau pathology by increasing p-tau, Aβ*56, neuroinflammation, 
oxidation and cognitive deficit [Rojo AI et al., 2017]. The levels of Nrf2 were 
decreased in the hippocampal neurons from AD patients and its activation has 
been proposed as a new goal for oxidative stress and inflammation 
suppression in AD pathology [Ramsey CP et al., 2007; Kedar N Prasad, 
2016]. 
Different works reported a link between NRF2 pathway and SIRTs in different 
pathological contexts, including neurodegenerative disorders and AD.  
As an example, Cui and colleagues reported that the antioxidant D3T exerted 
its neuroprotective effect on AD mice up-regulating SIRT1/NRF2 pathway, an 
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effect that was abolished by pharmacological inhibition of SIRT1 [Cui Y et al., 
2018], thus suggesting a direct link between SIRT1 function and NRF2 
beneficial effects.  
SIRT2 seems to be involved in NRF2 function too, in particular by 
deacetylating NFR2 and favouring its degradation, with consequent decrease 
of iron efflux from the cell and increase in intracellular iron levels [Yang X et 
al., 2017], an event that if pathologically imbalanced could favour the 
progression of oxidative damage.  
Given these assumptions, we hypothesized that with both SIRT1 activation 
and SIRT2 inhibition it could be possible to obtain increased NRF2 level 
improving the antioxidant response pathway in our pathologic context.  
We decided to assess the level of NRF2 in 3xTg-AD mice treated with 
SRT2104 and AK7. In parallel, we assessed the level of the antioxidant 
enzyme SOD1, another protein that is reportedly decreased in the brain of AD 
patients together with SIRT1 levels [Cao K et al., 2018]. Among the different 
antioxidant proteins, we selected SOD1 as an example of downstream players 
of the antioxidant machinery connected with NRF2 activation too [Park EY and 
Rho HM, 2002; Mota SI et al., 2015], but the assessment of other enzymes 
could be useful to make more complete picture of this pathway involvement 
(i.e. HO-1). 
The results showed that SIRT1 activation with SRT2104 significantly increased 
both hippocampal NRF2 and SOD1 levels, supporting the hypothesis of a 
SOD1 increase downstream consequence of NRF2 enhancement. In the case 
of SIRT2 inhibition with AK7, though, we were unable to obtain a significant 
NRF2 increase, and no effect on SOD1 level was appreciable too. 
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As for 3xTg-AD mice treated simultaneously with AK7 and SRT2104, they had 
increased levels of NRF2 and SOD1 as expected, indicating that with our 
treatment we could be able to improve the antioxidant defence machine that 
appears impaired in AD condition. 
Overall, in vivo results support the objective of this work, which was to affect 
different AD neuropathological alterations by modulating SIRT1 and SIRT2 
activity, finally obtaining a recovery of the cognitive deficit. The set of the 
carried-out analyses suggest that SIRT1 activation is more prone to affect 
different pathways and give a broader spectrum effect on neuroinflammation, 
synaptic function, antioxidative response and APP metabolism, while SIRT2 
inhibition seems to act more specifically on APP-relevant parameters with a 
negligible effect on other targets, at least in our context. 
However, some limitations of our main findings should be taken into account. 
First of all, the in vitro model may not be completely descriptive of the 
pathology, since we did not use neuronal-like cells that could have given more 
realistic and complete informations not only for APP metabolism, but also for 
other peculiar mechanisms that characterize neuronal functioning. Another 
point regards the key finding of sAPPα increase, that we obtained both in vitro 
and in vivo upon SIRT1 and SIRT2 treatments, as this was not paralleled by 
an effect on the alpha-secretase ADAM10 and this result does not reflect what 
has been reported in some literature works [Tippman F et al., 2009; Lee HR 
et al., 2014]. Anticipating that ADAM10 analysis is still lacking in in vivo 
experiments, we cannot definitely conclude that our model is inadequate for 
the analysis of this parameter.  
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In vitro data also showed some confounding results about the effect of the 
SIRT2 inhibitor AK7 on Aβ42, which need careful investigation to confirm if it 
could be a side effect, a model-dependent effect, or an anti-aggregant effect 
as hypothesized by us. 
In our in vivo experiments, despite we had a clear indication of the pro-
cognitive effect of the treatments on 3xTg-AD mice, some points need further 
investigation, since we described only one memory task (visual recognition 
memory), at one time-point and without considering other brain regions 
involvement other than the hippocampal one [Cohen SJ and Stackman RW, 
2015; Lueptow LM, 2017]. Moreover, we did not compare all the experimental 
groups in the same behavioural and biochemical analyses, keeping each 
treatment as an independent experiment. These shortcomings may not make 
the overall in vivo picture complete, as it could be interesting to know if the 
double treatment is able to produce greater effects on all parameters (memory 
and protein markers) with respect to the single modulation, giving integrative 
informations to those obtained in this thesis.  
The in vitro and in vivo data are, in our opinion, supportive of the combined 
approach in SIRTs modulation in AD therapy. However, several limitations are 
to be considered. One of these pertains to the available SIRTs modulators and 
their pharmacokinetic features.  
For this reason, in the last part of the thesis, we focused our attention on the 
preliminary characterization of a controlled release system for the 
administration of SIRTs modulators. Despite the growing development of 
compounds able to modulate SIRT1 and SIRT2 and their promising biological 
effects, it is difficult to optimize the pharmacokinetic characteristics of the 
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molecule in order to permit access to the brain and simultaneously allow a 
prolonged effect without rapid clearance. It is the case, for example, of the 
SIRT1 activator SRT1720 which we used for in vitro experiments, that is 
unable to cross the BBB. Likewise, AK7, despite its brain-permeability, has a 
very short half-life and needs repeated administrations. Therefore, a possible 
application of a controlled release system could be a peripheral implantation 
for brain-permeable compounds with poor pharmacokinetics, a CNS direct 
implant for those not brain-permeable and rapidly eliminated, but also for brain-
permeable molecules, to reduce the loss in other body districts and minimize 
associated side effects [Li J et al., 2016; Basso J et al., 2018; Garbayo E et 
al., 2013; Tunesi et al., 2014].  
Hydrogel-based DDS are three-dimensional, biocompatible, injectable, and 
perform in situ gelation. These characteristics allow their use for the release of 
neuroactive molecules in the CNS [Khaing Z et al., 2014]. In addition, 
hydrogels are biodegradable, and do not require surgery for their removal 
[Pakulska MM et al., 2012].  
Cooke et al, who developed a controlled epi-cortical DDS, proposed one 
promising application of hydrogel-based delivery systems. Their device 
consisted in a PEG-EGF-loaded hydrogel placed epicortically to treat stroke-
injured brain, aiming at a local, minimally invasive and controlled delivery to 
the brain [Cooke MJ et al, 2011]. Caicco and colleagues successfully 
reproduced the same approach in 2013 [Caicco MJ et al, 2013]. 
For the development of our DDS, we selected a semi-interpenetrated hydrogel 
[Hoare TR et al., 2008] made by type I Collagen and PEG2000. The safety of 
this matrix was tested in cellular models of neurodegeneration and by 
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intracranial and subcutaneous injection in AD and PD models [Tunesi M et 
al., 2013]. The lack of inflammatory potential was confirmed in this thesis 
through the air-pouch model, where the COLL-PEG2000 hydrogel resulted 
safe after 24 hours of implantation in CD-1 mice.  
We selected three SIRT1-2 modulators for our experiments. The first was 
SIRT1 activator SRT1720, which despite its higher potency respect to 
SRT2104 is not brain permeable. In addition, we selected AK7 SIRT2 inhibitor 
and AGK2, another compound that has a better IC50 despite not being brain-
permeable. 
AGK2 is a well-documented SIRT2 inhibitor and was used for in vitro 
experiments in a previous work from our laboratory [Scuderi C et al., 2014; 
Biella G et al., 2016]. 
For modulator quantification, we chose the UV-Vis spectrophotometric 
technique, and identified the maximum absorbance peak (λₘₐₓ) for each 
modulator. Unfortunately, AK7 did not show any absorbance peak and was 
excluded from further experiments. 
AGK2 was not eligible for our hydrogel-based approach, due to the 
impossibility of detecting its presence at any time-point.  
This result suggests that AGK2 is not released by the hydrogel, and could be 
trapped inside the matrix with some chemical or physical interaction with its 
components.  
On the contrary, SRT1720 was released from the COLL/PEG2000 hydrogel 
with decreasing speed over time. After 7 days, the percentage of molecule 
released is 92.8% of the loaded quantity, confirming that the hydrogel-based 
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system has some positive features for a prospective application in a 
therapeutic strategy involving SIRT1 activation. 
This preliminary picture needs implementation, particularly in the optimization 
of the release assessment for those compounds that were not suitable for our 
experimental setup, but also for the in vivo application in the 3xTg-AD mouse 
model to verify the efficacy of the release system. 
The development of an effective delivery system of SIRTs modulators could 
be a useful tool for in vivo drug-delivery, overcoming the limitations and 
invasiveness of conventional administrations. Moreover, this approach could 
potentially be of considerable impact in future clinical practice on AD, PD and 
other CNS disorders, as hydrogel-based DDS systems might improve the 
effective delivery of drugs to the target site thanks to their multiple beneficial 
features. However, much work will still be needed in formulation, 
characterization and production processes to effectively translate these 
systems in human CNS diseases.  
 
CONCLUSIONS 
In conclusion, the results obtained in this thesis support the main objectives of 
the project, demonstrating the feasibility of a combined treatment targeting 
SIRT1 and 2 and confirming the promising role of SIRT1 and SIRT2 as 
therapeutic targets for cognitive recovery in AD. The combined SIRT1 
activation and SIRT2 inhibition, an approach we propose for the first time in 
AD context, could represent a useful tool aimed at attacking the disease on 
multiple molecular aspects that integrate each other to ameliorate cognitive 
impairment (Fig. 6.1). 
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The most promising results have emerged with in vivo experiments. 3xTg-AD 
mice treated with a combination of SIRT1 activator and SIRT2 inhibitor had a 
recovery of cognitive impairment in the object recognition task, associated with 
hippocampal biochemical changes, such as non-amyloidogenic APP 
metabolism increase, reduced oligomeric Aβ and neuroinflammation markers 
GFAP and CD11b, increased Synaptophysin and antioxidant proteins NRF2 
and SOD1. Some of these changes seemed to depend on the single 
modulation of SIRT1, like neuroinflammation, antioxidant and synaptic 
markers, while Aβ-related parameters seemed more linked to SIRT2 inhibition, 
further supporting the complementarity of the double treatment at the 
neuropathological level. 
An important point to address is that both single treatments independently 
affected memory, producing a significant amelioration of object recognition 
performance. A possible explanation could reside in the fact that one main 
biochemical change shared by both SIRT1 and SIRT2 treatment is the 
boosting of sAPPα neuroprotective fragment, that alone can affect cognition. 
It is possible that this is the main molecular effector of the cognitive 
improvement, even if we cannot conclude that this is the only one.  
Although the double treatment did not show a cognitive effect different from 
that of the single treatments, thus making its added value negligible, its 
importance could lie in the interesting hints obtained from biochemical 
analyses.  
If on the one hand the increase in the α-cleavage could be the most important 
effect for the cognitive result, on the other hand AD is not only cognitive 
decline. The protective effect on other pathways that we took in consideration 
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could help in supporting neuroprotection acting on other behavioural 
disturbances or even on other neuropathological aspects such as 
neurovascular alterations (strictly connected to neuroinflammation and 
oxidative stress). Thus, it cannot be excluded that, besides APP processing, 
the other pathways contribute to the overall phenotypic effect, maybe through 
some synergic mechanisms that could emerge in future experimental settings. 
 
Figure 6.1 Summary of the key findings of this work, where cognitive recovery of 3xTg-AD 
mice seems to be attributable to a complementary effect of SIRT1 activation and SIRT2 
inhibition on different pathological pathways, supporting the potential of a multi-target strategy 
to counteract the multifactorial nature of AD pathogenesis. 
 
Finally, the preliminary characterization of a hydrogel-based system for the 
controlled release of SIRTs modulators with poor pharmacokinetics, proved to 
be promising for further optimization in the neurodegeneration context, to allow 
a more effective delivery of neuroactive compounds to the CNS.  
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FUTURE PERSPECTIVES  
The future perspectives of this project will aim at overcoming the limitations 
described during the discussion of the obtained results.   
To deepen the usefulness and clinical traslability of AK7 compound as SIRT2 
inhibitor, specific experiments should be dedicated to the investigation of its 
effects on the Aβ peptide aggregation and production, as described previously.  
In vivo behavioural analyses should focus on the memory recovery outcome 
comparing both NTg and 3xTg-AD mice receiving single and combined 
treatment, to have a quantitative measure of the memory improvement that the 
combination could give with respect to the single drug and to assess if the 
double treatment has not only complementaty, but also synergic effects. 
A detailed analysis of both short-term and long-term memory, together with the 
parallel assessment of other memory tasks, could be very useful to draw a 
complete cognitive picture after SIRTs modulation.  
In addition, we could propose to anticipate the timing of the pharmacological 
treatments in a preventive key, for mice with no cognitive deficit on which it 
could be interesting to see if the treatment delays it, or to postpone it in a 
curative key under full-blown pathology. 
Future biochemical experiments should focus both on hippocampus and cortex 
samples and paralleled with behavioural results. Those experiments should 
deepen the analysis of the treatment’s effect on ADAM10, clarify that on Aβ 
oligomers with more specific antibodies and extraction protocols, but also 
investigate those molecular pathways that could be involved in biochemical 
changes seen in our results (e.g. NfκB involvement in inflammation effects, 
microtubules dynamics and acetylation of tau).  
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Further experiments will be required to evaluate the potential use of SIRTs 
modulator-loaded hydrogels in vivo and to confirm the maintenance of the 
biological effects of the treatment. In addition, it would be interesting to explore 
the physical-chemical interaction between the matrix and the active molecules 
to overcome the limitations in the formulation of the system. 
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